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Abstract 
Skeletal muscle plays a central role in maintaining metabolic homeostasis in health 
and disease. An important metabolic component of muscle is the integrated 
metabolism of glucose and glucocorticoids (GCs) in the lumen of the sarcoplasmic 
reticulum (SR). Glucose-6-phosphate (G6P) transported into the SR by the G6P 
transporter (G6PT) is metabolised by hexose-6-phosphate dehydrogenase (H6PDH) 
to produce nicotinamide adenine dinucleotide phosphate reduced (NADPH) cofactor 
that is utilised by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) to reduce 
inactive GCs to their active forms. This thesis evaluated the SR unit as a site of 
integrated metabolism using a range of genetic models and screening methods. We 
demonstrate that perturbation of redox and metabolic balance through the distribution 
of H6PDH enzyme resulted in novel stress responses leading to shifts in redox and 
energy metabolism. Particularly, we show how the SR can elicit transcriptional 
changes that appear to adapt NADPH redox perturbation and also increase energy 
metabolism through augmented mitochondrial function. These data presented a 
novel sensing pathway within the SR unit that could have important relevance to 
metabolic and energetic control of skeletal muscle.  
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NaMN   Nicotinic acid mononucleotide 
NADP   Nicotinamide adenine dinucleotide phosphate  
NADPH  Nicotinamide adenine dinucleotide phosphate reduced 
NADH   Nicotinamide adenine dinucleotide reduced 
NAMPT  Nicotinamide phoshoribosyltransferase 
NaPRT  Nicotinate phosphoribosyltransferase 
NAPRT1   Nicotinate phosphoribosyltransferase domain containing 1 
ND                  NADH dehydrogenase 
NEB   Nebulin 
NF-κB   Nuclear factor-kappa B  
NMN   Nicotinamide mononucleotide  
NMNAT  Nicotinamide mononucleotide adenylyltransferase  
NMRK2  Nicotinamide riboside kinase 
NMP   Nucleoside monophosphate  
NR   Nicotinamide riboside 
 XXI 
 
QPRT   Quinolinate phosphoribosyltransferase 
Orn   Ornithine  
P450scc  P450 cholesterol side chain cleavage enzyme  
pA   Povine growth hormone polyadenylation sequence 
PBS   Phosphate-buffered saline 
Pax   Paired-box protein  
PC   Phosphatidylcholine 
PCOS   Polycystic ovary syndrome 
PCR   Polymerase chain reaction 
PCr   Phosphocreatine 
PDHC   The pyruvate dehydrogenase complex 
PDK4   Pyruvate dehydrogenase kinase, isozyme 4 
PERK   PKR-like ER protein kinase 
Pi   Inorganic phosphate 
PI3K   Phosphatidylinositol 3-kinase 
PGC-1α  Peroxisome proliferator activated receptor-γ co-activator 1α 
PKR   Protein kinase R 
PRRX1   Paired related homeobox 1 
PVDF   Polyvinylidene difluoride membrane 
PYCR1   Pyrroline-5-carboxylate reductase 1  
RC   Mitochondrial respiratory chain  
RNA   Ribonucleic acid 
rRNA    Ribosomal ribonucleic acid 
RT   Reverse transcription 
SA   Splice acceptor 
SCAD   Short-chain acyl-CoA dehydrogenase 
SIRT   Sirtuins 
SMOX   Spermine oxidase  
SR   Sarcoplasmic reticulum  
SRD   Short-chain alcohol dehydrogenase  
SULT2A1  DHEA sulfotransferase  
TAG   Triglyceride 
T2DM   Type 2 diabetes mellitus 
TC         Tissue culture 
TCA   Tricarboxylic acid  
TG   Triglyceride 
TGF-β  Transforming growth factor β  
THE   Tetrahydrocortisone  
THF   5β-tetrahydrocortisol  
TLC   Thin layer chromatography  
TRP   Tryptophan  
VLDL   Very low density lipoprotein 
WHO   World health organisation 
WT   Wild type 
XBP1   X-box-binding protein 1 
xLeu   xLeucine 
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1.1 Skeletal muscle as a metabolic tissue 
Skeletal muscle is a form of striated muscle along with cardiac and smooth muscle 
and is under the control of the somatic nervous system. It is the most abundant 
peripheral tissue type in the human body constituting approximately 40% of the total 
body mass (42% for an average adult male and 36% for an average adult female) 
(Smith and Muscat 2005). The major function of skeletal muscle is to generate motile 
force through contraction in order to provide the stability and power for all body 
movements (Schuler et al. 2005).  
Skeletal muscle as a metabolic tissue plays a major function in whole body metabolic 
energy regulation under different physiological conditions such as reduced blood flow 
and oxygen supply or increased energy demand during exercise (Dash et al. 2008). 
Muscle accounts for ~30% of total energy metabolism at rest whilst 90% of the  
20-fold increase at peak physical activity (Zurlo et al. 1990). 
Two metabolic patterns for skeletal muscle energy metabolism have been 
characterised (detailed in Section 1.1.3). The fast muscle fibres (type II fibres) use 
mainly glycolytic metabolism to generate short bursts of power mainly from 
phosphocreatine and glycogen. Conversely, type I fibres are classified as slow fibres 
use oxygen to produce adenosine triphosphate (ATP) in order to maintain long-term 
contractions (Ventura-Clapier et al. 2007). 
In addition, skeletal muscle provides the most significant store of essential amino 
acids in the body (Bronk 1999) and controls metabolism via modulation of both 
circulating and stored lipid flux. Lipid catabolism accounts for up to 70% of the energy 
requirements for resting muscle. After prolonged exercise, muscle oxidises 
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carbohydrates and lipids as the dominating ATP-producing systems through aerobic 
metabolism. Glucose as a major carbohydrate substrate is stored as muscle 
glycogen; however, the extracellular glucose contribution increases with exercise 
duration (Westerblad et al. 2010). Endurance exercise depends on fatty acids and 
lipid mobilisation from other tissue (Figure 1-1). This underlines the importance of 
glucose and fatty acids for supplying energy in muscle (Smith and Muscat 2005).  
 
Figure 1-1 Schematic representation of the relationship between different energy 
substrates as a function of exercise intensity 
The rate of ATP turnover was estimated in human leg muscles during upright cycling. 
Phosphocreatine (PCr) and lactate significantly contribute to ATP production only at 
high exercise intensities whereas the role of protein metabolism is considered to equal 
zero (Westerblad et al. 2010). 
 
An additional substrate for aerobic metabolism is amino acids derived from muscle 
protein degradation; however, this contributes very little to the overall energy 
metabolism during prolonged exercise (~5% with sufficient carbohydrate metabolism 
and ~10% in the almost complete lack of carbohydrate availability)  
(Westerblad et al. 2010).  
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Importantly, skeletal muscle plays a significant role in determining whole body insulin 
sensitivity and lipid profile as the regulator of metabolism. Muscle metabolism is a 
potentially important therapeutic target used in the battle against a number of 
diseases caused by caloric excess, physical inactivity or ageing that lead to skeletal 
muscle insulin resistance, a risk factor for the development of type II diabetes and 
cardiovascular disease or sarcopenia, consequently increasing mortality risk. Thus, 
fully defining the physiology of skeletal muscle is critical to design interventions to 
optimise an individual’s capacity to resist these diseases. 
Skeletal muscle could be regarded as being as important as the liver and adipose 
tissue when considering the metabolic development of obesity and insulin resistance. 
Glucocorticoids, a group of hormones, play an important role in the incidence and 
progression of muscle insulin resistance (Section 1.6.3.2). Therefore, the 
mechanisms by which glucocorticoid metabolism can influence muscle phenotype 
requires a full investigation. This thesis will examine the role of skeletal muscle in 
local and systemic glucocorticoid production impacting whole body metabolism. 
 
1.1.1 Myogenesis 
Skeletal muscle myogenesis is a multistep process of muscle cell formation that 
begins with the commitment of an embryonic precursor to the myogenic lineage, then 
the proliferation of these myoblasts followed by their differentiation into postmitotic 
myocytes and finally fusion of myocytes to form multinucleated fibres called 
myotubes (Figure 1-2). This process is regulated by the basic helix-loop-helix 
myogenic regulatory transcription factors (MRFs) including myogenic differentiation 1 
(MyoD), myogenic factor 5 (Myf-5), myogenin and muscle-specific regulatory factor 4 
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(Mrf-4) which are engaged in complex signaling cascades (Jin et al. 2007). During 
embryo development, the paired-box protein-3 (Pax-3) and Pax-7 maintain 
population of quiescent satellite cells and, together with Myf-5, play a role in the 
expansion of activated myoblasts. Additionally, MyoD determines the differentiation 
potential of an activated myoblast and acts together with myogenin and myocyte 
enhancer factor 2 (Mef-2) to drive differentiation. Finally, Mrf-4 is required for terminal 
differentiation and muscle hypertrophy (Jin et al. 2007). 
 
Figure 1-2 Schematic development of mature myotubes 
Muscle precursor cells fuse together forming multinucleated myotubes that express 
characteristic contractile proteins. 
 
Each mature muscle cell contains multiple nuclei and arises from separate myoblasts 
fused together. Single, elongated and cylindrical myotubes do not have a proliferative 
capacity (Rando and Blau 1994).  
The main source of cells for muscle formation during regeneration in response to 
injury, disease or training is muscle precursors called satellite cells (Figure 1-3). 
These cells are located between the basal lamina and the myofibre plasma 
membrane and are responsible for muscle postnatal growth (Morgan and Partridge 
2003;Yin et al. 2013). Satellite cells are predominantly quiescent in adult muscle, and 
they appear in the limbs at about 17.5 days postcoitum after primary muscle fibres 
Chapter 1                                                                                                                  General Introduction 
6 
 
have formed. They express a range of proteins including M-cadherin, a calcium-
dependent cell adhesion molecule, c-met, the receptor for HGF, myocyte nuclear 
factor (MNF) and Pax7. During postnatal growth, satellite cells proliferate and either 
fuse with each other to form myotubes and then myofibres or fuse with damaged 
muscle fibres. Some of them also form new satellite cells (Seale and Rudnicki 2000).  
 
Figure 1-3 Localisation of a satellite cell on skeletal muscle fibre 
Red arrows show satellite cells (A); schematic representation of a muscle fibre cross-
section with satellite cells attached to its surface (B). 
 
Interestingly, satellite cells isolated from old mice produce fewer colonies with lower 
reserve cells when compared to young mice. Therefore, ageing may impair the ability 
of some progenitors to produce reserve cells. Depletion of satellite cells could 
potentially contribute to the age-related decline in skeletal muscle quality and 
performance (Day et al. 2010). 
 
1.1.2 Skeletal muscle structure  
Skeletal muscle is composed of individual, elongated, multinucleated cells called 
myotubes or myofibres which lie in parallel linked by connective tissue. These 
components are organised into regular arrays of thin actin and thick myosin proteins 
that act as the integrated contractile and functional unit of muscle termed  
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the sarcomere, organised as repeated units in long filaments (Figure 1-4). 
Sarcomeres in series form myofibrils that determine the striated appearance of 
skeletal muscle (Brooks 2003).  
 
Figure 1-4 Structure of skeletal muscle 
Skeletal muscle is composed of muscle fibres formed from many cylindrical subcellular 
structures called myofibrils which display a repeat banding pattern of overlapping thin 
and thick filaments organised in sarcomeres. The thin filaments are composed of three 
proteins: actin, tropomyosin, and troponin whereas the thick filaments comprise a large 
molecular weight protein called myosin. Titin is a large molecular weight protein that 
extends from the M lines to the Z disks and is associated with thick filaments (Farah 
and Reinach 1995;Tajsharghi 2008). 
 
The thin filaments of skeletal muscle are composed of three proteins: actin, 
tropomyosin and troponin. Actin has myosin-binding sites and when the muscle  
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is at rest, tropmyosin blocks the myosin-binding sites, so that actin and myosin 
cannot interact. When contraction occurs, tropomyosin is displaced allowing actin 
and myosin to interact. This is caused by the Ca2+ sensitive conformational changes 
in the troponin complex (Farah and Reinach 1995). Troponin consists of three 
globular proteins located at regular intervals along the tropomyosin filaments. When 
the intracellular calcium ions concentration increases, calcium binds to troponin C 
resulting in a conformational change within troponin complex (Farah and Reinach 
1995;Tajsharghi 2008). During excitation-contraction coupling in skeletal muscle, 
calcium ions increase in the cytosol in response to depolarisation of the fibre’s 
exterior membranes. Excitation begins with the arrival of a neurotransmitter at the 
sarcolemma followed by the release of calcium ions from the sarcoplasmic reticulum 
resulting in muscle contraction (Wingertzahn and Ochs 1998). 
Skeletal muscle is intrinsically elastic and can stretch and return to its original length; 
however, actin and myosin filaments do not display long-range elasticity. Another 
integral part of the myofibril called titin, connecting myosin filaments, forms a third 
filament system of the sarcomere. This filament system spans from the Z disk to the 
M line (Wang et al. 1991) and is important for the structural integrity of the myofibril 
and the passive tension response of a stretched muscle fibre. Titin’s force repositions 
the thick filaments in the center of the sarcomere after contraction or stretches 
maintaining sarcomere length (Labeit et al. 1997).  
 
1.1.3 Skeletal muscle fibre types 
Skeletal muscle fibres are very heterogeneous in their structural and functional 
properties (Table 1-1). 
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Table 1-1 Similarities and differences between the fibre types of skeletal muscle 
 
Fibre type 
 
Type I fibres 
 
Type IIa fibres 
 
Type IIx fibres 
 
Type IIb fibres 
Contraction time Slow Moderately fast Fast Very fast 
Size of motor Small Medium Large Very large 
Resistance to fatigue High Fairly high Intermediate Low 
Activity used for Aerobic 
Long-term 
anaerobic 
Short-term 
anaerobic 
Short-term 
anaerobic 
Max. duration of use Hours <30 minutes <5 minutes <1 minute 
Power produced Low Medium High Very high 
Mitochondrial density High High Medium Low 
Capillary density High Intermediate Low Low 
Oxidative capacity High High Intermediate Low 
Glycolic capacity Low High High High 
Major storage fuel Triglycerides 
Creatine 
phosphate, 
glycogen 
Creatine 
phosphate, 
glycogen 
Creatine 
phosphate, 
glycogen 
Myosin heavy chain MYH7 MYH2 MYH1 MYH4 
 
In general, adult mammalian muscle can contain four major myosin heavy chain 
(MHC) isoforms which are functionally distinct. They present different actin-
activated ATPase actions and produce different rates of thin filament motility 
(Wells et al. 1996). Therefore, muscle fibres have been classified into two main 
types: type I (slow-twitch, oxidative) and type II (fast-twitch, glycolytic) and also into 
IIa / IIb / IIx subtypes. Type I fibres express slow MHC isoforms. These fibres are 
resistant to fatigue generating energy by oxidising fatty acids as a fuel source 
whereas type II fibres expressing fast MHC isoforms can achieve much higher 
shortening velocities, but fatigue relatively quickly when compared to type I fibres 
because they utilise anaerobic glycolytic metabolism for energy production  
(Bottinelli and Reggiani 2000;Brooks 2003). Type IIa and IIx fibres produce energy 
from fatty acid oxidation and glycolysis whilst type IIb fibres are solely glycolytic 
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(Bottinelli and Reggiani 2000). The majority of muscle beds are composed of both 
type I and type II fibres; however, the muscle composition varies according to its 
action. Exercise can influence MHC expression which consequently triggers 
switching from type IIb to type IIa and type I fibres (Jarvis et al. 1996). 
There is also type IId fibre types identified in mouse, rat and rabbit  
(Hamalainen and Pette 1993) as well as type IIc included within the type IIa fibre 
class and found in rat (about 4%) (Tasic Dimov and Dimov 2007), but they are very 
rare in human (less than 1-2%) (Billeter et al. 1980). In addition, muscle can also 
consist of “hybrid" fibres containing two MHC isoforms such as type I/IIa, IIax or IIxb 
found in both human and mouse (Bloemberg and Quadrilatero 2012; 
Smerdu et al. 1994). 
 
1.1.4 Regulators of skeletal muscle development 
Numerous environmental and hormonal factors are sensed by skeletal muscle to 
regulate proliferation and differentiation of satellite cells leading to muscle growth and 
development or atrophy. The positive signals (anabolic factors) include exercise, 
insulin-like growth factors (IGFs) and nutrients whereas negative inputs (catabolic 
factors) are derived from cytokines, glucocorticoids and myostatin (Figure 1-5). 
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Figure 1-5  A representation of genetic and environmental factors determining 
skeletal muscle size  
As a response to diverse stimuli, the protein kinase Akt plays a central role in 
integrating the anabolic and catabolic triggers by transducing growth factor and 
cytokine signals via changes in the phosphorylation of other metabolically important 
enzymes [mammalian target of rapamycin (mTOR)] and transcription factors (FoxO). 
The mTOR activates protein translation and synthesis via S6 kinase 1 (S6K1) and  
4E binding protein 1 (4EBP-1) phosphorylation to stimulate hypertrophy. In contrast, a 
decrease in Akt signalling stimulates the expression of FoxO-dependent atrophy 
related genes such as atrogin-1 and other components of the proteasome to degrade 
muscle protein and initiate muscle wasting. However, the peroxisome proliferator 
activated receptor-γ co-activator 1α (PGC-1α) protects muscle from atrophy by 
inhibiting FoxO (Frost and Lang 2007).  
 
 
The IGF-I, synthesised by skeletal myocytes and the liver, acts via an autocrine, 
paracrine and also endocrine mechanism through the IGF-insulin receptor (IGF-IR) 
which is expressed on the cell surface of skeletal muscle (Goldspink 1999). Initially, 
IGF-I inhibits differentiation and promotes myogenesis, subsequently stimulating 
differentiation of skeletal myoblasts (Adi et al. 2002;Engert et al. 1996).  
Myostatin, a member of the transforming growth factor β (TGF-β) superfamily, is an 
important regulator of muscle growth. Myostatin acts in vivo by regulating the balance 
between proliferation and differentiation of embryonic muscle progenitors.  
It promotes satellite cells terminal differentiation through the activation of p21 and 
MyoD (McCroskery et al. 2003). Loss of function of myostatin in mice and cattle 
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displays induced hyperplasia and, to a lesser extent, hypertrophy of muscle 
suggesting that myostatin negatively regulates muscle growth by inhibiting myoblast 
proliferation (Kambadur et al. 1997;Thomas et al. 2000;Zhu et al. 2000). 
There are also other factors associated with regulating myocyte development such 
as hepatocyte growth factor (HGF) and fibroblast growth factor-1 and -2 (FGF1, -2); 
they enhance muscle cells proliferation in response to muscle damage and regulate 
satellite cell activation in response to muscle injury, respectively  
(Flanagan-Steet et al. 2000;Maina et al. 1996). 
Additionally, certain endogenous steroids, including androgens such as testosterone 
in males and oestrogens in post-menopausal women on estrogen replacement 
therapy, impact upon myocyte development increasing skeletal muscle mass  
(Fink et al. 2006;Sipila and Poutamo 2003). 
 
1.1.5 Energy-supplying pathways during contraction in the skeletal muscle  
Skeletal muscle is vital to life by providing the mechanical power for locomotion, 
posture and breathing. Force in muscle is generated by the myosin “cross-bridges” 
formed by the myosin motor head interacting with specific sites on a thin actin 
filament. During this process, ATP binds to the ATPase site on the myosin motor 
head, upon which it is hydrolysed to adenosine diphosphate (ADP) and inorganic 
phosphate leading to a conformational change with actin release  
from the actin-myosin complex and the myosin filament movement along the actin 
filament (Geeves and Holmes 1999). 
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There are three sources of high-energy phosphate to keep the ATP pool in the range 
required for muscle contraction (Figure 1-6). Of greater quantitative importance for 
the ATP generation is the utilisation of creatine phosphate, also called 
phosphocreatine, stored in the muscle. Creatine phosphate contains a high-energy 
phosphate bond that can be hydrolysed to re-synthesize ATP. Skeletal muscle stores 
of creatine phosphate provide quantitatively the greatest contribution to energy 
provision in the first few seconds of high intensity exercise such as sprinting 
(Greenhaff 2001).  
 
Figure 1-6 Sources of energy for muscle contraction 
Three sources of high-energy phosphate to keep the ATP pool filled include creatine 
phosphate, glycogen and cellular respiration in the mitochondria of the fibres. 
 
In addition, ATP can be also generated through glycolysis by which glycogen and 
glucose are converted to two pyruvate molecules. During anaerobic glycolysis, 
pyruvate forms lactic acid via lactate dehydrogenase yielding only 3 ATP per 
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molecule of glycogen, but the maximum rate of glycolysis can be reached within a 
few seconds of the onset of exercise. In the presence of oxygen, pyruvate enters the 
Krebs cycle as acetyl-CoA via the pyruvate dehydrogenase complex (PDHC). In 
contrast, complete breakdown of glycogen via glycolysis, the Krebs cycle and the 
electron transfer chain yields 39 ATP per molecule of glycogen (Burton et al. 2003). 
Another energy source in the form of ATP for muscle contraction is provided by 
oxidation of blood glucose and β-oxidation of fatty acids (detailed in Section 1.1.7).  
 
1.1.6 Glucose metabolism in the skeletal muscle 
Of great importance is the role of skeletal muscle in metabolic regulation as the major 
site of glucose disposal after a meal either for storage as glycogen or its utilisation in 
energy generating pathways (Angione et al. 2011;Larsen et al. 2008). 
Glucose is an obligatory metabolic fuel used by all cells of the body, with some tissue 
such as the brain greatly dependent upon it. It is derived from three sources: 
intestinal absorption during the fed state, glycogenolysis and gluconeogenesis during 
fasting. In muscle, glucose is transported through the insulin-dependent glucose 
transporter type 4 (GLUT-4) on the cell membrane where it is irreversibly 
phosphorylated by the enzyme hexokinase to glucose-6-phosphate (G6P)  
(Whitesell et al. 2003), and then depending on requirements and hormonal signals, 
stored as glycogen or metabolised in a number of metabolic pathways (Figure 1-7). 
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Figure 1-7 Glucose sensing in the skeletal muscle  
In muscle, glucose is phosphorylated to G6P by hexokinase (HK), and then G6P is 
utilised in a variety of metabolic pathways. Abbreviations: GLUT4 (glucose transporter 
type 4), G6P (glucose-6-phosphate), TCA (tricarboxylic acid) cycle. 
 
Glycolysis is the metabolic pathway that converts glucose to the monocarboxylates 
such as pyruvate or L-lactate and is highly regulated by a number of factors including 
phosphofructokinase and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
The free energy released in this process is used to form the high-energy compounds 
ATP and reduced nicotinamide adenine dinucleotide (NADH)  
(Kockskamper et al. 2005). Lactate and pyruvate can be transported from muscle to 
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liver where they can be utilised as gluconeogenic precursors to form glycogen as 
required. Glycogenolysis involves the breakdown of glycogen to G6P, and 
subsequently G6P is hydrolysed by glucose-6-phosphatase to free glucose  
(Gerich et al. 2001). Interestingly, during fasting, muscle can decrease its glucose 
uptake using oxidised fatty acids as the main energy source and releasing alanine, 
glutamine and other amino acids that can be metabolised in gluconeogenesis for net 
glucose production by the liver (Larsen et al. 2008). Also, G6P can be converted to 
fructose-6-phosphate and then metabolised through the hexosamine pathway. The 
hexosamine pathway is a relatively minor branch of glycolysis encompassing ~3% of 
total glucose utilised. In the first step of this pathway, fructose-6-phosphate is 
converted to glucosamine-6-phosphate by the rate-limiting enzyme 
glutamine:fructose-6-phosphate amidotransferase. The end product of the 
hexosamine pathway, uridine diphosphate  N-acetylglucosamine, serves as a 
common precursor for all amino sugars used for synthesis of glycoproteins, lipids and 
proteoglycans (Schleicher and Weigert 2000). 
In addition, the pentose phosphate pathway is an alternative metabolic pathway for 
glucose breakdown that synthesises precursors for nucleotide biosynthesis and 
generates nicotinamide adenine dinucleotide phosphate reduced (NADPH). 
Depending on the cell requirements, NADPH can be utilised for anabolic reactions as 
well as maintaining cellular redox homeostasis. The pentose phosphate pathway is 
comprised of two phases: the oxidative and non-oxidative phases. The rate-limiting 
enzyme of this pathway is glucose-6-phosphate dehydrogenase (G6PDH) which 
converts G6P to 6-phosphoglucono-δ-lactone and consequently generates NADPH 
(Tsouko et al. 2014). 
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The citric acid cycle, also known as the tricarboxylic acid (TCA) cycle, or the Krebs 
cycle, is a key metabolic pathway that unifies carbohydrate, lipids and protein 
metabolism. Glycolysis supplies pyruvate that is oxidised by the mitochondrial TCA 
cycle, and the reducing equivalents are transferred through the electron transport 
chain for ATP production (Fernie et al. 2004).  
 
1.1.7  Fatty acids β-oxidation in the skeletal muscle 
Fatty acids provide highly efficient energy storage as they are stored as triglycerides 
in adipose tissue forming anhydrous fatty droplets. In the fasted state when glucose 
levels are low, lipid oxidation is the predominant metabolic activity of resting skeletal 
muscle (Kim et al. 2000). Free fatty acids are oxidised to provide energy in the form 
of ATP through the mitochondrial β-oxidation pathway. Fatty acids are transported in 
the form of acyl-CoAs across the outer mitochondrial membrane. This is a rate 
limiting step of β-oxidation dependent upon carnitine palmitoyltransferase-1 (CPT-1) 
which controls a long-chain fatty acid entry into the mitochondria forming 
acylcarnitine (Bruce et al. 2006;Dagher et al. 2001). Chemical inhibition of CPT1 by 
etomoxir promotes lipid deposition and insulin resistance in rats placed on a high-fat 
diet (Dobbins et al. 2001) whereas overexpression of CPT1 in skeletal muscle 
ameliorates high fat diet-induced insulin resistance by enhancing fatty acid oxidation 
(Bruce et al. 2009).  
Subsequently, acylcarnitine is transported across the inner mitochondrial membrane 
via carnitine translocase (CAT), and then is converted back to acyl-CoA by an 
enzyme located in the inner mitochondrial membrane, CPT2, leaving the free 
carnitine to cycle back to the cytosol. Once in the mitochondrial matrix, acyl-CoA is 
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broken down in four reactions that occur in repeating cycles involving the following 
enzymes: acyl-CoA dehydrogenase, enoyl-CoA hydratase, L-3-hydroxyacyl-CoA 
dehydrogenase and 3-ketoacyl-CoA thiolase. In each round, acyl-CoA  
is progressively shortened by two carbons producing acetyl-CoA and one molecule of 
NADH and flavin adenine dinucleotide (FADH2) respectively (Lopaschuk et al. 2010). 
Next, this acetyl-CoA enters the mitochondrial TCA cycle whereas both NADH and 
FADH2 are used by the electron transport chain to generate ATP molecules. 
 
1.1.7.1 Mitochondria in the skeletal muscle 
In metabolically active skeletal muscle, mitochondria accounts for ~5% of the fibre 
volume and are rigidly located between bundles of myofilaments (Liu et al. 2014). 
Mitochondria, called the ‘’biochemical powerhouse’’ of the cell, are highly dynamic 
organelles that undergo constant migration and morphological changes. Mitochondria 
are involved in a number of homeostatic and signaling processes such as the TCA 
cycle and β-oxidation of fatty acids (Liu et al. 2014;Patergnani et al. 2011). These 
organelles are the major site of oxidative metabolism playing critical role in ATP 
production. Mitochondria generate 36-38 of ATP molecules in the breakdown of a 
single glucose molecule by the reactions of the citrate cycle and the oxidation of the 
resulting NADH and FADH2 by the respiratory chain (Tarasov et al. 2012). 
Most mitochondria contain between one and ten copies of mitochondrial DNA 
(mtDNA) which is highly susceptible to oxidative damage mainly caused by the high 
concentration of reactive oxygen species within the mitochondrial matrix and the lack 
of DNA-protective histones. This results in strand breaks, abasic sites, base changes 
and deletions and consequently leads to malfunction of proteins synthesis and 
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altered mtDNA replication and/or transcription efficiency. The ratio of mtDNA to 
nuclear DNA is an indicator of mitochondrial biogenesis as the mitochondrial genome 
encodes most of the enzymatic subunits of the oxidative phosphorylation system 
(Phillips et al. 2014). 
 
1.2 Hormonal regulation of skeletal muscle 
Skeletal muscle is an endocrine organ producing systemic and local glucocorticoids 
(GCs). Muscle is also a target tissue for growth factors and hormones; amongst them 
are GCs and insulin. GC excess, seen in Cushing’s syndrome, leads to muscle 
atrophy and metabolic changes.  
 
1.2.1 Insulin 
The primary role of insulin is to lower blood glucose and maintain its levels within an 
optimal range for normal physiological function. Insulin is a peptide hormone 
synthesised as a preprohormone in the β-cells of islets of Langerhans in the 
pancreas and is produced and stored in the body as an inactive hexamer. Circulating 
and biologically active insulin is a monomer composed of two polypeptide chains of 
21 and 20 amino acids connected by two disulfide bridges (Sanger 1959).  
Insulin secretion is mainly regulated by plasma glucose levels; however, other stimuli 
such as amino acids can also enhance its secretion. Circulating glucose enters 
pancreatic β-cells via the glucose transporter 2. Glucose is then phosphorylated by 
the enzyme glucokinase and further metabolised in the mitochondria generating ATP. 
Elevated ATP/ADP ratio closes the ATP-dependent K+ channels on the β-cell 
membrane. Decreased efflux of potassium ions and their increased levels at the 
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inner leaflet of the membrane lead to the cell membrane depolarisation and 
consequently open the voltage-dependent calcium channels increasing calcium 
concentration in the cytosol and subsequently leading to insulin secretion. Elevated 
blood glucose levels induce insulin release from the β-cells whilst a drop in blood 
glucose levels results in reduced rate of glycolysis and insulin secretion  
(Larsen et al 2008). 
The action of insulin is mediated through the activation of cell surface receptors, 
mainly the insulin receptor (InsR) responsible for metabolic regulation but also 
insulin-like growth factor receptor (IGF-IR) involved in normal growth and 
development. The insulin signalling pathway is initiated by insulin binding to its 
receptors and their autophosphorylation on multiple tyrosine residues which lead to 
the activation of multiple signalling molecules. Insulin signalling induces glucose 
uptake and metabolism and also changes in lipid and protein metabolism  
(Larsen et al. 2008;Morgan et al. 2009).  
   
1.2.2 Glucocorticoid structure, synthesis and action 
Glucocorticoids (cortisol in humans and corticosterone in rodents) are endogenous 
steroid hormones released naturally from the adrenal cortex via stress-mediated or 
circadian activation of the hypothalamic-pituitary-adrenal axis (Section 1.2.2.3). They 
play an important role in energy homeostasis, immune response, skeletal muscle 
growth, cell proliferation and survival (Patel et al. 2014). GCs also exert critically 
important roles in muscle permissive and adaptive metabolism. They promote 
skeletal muscle atrophy by enhancing protein degradation and reducing protein 
synthesis pathways. These steroid hormones are widely used clinically for the 
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suppression of inflammation in chronic inflammatory diseases such as asthma, 
rheumatoid arthritis and autoimmune diseases.  
The predominant actions of GCs are through the glucocorticoid receptor (GR), which 
forms a heterocomplex with 2 molecules of heat shock protein-90  
(HSP90), stoichiometric amounts of heat shock protein-70 (HSP70), p23 and 
immunophilin (Pratt and Toft 1997). The GR is transferred between the cytoplasm 
and nucleus upon ligand binding. Steroid binds to GR leading to hsp-immunophilin 
complex dissociation. Subsequently, the liganded GRs rapidly dimerise and 
translocate into the nucleus where they bind to glucocorticoid response elements 
(GRE) on glucocorticoid-responsive genes resulting in modified transcription  
(Figure 1-8) (Barnes 1998).  
 
Figure 1-8 Genomic actions of glucocorticoids 
Upon steroid binding to GR in the cytoplasm, the GR dimer translocates into the 
nucleus and regulates gene transcription. 
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However, not all responses to GCs are dependent upon GR dimers binding directly 
with DNA. Other pro-inflammatory signalling pathways involve GR monomers 
tethering with DNA-bound pro-inflammatory transcription factors such as nuclear 
factor-kappa B (NF-κB) (Nixon et al. 2011). 
In addition to the genomic actions of GCs, some effects can occur within minutes of 
drug administration and are insensitive to transcriptional inhibition. These non-
genomic GC effects are mediated by membrane-bound receptors or by 
physiochemical interactions with cellular membranes (Liu et al. 2005), and their 
example is the activation of the insulin signalling factors phosphatidylinositol  
3-kinase (PI3K) and protein kinase B/akt demonstrated in human vascular 
endothetial cells (Hafezi-Moghadam et al. 2002). Recent findings suggest that  
non-genomic activity might be important in mediating the therapeutic effects when 
used in high dose to reduce side effects (Liu et al. 2005).  
Physiologically, GCs increase blood glucose and fatty acids stimulating hepatic 
gluconeogenesis and adipose tissue lipolysis in the fasting state. Though, in the fed 
state they work with insulin to promote carbohydrate and lipid storage. GCs also 
inhibit the translocation of the GLUT-4 to the cell membrane consequently leading to 
reduced level of intracellular glucose (Morgan et al. 2004). They inhibit the activity of 
lipoprotein lipase in skeletal muscle and the uptake of circulating triglyceride leading 
to dislipidemia (Whorwood et al. 2002). Overall, the action of glucocorticoids mainly 
depends on the levels of circulating GC and GR expression (Abdallah et al. 2005a). 
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1.2.2.1 Adrenal glands 
Glucocorticoids such as cortisol can be synthesised by the adrenal glands in 
response to stress (van Raalte et al. 2009). These organs are positioned above the 
kidneys and surrounded by a capsule of adipose and fibrous tissue. Each gland is 
composed of two distinct structures called the medulla and the cortex. The adrenal 
cortex constitutes 90% of the weight of the adrenal gland and is divided into three 
distinct zones: the outer zone called zona glomerulosa located beneath the capsule; 
the thickest zone, zona fasciculata, (>70% of the cortex) and the zona reticularis 
located next to the medulla (Figure 1-9). The adrenal glands have one of the highest 
blood supplies per gram of tissue, delivered to this gland by the inferior phrenic 
artery, the renal arteries and the aorta (Arlt and Stewart 2005;Rosol et al. 2001). 
 
 
Figure 1-9 The structure of adrenal glands 
The adrenal glands are located above the kidneys and are divided into two distinct 
structures: the outer adrenal cortex and the inner adrenal medulla. The cortex 
comprises three distinct zones: the glomerulosa, fasciculata and reticularis. 
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1.2.2.2 Steroidogenesis 
There are three main types of hormones produced by the adrenal cortex: 
glucocorticoids (cortisol, corticosterone), mineralocorticoids (aldosterone, 
deoxycorticosterone) and sex steroids [dehydroepiandrosterone (DHEA), 
androstenedione]. All steroid hormones are derived from the 
cyclopentanoperhydrophenanthrene structure which contains three cyclohexane 
rings and a single cyclopentane ring (Figure 1-10). Cholesterol is the precursor for all 
adrenal hormones, and it can be either generated de novo from acetyl-CoA within the 
adrenal cortex or provided from the circulation in the form of low-density lipoprotein 
(LDL) cholesterol (Arlt and Stewart 2005;Larsen et al. 2008). 
 
Figure 1-10 The cyclopentanoperhydrophenanthrene structure of adrenal 
steroids 
The letters designate the rings whereas the numbers designate the carbon atoms. 
 
There are a number of enzymes driven by biochemical pathways and involved in the 
synthesis of steroids which takes place in three different zones of the adrenal cortex 
(Figure 1-11). The initial step of steroidogenesis is the transport of intracellular 
cholesterol from the outer to inner mitochondrial membrane where it is converted to 
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pregnenolone by the P450 cholesterol side chain cleavage enzyme (P450scc). In the 
cytoplasm, 3β-hydroxysteroid dehydrogenase type II (3β-HSD) converts 
pregnenolone to progesterone which is hydroxylated to 17-OH-progesterone by 
P450c17. 17-Hydroxylation is important for glucocorticoid synthesis secreted in high 
amounts from the zona fasciculata under the control of adrenocorticotropic hormone 
(Arlt and Stewart 2005). By contrast, the zona glomerulosa is specialised for 
mineralocorticoid synthesis because of the zonal-specific expression of aldosterone 
synthase (CYP11B2, P450c18). Both zona fasciculata and zona reticularis express 
P450c17 which beside 17α-hydroxylase also possesses 17,20 lyase activity resulting 
in the production of  DHEA and androstenedione in zona reticularis. DHEA is 
coverted to DHEAS, the major product of adrenal steroidogenesis, by DHEA 
sulfotransferase (SULT2A1) (Arlt & Stewart 2005;Larsen et al. 2009). 
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Figure 1-11 Adrenal steroidogenesis 
Each zona of the adrenal cortex has distinct enzyme profile and is responsible for 
synthesis of specific steroids. 
 
In contrast to humans, rodents do not express P450c17 in the adrenal glands 
consequently lacking 17α-hydroxylase activity to produce cortisol. Therefore, the 
most abundant naturally occurring GC they generate is corticosterone  
(Košir et al. 2011). 
 
1.2.2.3 The hypothalamus-pituitary-adrenal axis 
Glucocorticoid hormones are secreted by the cortex of the adrenal gland under the 
control of the hypothalamic-pituitary-adrenal (HPA) axis (Figure 1-12)  
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(van Raalte et al. 2009). In response to stress, the hypothalamus releases 
cortocotropin-releasing hormone (CRH) into the hypophyseal portal vein. CRH 
stimulates the anterior pituitary to secrete adrenocorticotropic hormone (ACTH) into 
the circulation. Subsequently, ACTH drives the adrenal gland to secrete cortisol 
which can inhibit its own release through a classical feedback process involiving the 
negative regulation of CRH and ACTH release (Gathercole et al. 2013). 
 
 
Figure 1-12 Regulation of adrenal glucocorticoid secretion by HPA axis 
ACTH is secreted from the anterior pituitary under the influence of CRH which is 
released by the hypothalamus in response to stressors (hypoglycaemia, hypotension, 
surgery, injury etc.). Negative feedback of cortisol inhibits both CRH and ACTH 
secretion. Abbreviations: CRH (cortocotropin-releasing hormone), ACTH 
(adrenocorticotropic hormone). 
 
Corisol is secreted at a rate of 10-15 mg/dL in a pulsatile fashion with a circadian 
rhythm with different levels throughout a 24 hour cycle (highest levels on wakening 
followed by a slow decline through the day). Circulating GC levels are greater during 
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the activity period [day for diurnal species (humans) and night for nocturnal species 
(rodents)] reaching their peak levels at the beginning of the activity period 
(Gathercole et al. 2013;Larsen et al. 2008).  
 
1.2.2.4 Metabolic actions of glucocorticoids 
Physiologically, GCs are released as a part of the response to stress, inflammation, 
pain or infection. They are among the most effective medications for the treatment of 
inflammatory disease (rheumatoid arthritis), autoimmune and allergic diseases  
(Song et al. 2011). However, long exposure to GCs leads to muscle myopathy, 
osteoporosis, accumulation of visceral fat depot or metabolic disease such as insulin 
resistance and type 2 diabetes (Figure 1-13) (Gathercole et al. 2013).  
 
 
Figure 1-13 A summary of selected GC-induced pathways and GC-responsive 
tissues  
GCs have diverse actions that affect a number of tissues including liver, skeletal 
muscle and adipose tissue. Abbreviations: GC (glucocorticoid), TG (triglyceride). 
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GCs regulate numerous tissue-specific physiological processes. In liver, they 
enhance gluconeogenesis and glucose release stimulating the activity of 
gluconeogenic enzymes. GCs also control carbohydrate metabolism by increasing 
hepatic glucose output during fasting contributing to the hyperglycaemic state 
(Gathercole et al. 2013;Kraus-Friedmann 1984). In addition, GCs inhibit hepatic 
lipolysis by stimulating the production of the LDL particles and decreasing 
intrahepatic triglyceride turnover (Dolinsky et al. 2004).  
In adipose tissue, GCs regulate both adipogenesis and hypertrophy enhancing pre-
adipocyte differentiation and triglyceride (TAG) accumulation resulting in central 
obesity seen in the Cushing’s syndrome. However, GCs increase lipolysis leading to 
elevated circulating free fatty acid levels (Peckett et al. 2011). Thus, the effect of GCs 
in adipose tissue differs depending on the depot; hence, their impact on insulin 
sensitivity in adipose tissue still remains unclear. 
In skeletal muscle, GCs directly interfere with the insulin signaling cascade resulting 
in decreased insulin-mediated glucose uptake (IMGU) and glycogen synthesis 
(Peppa et al. 2010). GCs inhibit glucose uptake mainly through inhibition of GLUT4 
translocation to the membrane and glucose utilisation in skeletal muscle  
(Patel et al. 2014). Furthermore, GCs reduce skeletal muscle mass both by inhibiting 
protein synthesis and by inducing protein degradation known as steroid myopathy 
(Long et al. 2001). They decrease protein synthesis by reducing transport of amino 
acids into muscle and by inhibiting the anabolic effects of insulin and IGF1  
(Biedasek et al. 2011;Itoh et al. 2004;van Raalte et al. 2009). GC excess induces 
muscle atrophy by stimulating catabolic pathways (protein breakdown) through 
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increased expression of the two E3 ubiquitin ligases atrogin-1 and muscle ring  
finger 1 (MuRF-1) and inhibiting anabolic pathways (protein synthesis)  
(Biedasek et al. 2011;Bodine et al. 2001). Glucocorticoid-induced activation of the 
ubiquitin-proteasome-system and increased expression of the MuRF-1 and  
Antrogin-1 lead to muscle atrophy. Pharmacological use of GCs induces skeletal 
muscle catabolism which in rats, can be prevented with growth hormone or IGF-1 
treatment (Itoh et al. 2004). 
 
1.2.2.5 GC metabolism 
Once in circulation, approximately 90% of cortisol is bound to a specific 
glucocorticoid α2-globulin leaving only 10% circulating in a free form. Endogenous 
and exogenous glucocorticoids act on intracellular receptors to regulate the 
transcription of specific target genes. The GR or type 2 corticosteroid receptor is 
ubiquitously expressed throughout the body whereas the mineralocorticoid receptor 
(MR or type 1 corticosteroid receptor) is mainly localised in specific anatomical sites, 
including the kidney, distal nephron, colon and sweat glands. Pre-receptor 
metabolism of glucocorticoids determines tissue-specific sensitivity. The MR is 
protected from glucocorticoid activation by the enzyme 11β-hydroxysteroid 
dehydrogenase type 2 (11β-HSD2) that converts active cortisol to inactive cortisone 
in humans whereas GR activation can be amplified by the enzyme 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalysing the reverse reaction 
(Tomlinson et al. 2004). 
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1.2.2.6 11β-HSD and pre-receptor metabolism 
Two isoforms of the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD) have 
been characterised and cloned: 11β-HSD1 and 11β-HSD2. Their N-terminal anchor 
sequences determine both dehydrogenases orientation exclusively to the 
endoplasmic reticulum (ER) membrane (Odermatt et al. 1999). The catalytic domain 
of 11β-HSD1 is located within the lumen of the ER (Ozols 1995) whereas the 
catalytic domain of 11β-HSD2 is orientated towards the cytosol  
(Odermatt et al. 1999).  
The 11β-HSDs catalyse the convertion of hormonally active cortisol and inactive 
cortisone (Figure 1-14). 11β-HSDs belong to the short-chain 
dehydrogenases/reductases (SRDs) superfamily, also known as short-chain alcohol 
dehydrogenases. 11β-HSD1 is a predominantly NADPH-dependent isozyme acting 
mainly as a nicotinamide adenine dinucleotide phosphate (NADP+)-dependent 
dehydrogenase in the cell-free system and a NADPH-dependent oxo-reductase in 
intact cells and tissues. 11β-HSD2 is a nicotinamide adenine dinucleotide  
(NAD+)-dependent dehydrogenase (Tomlinson et al. 2004).  
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Figure 1-14 Cortisol-cortisone interconversion by the 11β-HSD enzymes 
11β-HSD1 converts hormonally active cortisol in humans and corticosterone in rodents 
to inactive cortisone and 11-dehydrocorticosterone respectively whereas 11β-HSD2 
catalyses the reverse reaction. 
 
1.2.2.6.1 11β-hydroxysteroid dehydrogenase type 2 
11β-HSD2 is a high-affinity NAD+-dependent dehydrogenase that irreversibly 
converts active cortisol to cortisone. 11β-HSD2 is expressed mainly in kidneys and 
colon. The main function of this enzyme in the kidney is to exclude cortisol from 
binding to and activating the mineralocorticoid receptor (Edwards et al. 2007). 
Inactivating mutations in the HSD11B2 gene lead to a syndrome named apparent 
mineralocorticoid excess (AME), in which GCs activate renal MR resulting in sodium 
retention, hypertension and hypokalemia. In addition, pharmacological inhibition or 
mutation of 11β-HSD2 in placenta reduces fetal growth and alters tissue maturation 
(Cottrell et al. 2013;Seckl 2004).  
 
1.2.2.6.2 11β-hydroxysteroid dehydrogenase type 1 
The HSD11B1 gene is located on chromosome 1q32.2. It was first purified from rat 
liver by Carl Monder’s group in 1988 (Lakshmi and Monder 1988). The human 
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enzyme was purified in 2002. The HSD11B1 gene is over 30 kb in length consisting 
of 6 exons and 5 introns; it encodes a 34 kDa glycosylated enzyme  
(Tomlinson et al. 2004). 
11β-HSD1 is highly expressed throughout the body in many metabolically active 
tissues such as liver, adipose tissue, skeletal muscle and brain. 11β-HSD1 is a 
bidirectional enzyme which predominantly acts as an oxo-reductase converting 
hormonally inactive cortisone in humans and 11-dehydrocorticosterone (11-DHC) in 
rodents to active cortisol and corticosterone, respectively, thereby increasing 
intracellular GCs and regulating metabolic processes including hepatic glucose 
output, cellular differentiation and energy metabolism (Hewitt et al. 2005; 
Jang et al. 2007;Lavery et al. 2007;Zielinska et al. 2011). 
 
1.3 The SR as a metabolic unit to support GC metabolsim 
The sarcoplasmic reticulum (SR) as a skeletal muscle metabolic unit compromises 
several metabolic pathways related to carbohydrate metabolism, biotransformation, 
steroid metabolism and protein processing.  
The ER/SR is a specialised three-dimensional network of endomembranes, 
comprising a complex grid of microtubules and cisternae, responsible for protein 
folding, processing and trafficking to the cell surface (Deldicque 2013). The ER 
lumen is considered to be the largest intracellular organelle constituting about 10% of 
the total cell volume (Csala et al. 2006;Patergnani et al. 2011). There are three types 
of ER including smooth ER, rough ER and the nuclear envelope. Structural diversity 
of the ER is related to the variety of its cellular functions. Additionally to the protein 
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synthesis and maturation, the ER acts as proteins transport route and a dynamic 
reservoir of calcium ions (Patergnani et al. 2011).  
The SR of skeletal muscle resembles the smooth ER found in other cell types. 
Importantly, the SR is the primary site of intracellular calcium storage, release and 
uptake in skeletal muscle (Rossi and Dirksen 2006). It controls the contraction-
relaxation cycle of muscle by regulation of calcium ions in the cytosol (Section 1.1.2) 
(Xia et al. 2003).  
Skeletal muscle can generate glucose from G6P through the SR luminal glucose-6-
phosphatase-β (G6Pase-β) at the terminal step of glycogenolysis. This step requires 
transfer of G6P by the G6P transporter (G6PT) from cytosol to the lumen of the SR 
where G6Pase-β hydrolyses G6P to glucose and inorganic phosphate  
(Chen et al. 2010). G6P can be also metabolised by an enzyme, 
hexose-6-phosphate dehydrogenase (H6PDH), to produce 6-phosphogluconate 
(6PGL) and NADPH used by 11β-HSD1 for glucocorticoid activation  
(Section 1.2.2.6.2) (Figure 1-15) (Lavery et al. 2008b). 
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Figure 1-15 G6P metabolism in the SR lumen 
G6P can be utilised in a number of pathways (A; detailed in Section 1.1.6); however, 
G6P can be also transported by G6PT from cytosol to the ER/SR lumen where is 
metabolised by H6PDH to produce NADPH utilised by 11β-HSD1 for GC activation (B). 
 
1.3.1 Glucose-6-phosphate transporter (G6PT, Slc37a4) 
G6P concentration in ER lumen is essential for determining 11β-HSD1 oxo-reductase 
activity (Walker et al. 2007). The primary function of G6PT is translocation of G6P 
from the cytoplasm to the lumen of the ER (Agrawal et al. 2012). G6P is then 
hydrolysed to glucose and inorganic phosphate by either G6Pase-α (restricted to 
liver, kidney and intestine) or G6Pase-β which is expressed ubiquitously  
(Shieh et al. 2003). A previous study showed that the concerted action of both G6PT 
and G6Pase-α is required to maintain glucose homeostasis between meals whereas 
the synchronised action of G6PT and G6Pase-β is important for normal neutrophil 
function (Pan et al. 2009). Furthermore, G6P transported by G6PT to the ER/SR can 
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also be utilised by enzyme H6PDH to produce 6PGL with the concomitant generation 
of NADPH, thereby maintaining adequate levels of reductive cofactors in the 
oxidising environment for 11β-HSD1 mediated glucocorticoid activation  
(Lavery et al. 2008b). 
Human G6PT is a single copy gene consisting of 9 exons of approximately 5.3 kb of 
DNA located on chromosome 11q23. Human G6PT is a 10-transmembrane domain 
protein located in the ER lumen (Chen et al. 2003a).  
Importantly, glycogen storage disease type I (GSD-I) is a group of autosomal 
recessive disorders caused by a deficiency in the enzyme G6Pase (GSD-Ia) or G6PT 
(GSD-Ib) (Chen et al. 2002). Together, G6PT and G6Pase maintain glucose 
homeostasis. Because their activities are co-dependent, both GSD-Ia and GSD-Ib 
patients manifest the symptoms of failed G6P hydrolysis such as growth retardation, 
hypoglycaemia, hepatomegaly, nephromegaly, hyperlipidemia and lactic academia 
(Chen et al. 2003b;Shieh et al. 2003). In addition, GSD-Ib patients present the 
symptoms of neutropenia and myeloid dysfunctions (Chen et al. 2003b). Mutations in 
G6PC (GSD-Ia) cause approximately 80% of GSD-I whereas mutations 
in Slc37a4 (GSD-Ib) lead to 20% of GSD-I (Bali et al. 1993). 
 
1.3.2 H6PDH and muscle function 
H6PDH is a bifunctional enzyme that catalyses the first two steps of an ER-specific 
pentose phosphate pathway generating the cofactor, NADPH, for 11β-HSD1 
promoting its oxo-reductase activity. H6PDH is a free-floating enzyme within the ER 
lumen whereas 11β-HSD1 is bound to the inner ER membrane  
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(Odermatt et al. 2001). H6PDH regulates the direction of endogenous 11β-HSD1 
enzyme activity within the ER/SR lumen (Lavery et al. 2008b).  
H6PDH was initially purified from rabbit liver microsomes and subsequently the 
human H6PDH cDNA and gene were cloned and identified (Mason et al. 1999). 
Sequence analyses indicate that H6PDH is biochemically distinct from its cytosolic 
homolog, G6PDH (Hewitt et al. 2005; White et al. 2007). Similarities and differences 
between both enzymes are summarised in the Table 1-2 (Senesi et al. 2010). 
 
Table 1-2 Comparison of G6PDH to H6PDH 
 
Characterisation G6PDH H6PDH 
Chromosome 
location 
Xq28 1p36 
Sequence length 515 AA 791 AA 
Catalysed 
reaction 
D-G6P + NADP+= D-
glucono-1,5-lactone-6-
phosphate + NADPH 
D-G6P + NAD(P)+ + H2O= 6-
phospho-D-gluconate + 
NAD(P)H 
Cofactors NADP+ NAD(P)+, deoxy NADP+ 
Substrates G6P 
G6P, hexose-6-phosphates, 
glucose-6-sulfate, glucose 
Intracellular 
location 
Cytosol, soluble ER, soluble 
Interactions Homodimer or homotetramer 
Homodimer, association to 
11β-HSD1 
Involvement in 
pathology 
Chronic non-spherocytic 
hemolytic anemia 
Apparent cortisone 
reductase deficiency, 
skeletal myopathy 
 
To investigate the role of H6PDH in regulating 11β-HSD1 activity and GC 
metabolism, H6PDH global knockout (H6PDHKO) mice were previously generated. 
Inactivation of murine H6PD gene changes the direction of 11β-HSD1, only 
dehydrogenase activity was detectable in a variety of H6PDHKO tissues. 
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Additionally, urine analysis from H6PDHKO mice revealed the presence of mostly 
metabolites of 11-DHC. These findings confirm that H6PDH plays an essential role in 
the regulation of NADPH-dependent oxo-reductase activity of 11β-HSD1  
(Lavery et al. 2006). 
 
1.3.2.1 NADPH/NADP+ redox status in the SR 
H6PDH is a housekeeping enzyme, and within the SR utilises G6P and NADP+ to 
generate reducing NADPH for several ER reductases including 11β-HSD1. H6PDH 
may act as a metabolic sensor by connecting intermediary metabolism to hormonal 
signalling (Banhegyi et al. 2009). Changes in an NADPH/NADP+ ratio in the SR 
might cause disruption in the thiol-disulfide redox leading to incorrect protein folding 
and activation of the unfolded protein response (UPR) pathway as a compensatory 
mechanism and consequently resulting in myopathy development  
(Rogoff et al. 2010). Previous findings show that cortisone reduction by 11β-HSD1 is 
driven by the luminal generation of NADPH by H6PDH and is independent of 
cytosolic NADPH resources (Csala et al. 2006). Therefore, H6PDH activity relies on 
the G6P transport across the ER membrane by G6PT (Zielinska et al. 2011). 
 
1.3.2.2 NADH/NAD+ redox status in the cytosol 
Interestingly, the cytosolic NADH/NAD+ redox is essential for initiation of muscle 
contraction as it triggers release of intracellular calcium ions from the SR by the 
calcium release channels or ryanodine receptors (RyR). Cytosolic NADH/NAD+ levels 
are regulated by GAPDH which is associated with the SR membrane. Therefore, 
changes in activity of this enzyme might lead to more significant changes of local 
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NADH/NAD+ levels in close proximity to SR bound proteins (such as the RyR  
and SERCA) (Zima et al. 2003). The ratio of NADH/NAD+ varies as a response to 
changes in metabolism and indicates the metabolic state of a cell or tissue, for 
instance, during ischemia cytosolic NADH/NAD+ ratio increases up to 30 times  
(Park et al. 1998). 
 
1.3.2.3 NAD+ metabolism  
The role NAD+ fulfils in muscle energy signalling and homeostasis, and its ability to 
stimulate mitochondrial function, has recently risen to prominence. NAD+ is an 
enzyme co-factor central to metabolism and essential for life in all organisms and 
importantly, fundamental to skeletal muscle metabolism. It functions both as a  
co-enzyme for oxidoreductases and as a source of ADP-ribosyl groups for the 
sirtuins (SIRT) family of protein deactylases which can signal to increase 
mitochondrial metabolism and insulin sensitivity in skeletal muscle playing an 
important role in life span extension (Bieganowski and Brenner 2004; 
Tempel et al. 2007). Among seven members of the sirtuin family, SIRT1 and SIRT3 
are of particular interest with regard to skeletal muscle metabolism following the 
discovery that they positively regulate the PGC-1α, a potent transcriptional  
co-activator of mitochondrial biogenesis. SIRT1 is involved in the process of glucose 
metabolism and insulin secretion. Down-regulation of SIRT1 protein levels under 
insulin-resistant conditions in C2C12 myotubes leads to insulin resistance  
(Sun et al. 2007) whereas SIRT3 is localised primarily in mitochondria and is 
associated with ageing by regulating mitochondrial function (Jing et al. 2011). As a 
substrate for SIRT1/3, NAD+ is rapidly consumed; thus, there is a necessity to 
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generate new NAD+ or re-synthesise NAD+ from by-products of the NAD+-
degradation reaction.  
NAD+ can be de novo synthesised from tryptophan taken up from the diet or in the 
Preiss-Handler pathway by utilising the vitamin precursor of NAD+, nicotinic acid (Na) 
(Houtkooper et al. 2010). Na is generally acquired from the diet or from the hydrolysis 
of nicotinamide (NAM), whereas NAM is the breakdown product of NAD+. Both Na 
and NAM are first converted to their mononucleotide forms: nicotinic acid 
mononucleotide (NaMN) or nicotinamide mononucleotide (NMN), and then the 
enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT) produces the 
nicotinic acid adenine dinucleotide (NaAD+) or NAD+ respectively. Finally, NaAD+ is 
converted to NAD+ by the enzyme NAD+ synthetase (Khan et al. 2007). In cytosol, 
NAD+ can be phosphorylated by NAD+ kinase to NADP+ which then can be further 
reduced to NADH or NADPH in the pentose phosphate pathway (Figure 1-16) 
(Outten and Culotta 2003). 
 
Figure 1-16 Schematic representation of NAD+ and NADP+ conversion  
Because cellular NAD+ is consumed in numerous pathways, its replenishment is critical 
to preserving signalling competency and supporting NAD(P)(H)-dependent reactions.  
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1.4 In vivo genetic manipulations of ER/SR genes 
1.4.1 11β-HSD1 mouse models 
11β-HSD1 animal models have highlighted the critical role of 11β-HSD1 in the 
regulation of metabolic phenotype in different tissues as well as its impact on global 
metabolic phenotype.  
Global knockout of 11β-HSD1 in mice has a beneficial metabolic (cardioprotective) 
phenotype. 11β-HSD1 mice are protected from the metabolic consequences of 
obesity having improved glucose tolerance, increased insulin sensitivity, 
“cardioprotective” high density lipoprotein (HDL)-cholesterol level and lower plasma 
triglyceride (Kotelevtsev et al. 1997a). 11β-HSD1 KO mice are also protected from 
type 2 diabetes while on a high fat diet (Morton et al. 2004).  
Most recent research has examined the insulin sensitivity in 11β-HSD1KO mice 
focussing on the liver and adipose tissue considering 11β-HSD1 inhibitors  
(Section 1.4.1.1) as attractive targets for a number of disorders including type 2 
diabetes, insulin resistance and associated cardiovascular disease. 
Interestingly, mice overexpressing 11β-HSD1 in adipose tissue develop visceral 
obesity, insulin resistance, hypertension and dyslipidemia  
(Masuzaki et al. 2001;Masuzaki et al. 2003). In addition, liver-specific overexpression 
of 11β-HSD1 leads to insulin resistance and hypertension, but not obesity  
(Paterson et al. 2004). Circulating corticosterone levels were not increased in  
liver-specific 11β-HSD1KO model indicating a minor contribution of liver 11β-HSD1 to 
the urinary steroid phenotype observed in the 11β-HSD1KOs and highly suggesting 
the importance of other tissues.  
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Although it is clear that 11β-HSD1 has a critical role to play in governing GC 
availability, its metabolic role in skeletal muscle metabolism and contribution to global 
homeostasis have not yet been explored. 
 
1.4.1.1 Therapeutic inhibition of 11β-HSD1  
The pharmacological inhibition of 11β-HSD1 is to great interest of many 
pharmaceutical companies. 11β-HSD1 has become an attractive therapeutic target 
for many years; therefore, the manipulation of tissue levels of glucocorticoids through 
targeted inhibition of cortisol metabolic pathways has been widely investigated.  
Previously, human studies using the non-specific 11β-HSD inhibitor, carbenoxolone, 
have shown that this compound improved whole body insulin sensitivity in healthy 
individuals whereas in patients with type 2 diabetes, it reduced hepatic glucose 
production rate. Carbenoxolone has a poor selectivity for 11β-HSD1 as it also inhibits 
11β-HSD2 resulting in cortisol-dependent mineralocorticoid excess and hypertension 
(Andrews et al. 2003;Latif et al. 2005;Walker et al. 1995). Thus, selective 11β-HSD1 
inhibitors have now been developed by a number of pharmaceutical companies.  
The first selective inhibitor to be described was a benzene sulphonamide, BVT2733, 
which has a >200-fold selectivity for inhibiting 11β-HSD1 (IC50 96nM) compared to 
11β-HSD2 (Barf et al. 2002). When administrated to rodents, this compound reduced 
fasting blood glucose and insulin levels, lowered free fatty acids, cholesterol and 
TAG as well as decreased total body weight (Alberts et al. 2003). The BVT2733 is 
highly effective at inhibiting rodent 11β-HSD1; however, it is less effective at 
inhibiting the human isozyme (IC50 of 3341nM) (Barf et al. 2002). 
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In addition, the Merc inhibitor 544, an adamantyl triazole compound, has been tested 
in several rodent models. It lowered fasting glucose, TAG, insulin and cholesterol 
when administrated to diet-induced obese mice for 11 days. It also reduced the 
plaque formation in mice with targeted deletion of apolipoprotein E suggesting its 
potential beneficial application in reducing cardiovascular disease (CVD) progression 
(Hermanowski-Vosatka et al. 2005). 
Interestingly, another selective 11β-HSD1 inhibitor developed by Merc, Compound A, 
decreased hepatic steotosis in diet-induced obese rats (Berthiaume et al. 2009) 
In the context of animal studies, clinical studies targeting 11β-HSD1 inhibition in man 
are of great importance for treatment of metabolic disease such as insulin resistance, 
obesity and type 2 diabetes. Recently, the Incyte selective 11β-HSD1 inhibitor, 
INCB013739, was administered to patients with type 2 diabetes (twice a day for 2 
weeks) and completely inhibited cortisone to cortisol conversion resulting in reduced 
fasting glucose, total and LDL cholesterol. In addition, this compound was 
administrated in combination with metformin in patients with type 2 diabetes. After 
the 12 week trial with both drugs, the INCB13739 treatment group had reduced 
HbA1c and total cholesterol levels when compared to the metformin alone 
suggesting beneficial effects of this compound on both carbohydrate and lipid 
metabolism (http://www.clinicaltrials.gov/ct2/show/NCT00398619). Data from clinical 
studies on selective 11β-HSD1 inhibitors which can be applied in the treatments of 
human metabolic disease are still continuing to emerge.  
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1.4.2 H6PDH global knockout (H6PDHKO) 
To determine the role of H6PDH in regulating 11β-HSD1 and GC metabolism, 
H6PDHKO mice were generated by homologous recombination in mouse embryonic 
stem cells to replace exons 2 and 3 with a neomycin resistance cassette. This study 
confirmed that H6PDH is crucial for the regulation of 11β-HSD1 oxo-reductase 
activity which is dependent on the supply of NADPH cofactor. It has been shown that 
H6PDHKO mice have a switch in 11β-HSD1 activity from oxo-reductase to 
dehydrogenase (Lavery et al. 2008b). There are a number of features in different 
tissues associated with H6PDH deficiency (Figure 1-17) (Zielinska et al. 2011).  
 
 
 
Figure 1-17 Major features present in mice tissue and system with H6PDH 
deficiency 
In H6PDHKO mice, H6PDH does not metabolise G6P that results in no NADPH 
production. Therefore, 11β-HSD1 switches its activity to dehydrogenase inactivating 
GCs. A number of tissues and systems are affected including metabolism and liver, 
HPA axis, muscle and adipose tissue (Zielinska et al. 2011). 
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Previous work has shown that H6PDHKO mice display reduced skeletal muscle 
mass and locomotor activity with fasting hypoglycaemia and increased insulin 
sensitivity. H6PDHKO mice develop severe muscle myopathy characterised by the 
occurrence of large membranous vacuoles and the triad junction abnormalities 
(Figure 1-18) (Lavery et al. 2008b). Affected muscle indicates defects in structure 
and function of the SR with dysregulated proteins involved in calcium metabolism 
such as the ER/SR calcium ATPase (SERCA), calreticulin, and calsequestrin. In 
addition, microarray analysis identified a large set of differentially expressed genes 
enriched for networks of the ER stress and the UPR pathways, predominantly in fast-
twitch muscles with the slow-twitch muscle being relatively resistant  
(Lavery et al. 2008b). Muscle myopathy is also associated with the switching of type 
II to type I muscle fibres and elevated glycogen accumulation in skeletal muscle. 
However, underlying mechanism of the muscle myopathy is still not fully understood 
and need to be further elucidated. 
 
 
Figure 1-18 Histological defects in skeletal muscle of H6PDHKO mice 
Periodic acid-Schiff-stained gastrocnemius sections comparing KO with WT muscles 
show the presence of vacuoles and increase in glycogen content in some KO fibres. 
The reference bar is 80 µM (Lavery et al. 2008b). 
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1.4.2.1 ER stress and the unfolded protein response pathway 
A number of factors leading to impaired ER homeostasis such as glucose 
deprivation, disturbances in calcium and redox regulation as well as viral infection 
can result in ER stress and consequently in activation of the UPR pathway 
(Deldicque et al. 2012). The UPR is a signaling pathway that protects the cellular 
integrity by restoring ER folding capacity, initiating protein translation and preventing 
accumulation of unfolded and misfolded proteins (Deldicque 2013; 
Schroder and Kaufman 2005). The UPR mechanism involves the activation of three 
ER resident transmembrane proteins: the inositol requiring enzyme 1 (IRE1), 
activating transcription factor-6 (ATF6) and protein kinase R (PKR)-like ER protein 
kinase (PERK). These stress transducers consist of an ER-luminal part and a 
cytoplasmic part that sense the protein folding status in the ER and transmit this 
information across the ER membrane to the cytosol. They are associated with the 
chaperone binding immunoglobulin protein (BiP) and upon unfolded/misfolded 
proteins accumulation, they disassociate from BiP, consequently leading to their 
activation. In the chronic state of ER stress, inflammatory responses are activated 
mainly by Jun NH2-terminal kinase (JNK) and nuclear factor-kappa B (NF-κB). 
However, uncontrolled and excessive ER stress leads to apoptosis and cell death 
through the intrinsic and extrinsic pathways. The intrinsic pathway responds to 
intracellular insults such as DNA damage whereas extrinsic pathway is triggered by 
self-association of cell surface receptors, recruitment of caspases and attenuation of 
a caspase cascade (Deldicque 2013;Ron and Walter 2007). 
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1.4.2.2  ER stress in the skeletal muscle 
ER stress is involved in the pathology of various metabolic diseases including 
obesity, insulin resistance and diabetes. In addition, ER stress is associated with 
muscle myopathies such as myotonic dystrophy type 1 (Botta et al. 2013; 
Ikezoe et al. 2007), dysferlin-deficient muscular dystrophy (Ikezoe et al. 2003) and 
myositis (Nagaraju et al. 2005). To date, a number of studies have examined the 
UPR activation in skeletal muscle. Both ER stress and UPR induction were observed 
in skeletal muscle in high-fat-fed mice, in palmitic acid-treated C2C12 muscle cells 
and also in humans after extreme endurance exercise (Rayavarapu et al. 2012). ER 
stress contributes to muscle myopathy development directly by promoting cell death 
or indirectly by inhibiting the mammalian target of rapamycin complex 1 (mTORC1) 
pathway. The mTORC1 pathway positively regulates cell growth and proliferation and 
by promoting a number of anabolic processes such as biosynthesis of lipids and 
proteins and reducing catabolic processes for instance autophagy. The mTORC1 
inhibition as a consequence of ER stress, generates a state of anabolic resistance 
and therefore leads to decreased muscle mass (Figure 1-19) (Deldicque 2013; 
Laplante and Sabatini 2009). 
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Figure 1-19 Schematic model for the involvement of ER stress in the muscle 
mass reduction 
A number of factors lead to ER stress which can promote cell death or inhibition of 
mTORC1 consequently reducing muscle mass. 
 
1.4.3 11β-HSD1/H6PDH global double knockout  
In an effort to delineate further the roles that H6PDH and 11β-HSD1 play in 
metabolism and muscle function, a H6PDH/11β-HSD1 double KO (DKO) mouse 
model has been developed in which dehydrogenase activity of 11β-HSD1 seen in the 
H6PDHKO mouse is negated (Semjonous et al. 2011). It has been shown that DKO 
mouse model is a phenocopy of the salient features of the myodegeneration seen in 
the H6PDHKO mice displaying reduced body mass, muscle atrophy and vacuolation 
of type II fibre rich muscle, maintained fasting hypoglycaemia, increased muscle 
Chapter 1                                                                                                                  General Introduction 
49 
 
glycogen deposition and elevated expression of UPR genes  
(Lavery et al. 2008b;Semjonous et al. 2011). Effectively, the DKO model returns GC 
metabolism, GC sensitivity and the HPA axis set point to levels seen in the  
11β-HSD1KO mouse (Semjonous et al. 2011). Because 11β-HSD1KO mice have no 
reported skeletal muscle phenotype (Kotelevtsev et al. 1997b), this suggests that the 
mechanism eliciting myopathy in both H6PDHKO and DKO mice is 11β-HSD1 and 
GC independent (Semjonous et al. 2011). Consequently, this study has identified a 
novel role for H6PDH in muscle homeostasis through maintaining the NADPH/NADP+ 
redox environment within the SR lumen and highlighting the importance of the 
G6PT/H6PDH pathway for G6P disposal in the SR. 
 
1.4.4 H6PDH overexpression in adipose tissue 
A mouse model overexpressing H6PDH under the control of the enhancer-promoter 
region of the adipocyte fatty acid-binding protein (aP2) gene (aP2/H6PDH mice) were 
previously generated in order to determine the role of adipose H6PDH  
in the pre-receptor modulation of 11β-HSD1 and metabolic phenotypes.  
The aP2-H6PDH mice have elevated 11β-HSD1 expression and enzyme activity 
correlated with increased H6PDH expression in adipose tissue (Wang et al. 2014). 
Additionally, the aP2-H6PDH mice demonstrate fasting hyperglycaemia and glucose 
intolerance along with elevated levels of the fasting plasma insulin and free fatty acid 
(FFA) suggesting that these mice exhibit features of the modest metabolic syndrome 
and insulin resistance due to increased adipose corticosterone production 
(Wang et al. 2014). 
Chapter 1                                                                                                                  General Introduction 
50 
 
Interestingly, increased mRNA levels of 11β-HSD1 and H6PDH were found in 
visceral and subcutaneous adipose tissues from patients with type 2 diabetes. This 
leads to elevated local cortisol activation and induction of abdominal adipose  
11β-HSD1 activity and might contribute to the development of type 2 diabetes 
mellitus (T2DM) (Uckaya et al. 2008). Therefore, it suggests that H6PDH could play 
an important role in the pathogenesis of metabolic syndrome and T2DM. 
 
1.5 Genetic defects in H6PD and HSD11B1 
Mutations in the H6PD gene (encoding H6PDH) cause apparent cortisone reductase 
deficiency (ACRD) whereas in the HSD11B1 gene (encoding 11β-HSD1) cause 
‘’true’’ CRD. Both CRD and ACRD are characterised by the failure to produce active 
glucocorticoid, cortisol, from inactive cortisone resulting in the activation of HPA axis 
and ACTH-mediated adrenal glucocorticoid and androgen secretion (Figure 1-20).  
 
Figure 1-20 Biochemical scenario in CRD/ACRD 
Mutations in 11β-HSD1 and H6PDH lead to elevated cortisol to cortisone conversion 
resulting in decreased cortisol feedback to the HPA axis and subsequently increased 
cortisol levels. Thus, increase androgen production by the adrenal glands. Circulating 
cortisol (F) levels remain normal due to a balance between elevated F metabolism and 
its increased secretion (Draper and Stewart 2005). 
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To date, approximately 14 cases with a spectrum of biochemical and clinical 
syndrome consistent with ACRD or CRD have been reported in the literature. 
Affected adult females present with polycystic ovary syndrome (PCOS)-like 
phenotype whereas children with premature adrenarche including pubarche. Urinary 
steroid analysis indicate increase of cortisone metabolites [tetrahydrocortisone 
(THE)] relative to cortisol metabolites [tetrahydrocortisol (THF+5α-THF)] together with 
a decrease in 5α/5β tetrahydrocortisol demonstrating impaired 11β-HSD1 activity 
(Lavery et al. 2008a;Lavery et al. 2013;Lawson et al. 2011). In the ER lumen, H6PDH 
maintains a NADPH/NADP+ ratio for 11β-HSD1 oxo-reductase activity. Mutations in 
the HSD11B1 gene lead to CRD and a loss of cortisol regeneration with elevations in 
cortisone metabolites and secondary activation of the HPA axis whereas mutations in 
H6PD cause ACRD with the loss of 11β-HSD1 oxo-reductase activity, but a gain of 
dehydrogenase activity and compensatory HPA axis activation seen in H6PDHKO 
mice (Lavery et al. 2008b;Lavery et al. 2013). 
 
1.6 Metabolic disease and muscle 
1.6.1 Type 2 diabetes  
Type 2 diabetes mellitus is an endocrine disorder characterised by increased plasma 
glucose levels caused by peripheral insulin resistance (Larsen et al. 2008). T2DM is 
a progressive condition resulting from a variety of genetic and environmental factors 
which can affect both insulin secretion and action. According to the World Health 
Organisation (WHO), more than 220 million people worldwide are diagnosed with 
diabetes, and it is estimated that this number will increase up to 366 million by 2030 
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(Wild et al. 2004), mainly due to ageing population, rapidly rising obesity and physical 
inactivity (Froguel and Velho 2001). 
Insulin secretion from the pancreas reduces glucose output by the liver, increases 
glucose uptake by skeletal muscle and suppresses fatty acid release from fat tissue. 
Patients with T2DM have impaired fasting glucose and elevated glucose production 
(Nielsen et al. 2000). This increase occurs in the presence of hyperinsulinaemia; 
therefore, hepatic insulin resistance is the driving force of hyperglycaemia in T2DM. 
A number of factors contribute to the pathogenesis of type 2 diabetes affecting both 
insulin secretion and insulin action. Decreased insulin secretion will reduce insulin 
signalling in its target tissues. Insulin resistance pathways have a negative effect on 
insulin action in adipose tissue, liver and skeletal muscle leading to increased 
circulating fatty acids and the hyperglycaemia of diabetes. Consequently, the raised 
concentrations of glucose and fatty acids in the bloodstream worsen both insulin 
secretion and insulin resistance (Figure 1-21) (Girard 2006;Rizza 2010). 
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Figure 1-21 Pathophysiology of hyperglycaemia and elevated insulin resistance 
associated with T2DM 
 
Diabetes increases the risk of CVD (50% of people with diabetes die of heart attack 
and stroke), blindness and kidney failure. Furthermore, diabetes is associated with a 
significantly increased risk of death compared to healthy people. 
 
1.6.2 Skeletal muscle insulin resistance and the metabolic syndrome 
Skeletal muscle as an endocrine tissue plays an important role in the pathogenesis of 
the metabolic syndrome. Previous studies have shown that reversing skeletal muscle 
insulin resistance might be a promising way to prevent the development of 
atherogenic dyslipidemia and non-alcoholic fatty liver disease associated with the 
metabolic syndrome (Jornayvaz et al. 2010). 
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The metabolic syndrome (Syndrome X; Insulin resistance syndrome) is a multiplex of 
interrelated risk factors that occur together and increase the risk of CVD, stroke and 
T2DM. The metabolic syndrome is associated with abdominal obesity, impaired 
fasting glucose, hypertension, dyslipidemia, low plasma HDL and elevated serum 
uric acid concentration (Larsen et al. 2008). In 1988, Reaven postulated that people 
with insulin resistance and hyperinsulinaemia are more likely to have hypertension, 
hyperlipidemia and diabetes which are the main cause of CVD (Kahn et al. 2005). 
However, over the years a number of organisations have published their definition of 
the “metabolic syndrome” and its underlying pathogenesis (Table 1-3). 
 
Table 1-3 Criteria for clinical diagnosis of metabolic syndrome 
Abbreviations: WHO (World Health Organisation), ATP III (Third Report for the National 
Cholesterol Education Program’s Adult Treatment Panel), AHA/NHLBI (American Heart 
Association/National Heart, Lung, and Blood Institute), BMI (body mass index), IGT 
(impaired glucose tolerance), IFG (impaired fasting glucose), T2DM (type 2 diabetes 
mellitus). 
 
CLINICAL MEASURE WHO ATP III AHA/NHLBI 
Abdominal obesity 
Waist to hip ratio: 
˃0.9 (men) 
˃0.85 (women) 
BMI˃30 kg/m2  
≥102 cm  (m) 
≥88 cm (w) 
≥102 cm  (m) 
≥88 cm (w) 
 
Fasting glucose 
 
IGT, IFG, T2DM, 
Insulin resistance 
≥100 mg/dL ≥100 mg/dL 
Blood pressure ≥140/90 mmHg ≥130/85 mmHg ≥130/85 mmHg 
Low HDL cholesterol 
˂35 mg/d L (m) 
˂39 mg/dL (w) 
˂40 mg/dL (m) 
˂50 mg/dL (w) 
<40 mg/dL (m) 
<50 mg/dL (w) 
Triglycerides ≥1.7 mmol/L ≥1.7 mmol/L ≥1.7 mmol/L 
 
Microalbumineria 
 
Urinary albumin 
excretion rate 
˃20 µg/min 
albumin:creatinine 
ratio 30 mg/g 
  
Chapter 1                                                                                                                  General Introduction 
55 
 
The first definition of the metabolic syndrome was proposed in 1998 by the WHO. 
According to WHO, a subject can be diagnosed with the metabolic syndrome if 
glucose intolerance, impaired glucose tolerance (IGT) or diabetes and/or insulin 
resistance appear together with two or more of the listed criteria whereas the Third 
Report for the National Cholesterol Education Program’s Adult Treatment Panel 
(ATPIII) needs three or more of the five risk factors (Grundy et al. 2005). The 
presence of any 3 of 5 risk factors constitutes a diagnosis of metabolic syndrome for 
American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) 
(Alberti et al. 2009). 
The majority of people diagnosed with the metabolic syndrome are insulin resistant. 
Insulin resistance is characterised by the presence of an impaired biologic response 
to either endogenously secreted or exogenously administrated insulin. Insulin 
resistance enhances the risk of the metabolic syndrome sufferers becoming type 2 
diabetic which leads to increased risk factors for CVD and can cause hypertension, 
dyslipidemia, impaired glucose tolerance and blood vessel endothelial dysfunction 
(Reaven 1988;Ruderman et al. 2013). 
 
1.6.2.1 Mitochondrial dysfunction in skeletal muscle 
Skeletal muscle insulin resistance is a key contributor to the pathophysiology of 
T2DM. Recent studies have shown that insulin resistance, in a number of conditions 
such as T2DM and ageing as well as in offspring of T2DM, is associated with 
impaired mitochondrial oxidation in muscle (Befroy et al. 2007).  
Previous studies of insulin-resistant offspring of T2DM patients have demonstrated 
increased plasma fatty acid concentrations (Perseghin et al. 1997) and elevated 
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intramyocellular lipid (Jacob et al. 1999;Perseghin et al. 1999) suggesting 
dysregulation of lipid metabolism in this cohort of subjects. Other studies have 
revealed an increase of approximately 80% in the intramyocellular lipid content 
correlated with reduced synthesis of mitochondrial ATP by approximately 30% in the 
muscle of lean, insulin-resistant offspring of T2DM patients (Petersen et al. 2004). In 
this study, the insulin-stimulated glucose uptake was also approximately 60% lower 
in the insulin-resistant cohort of subjects. These findings indicate a potentially 
important role for mitochondrial dysfunction in muscle in the pathogenesis of type 2 
diabetes. In addition, it has been shown that decreased mitochondrial density, 
determined by electron microscopy, is associated with impaired insulin signaling 
(Morino et al. 2005).  
 
1.6.3 GCs, atrophy and insulin resistance in the skeletal muscle 
1.6.3.1 Glucocorticoids and skeletal muscle atrophy 
Skeletal muscle atrophy is characterised by a decrease in muscle fibres size and is 
often associated with an increase in circulating GC levels (Schakman et al. 2013). 
Glucocorticoids catabolic effects on inducing protein breakdown, in particular through 
the ubiquitin- proteasome and lysosomal systems (Schakman et al. 2008) and 
reducing protein synthesis play a major role in the activation of muscle proteolysis. 
Muscle wasting process is partly attenuated by suppression of the IRS1-associated 
PI3K/Akt pathway (Zheng et al. 2010) leading to dephosphorylation and activation of 
the forkhead family of transcription factors (e.g. FOXO1) as well as inhibition of 
mTOR pathway (Schakman et al. 2013) resulting in increased atrogin-1 transcription 
and consequently accelerated protein breakdown (Sandri et al. 2004). However,  
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it was shown previously that endogenous GCs activate the GR which competes with 
IRS1 for PI3K; therefore, leading to muscle cell catabolism (Hu et al. 2009).  
The GC-induced muscle atrophy is also triggered by induction of muscle-specific E3 
ubiquitin-ligase expression called atrogin-1 and MuRF-1. The atrogin-1 gene 
transcription is regulated by FOXO whereas MuRF1 by FOXO (indirect transcriptional 
activation) and GR itself (Waddell et al. 2008). Deletion of atrogin-1 or MuRF1 in 
mice results in significant muscle mass loss associated with denervation 
(Bodine et al. 2001). However, when these animals are exposed to GC excess, 
muscle atrophy is increased only in MuRF1 KO mice. The actions of GCs upon 
MuRF1 expression are via the association between activated GR and GRE located 
within the MuRF1 promoter (Waddell et al. 2008). 
 
1.6.3.2 Glucocorticoids and insulin resistance 
Type 2 diabetes and accumulation of intramyocellular lipids are associated with 
insulin resistance in both humans (Krssak et al. 1999) and rats 
(Korach-Andre et al. 2005). In addition, prolonged exposure to glucocorticoids has 
been linked with the development of insulin resistance inducing accumulation of lipids 
and their metabolites within the skeletal muscle. A previous study has shown that in 
high fat diet-fed mice treated with the synthetic glucocorticoid, dexamethasone, had 
increased intramyocellular lipid content and diacylglyceride levels in skeletal muscle 
coupled with insulin resistance (Gounarides et al. 2008).  
In addition to the effect of exogenous glucocorticoids, pre-receptor metabolism of 
endogenous glucocorticoids by 11β-HSD1 is a crucial regulator of insulin sensitivity 
in skeletal muscle (Morgan et al. 2009). Increased expression of 11β-HSD1 has been 
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described in skeletal muscle of a rodent model of diabetes (Zhang et al. 2009) and 
myotubes isolated from patients with insulin resistance and type 2 diabetes  
(Abdallah et al. 2005b). Importantly, GCs elevate lipolysis and FFA generation and 
uptake which may be an important contributor to the insulin resistance  
(Morgan et al. 2009).  
 
1.6.4 Mitochondrial myopathy 
Muscle impairment can also be caused by mitochondrial dysfunction consequently 
leading to muscle weakness and exercise intolerance (Yamada et al. 2012). Skeletal 
muscle utilises oxidative ATP for energy production and highly depends on the 
mitochondrial respiratory chain (RC) function. A progressive dysfunction of RC can 
cause the development of adult-onset myopathies that can affect individuals from 
early infancy to late adulthood (Tyynismaa et al. 2010). Mitochondrial impairment has 
also been implicated in other diseases including heart failure and type 2 diabetes 
(Wallace et al. 1999) as well as in the ageing process (Trifunovic et al. 2004).  
In a previous study, a mouse model for mitochondrial myopathy was generated by 
disrupting mitochondrial transcription factor A (Tfam) in skeletal muscle. The Tfam 
gene is ubiquitously expressed and essential for mtDNA transcription and translation; 
therefore, its depletion leads to loss of mtDNA transcripts, mtDNA-encoded peptides 
and severe deficiency of all RC subunits affecting complexes I, III, IV and V 
(Wredenberg et al. 2002). The muscle weakness seen in Tfam KO muscles was 
found to be due to decreased Ca2+ release from the SR during tetanic stimulation and 
thereby reduced activation of the contractile machinery (Aydin et al. 2009). Mutations 
in mtDNA cause a wide range of syndromes including mitochondrial myopathies; 
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however, treatment options still remain limited and further understanding of the 
molecular basis of these conditions need to be undertaken. 
 
1.6.5 Duchenne muscular dystrophy (DMD) 
The majority of the skeletal muscle pathologies are caused by defects either in 
structural or cytoskeletal proteins or in mitochondria. The most common and severe 
muscle dystrophy is DMD which is an X-linked recessive disorder resulting from 
mutations in the gene encoding dystrophin, a subsarcolemmal protein functioning 
within the dystrophin-associated glycoprotein complex (DGC), responsible for 
maintaining muscle integrity (Lynch et al. 2001;Turk et al. 2005). This gene is 
expressed in skeletal, cardiac and smooth muscle. The DGC complex plays a critical 
role by connecting the actin-based subsarcolemmal cytoskeleton to the extracellular 
matrix component laminin (merosin) (Chamberlain et al. 2007;Lynch et al. 2001). The 
DGC is localised at the Z-lines of the sarcomere and allows the transmission of force 
across the muscle fibre. When disrupted, it results in membrane instability and 
consequently leads to sarcolemmal ruptures. In addition, the extracellular calcium 
influx activates proteolytic activity. Subsequently, affected muscle fibres become 
necrotic or apoptotic followed by initiation of inflammatory processes. Cycles of both 
degeneration and regeneration eventually lead to irreversible muscle wasting and 
substitution by fibrotic and adipose tissue (Turk et al. 2005). 
The DMD is characterised by severe and progressive skeletal muscle degeneration; 
therefore, the mdx mouse model, with a point mutation in the dystrophin gene and a 
lack of dystrophin expression in muscle tissues, has been utilised in a wide range of 
studies to investigate the underlying mechanisms and potential remedies  
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of this muscle wasting disease (Bulfield et al. 1984;Chamberlain et al. 2007). 
Currently, there are a number of clinical trials trying to find effective treatments for 
DMD-affected boys. One such treatment is administering glucocorticoids in order to 
improve walking ability and increase lifespan of DMD patients. This trial also aims to 
increase steroid efficacy as well as reduce side effect and toxicity of this 
treatment (Angelini et al. 2012).  
 
1.6.6 Sarcopenia 
 Ageing and increased physical disability are associated with elevated fat mass, 
mainly visceral fat and lead to development of metabolic syndrome and CVD 
(Kim and Choi 2013). One of the most consistent physiological manifestations of 
ageing, observed across a wide range of species, is the progressive loss of skeletal 
muscle mass and function termed sarcopenia, defined as an aged-related 
progressive loss of muscle mass, force and strength that could lead to functional 
impairment, decreased mobility and consequently to mortality. In the elderly, skeletal 
muscle wasting and fat mass increase are correlated with the sedentary lifestyle and 
disability (Song et al. 2004). Skeletal muscle mass declines by up to 1% a year 
beginning at approximately 40 years of age. This progressive loss has been 
estimated at about 8% per decade until the age of 70 years and afterwards about 
15% per decade (Malafarina et al. 2012;Paddon-Jones et al. 2008). Currently, 
sarcopenia affects more than 50 million people worldwide and predictions are that 
this number will increase to 200 million over the next 40 years (Kim et al. 2014). 
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Ageing muscle demonstrates reduction of type II fibre size with a lesser effect on 
type I fibre size. However, the total number of type I and type II fibres are significantly 
decreased with age to a similar extent (Kamel 2003). 
A number of factors lead to sarcopenia including decreases in IGF-1 and GH levels, 
induction in proinflammatory cytokines (TNF-α, IL-1β and IL-6), long term GC 
treatment, neurodegenerative processes and mitochondrial dysfunction (Figure 1-22) 
(Sakuma and Yamaguchi 2012;Schrager et al. 2007).  
 
 
Figure 1-22 Mechanisms of sarcopenia 
A number of factors lead to sarcopenia development; therefore, fully defining the 
physiology of ageing skeletal muscle is critical to design interventions to optimise an 
individual’s capacity to resist sarcopenia and age-related disease. 
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Treatment of sarcopenia has become a major focus for drug discoveries in order to 
develop approaches to counteract its effects and thereby help in slowing down or 
reversing this age-related muscle decline and disability.  
 
1.7 Thesis rationale 
Skeletal muscle is a central site of energy metabolism that impacts whole body 
energy homeostasis. The SR is a skeletal muscle unit integrating redox balance, 
glucose and GC metabolism mediated by the G6PT/H6PDH/G6Pase-β/11β-HSD1 
enzymatic system. Perturbation of this unit has varying impacts and associated 
phenotypes. This thesis will further define the roles that H6PDH and 11β-HSD1 play 
in local skeletal muscle homeostasis in an effort to provide insight into novel 
mechanisms and pathways regulating muscle metabolism. 
 
1.8 Hypothesis 
We hypothesise that H6PDH and 11β-HSD1 link the redox and metabolic status of 
the SR to the cytosol and therefore intermediary energy metabolism, that when 
depleted in muscle elicit a series of signalling responses that impact on local and 
systemic homeostasis. I wish to define the metabolic profiles associated with 
perturbation of the SR unit in skeletal muscle that will lead to better understanding of 
the metabolic interplay between the SR and the cytosol and the role H6PDH and 
11β-HSD1 play in skeletal muscle.  
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1.9 Aims 
 To determine the expression of G6PT/H6PDH/G6Pase-β/11β-HSD1 pathway 
in differentiating skeletal muscle cells. Also, to understand the role of muscle 
H6PDH in metabolic physiology and SR metabolism independently of other 
metabolic tissue using a muscle-specific knockout of H6PDH (H6MKO) mice. 
The H6MKO has been generated during this PhD to help to better understand 
H6PDH function in metabolic homeostasis and its potential role and 
manipulation in metabolic disease (Chapter 3). 
 
 To evaluate the muscle-specific role of 11β-HSD1 and GC metabolism in 
determining global and tissue-specific metabolic phenotype using  
a muscle-specific knockout of 11β-HSD1 (HSD1MKO) (Chapter 4). 
 
 To expression profile H6PD depleted muscle samples and attempt to discover 
changes in transcription that may identify factors contributing to myopathy and 
to establish the role of H6PDH in skeletal muscle biology (Chapter 5). 
 
 To exploit metabolomics technology to evaluate muscle myopathy in the 
absence of H6PDH (Chapter 6). 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 2- General Methods 
Unless stated, all methods were carried out using chemicals purchased  
from Sigma-Aldrich Chemical Company (Poole, Dorset, UK) and cell culture 
plasticware from Corning (Artington, Surrey, UK). 
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2.1 Maintenance of tissue culture cell line C2C12 
All cell culture work was undertaken in sterile conditions in a Class I biological safety 
cabinet (Holten LaminAir). Cell incubation was carried out at 37ºC in a Sanyo CO2 
incubator supplemented with 5% CO2/95% air.  
 
2.1.1 C2C12 cell line 
The mouse myoblast cell line, C2C12, is a well-established model of both skeletal 
muscle proliferation and differentiation. They were originally generated through serial 
passage of myoblasts cultured from the thigh muscle of injured C3H mice collected 
70 h following a crash accident (Yaffe and Saxel 1977). A subclone of these 
myoblasts was selected because of its ability to differentiate rapidly and express 
characteristic muscle proteins (Blau et al. 1985). 
 
2.1.2 Proliferation 
C2C12 myoblasts were purchased from the European Collection of Cell Cultures 
(Salisbury, UK). Cells were maintained in a 75 cm3 tissue culture (TC) flask in 
antibiotic-free complete growth medium (GM) comprising of Dulbecco’s modified 
eagle medium (DMEM) (PAA, Somerset, UK) supplemented with 10% (v/v) fetal calf 
serum (FCS), 2 mM L-glutamine and 4.5 g/L glucose. Cells were trypsinised when 
they reached 60-70% confluence and re-seeded into fresh flasks. Prior to 
experiments, cells were trypsinised and subcultured into 12-well TC plates. 
Proliferation medium was replaced every 48 h until cells reached 60-70% confluence. 
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2.1.3 Differentiation 
Differentiation was initiated when myoblasts reached 60-70% confluence by 
replacing GM medium with DMEM supplemented with 5% horse serum. 
Differentiation medium (DM) was changed every 48 h. Myoblasts have formed 
multinucleated myotubes after 8 days of differentiation (Figure 2-1).  
 
Figure 2-1 C2C12 cells have formed multinucleated myotubes after differentiation 
in DM for 8 days 
 
2.1.4 Freezing down 
To prepare cells for long-term storage, cells were grown in 75 cm3 TC flasks until 60-
70% confluence. They were trypsinised, re-suspended in 10 mL of proliferation 
medium and centrifuged at 1,000 g for 10 minutes. Medium was aspirated, and the 
cell pellet was re-suspended in 3 mL of FCS supplemented with 10% dimethyl 
sulfoxide (DMSO). Then, 1 mL of the cell mixture was transferred into a 1.5 mL 
cryovials and slowly cooled down to -80ºC at a rate of 1ºC/min in a cryofreezing 
chamber (Nalgene, Hereford, UK) containing isopropanol. Afterwards, cells were 
transferred to liquid nitrogen. 
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2.2 Murine primary skeletal muscle cell culture 
2.2.1 Primary skeletal muscle cells 
Skeletal myofibres were isolated from mouse extensor digitorum longus (EDL) 
muscle by digestion in 7 mL of DMEM supplemented with 0.2% collagenase type I in 
the water bath with gentle agitation at 37ºC for 90 mins. When digestion was 
complete, the collagenase solution was discarded, and the muscle was transferred 
into a Petri dish with 8 mL DMEM for further incubation at 37ºC for 20 mins. 
Subsequently, the Petri dish was placed under the microscope, and the muscle was 
gently titurated using a Pasteur pipette rinsed in 10% horse serum/DMEM.  
The hair-like single fibres were liberated from the muscle along with fat, tendon and 
other debris. Finally, single myofibres were transferred into a 12-well plate containing 
GM and incubated at 37ºC until proliferation. 
 
2.2.2 Proliferation 
Primary myoblasts were maintained in 12-well plates in 1 mL of DMEM 
supplemented with 10% horse serum, 0.5% chick embryo extract (Sera Lab, West 
Sussex, UK), 2 mM L-glutamine and 4.5 g/L glucose. Prior to experiments, cells were 
trypsinised and subcultured into 12-well TC plates and cultured until 60-70% 
confluence. Proliferation medium was replaced every 48 h.  
 
2.2.3 Differentiation 
Differentiation was initiated after myoblasts reached 60-70% confluence by replacing 
proliferating medium with DMEM supplemented with 2% horse serum and 0.5% chick 
embryo extract (Sera Lab, West Sussex, UK). Both proliferation and differentiation 
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media contained penicillin (100 IU/mL) and streptomycin (100 µg/mL). Differentiation 
medium was replaced every 48 h. After 8 days of differentiation, myoblasts fused to 
form multinucleated myotubes (Figure 2-2). 
 
Figure 2-2 Primary myoblasts have formed multinucleated myotubes  
after differentiation for 8 days 
 
2.3 RNA extraction 
To extract total RNA from cultured cell monolayers or tissue explants, Chomczynski’s 
single step procedure is applied (Chomczynski and Sacchi 1987). Cultured cells are 
lysed in TRI reagent that contains phenol and guanidine thiocyanate and effectively 
inhibits RNase activity. Subsequently, chloroform is added, and the samples are 
centrifuged (10,000 g at 4ºC for 15 mins) to obtain three phases. The top aqueous 
phase contains RNA which is precipitated with isopropanol. 
For cultured cell monolayers, medium was removed from the flasks, cells were 
washed with phosphate-buffered saline (PBS), and 1 mL of TRI reagent was added 
per well (for a 12-well plate) and incubated at room temperature for 5 mins. For tissue 
explants, ~20 mg of tissue was homogenised in 1 mL of TRI reagent and then 
incubated at room temperature for 5 mins. For both cultured cell monolyers  
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and tissue explants, cell or tissue lysate in TRI reagent were transferred to 
Eppendorfs tubes, and 200 µL of chloroform was added, followed by vortexing and 
incubation at room temperature for 10 mins. The mixture was centrifuged at 10,000 g 
at 4ºC for 15 mins. The aqueous phase containing RNA was transferred to a fresh 
Eppendorf tube and 500 µL of isopropanol was added. The tubes were incubated on 
ice for 30 mins for RNA precipitation and then vortexed followed by centrifuging at 
10,000 g at 4ºC for 15 mins. The RNA pellet was washed with 75% ethanol, 
centrifuged, air dried after ethanol was aspirated and re-suspended in 50 µL of 
nuclease free water. 
 
2.3.1 RNA quantification 
RNA concentration was measured using the NanoDrop ND-1000 UV-Vis 
Spectrophotometer (Thermofisher, Surrey, UK). The OD260/OD280 ratio indicates the 
RNA purity, and only these ratios in the range of 1.8-2.0 were used. All 
measurements were made using 1.5 µL of RNA with respect to a blank measurement 
(nuclease free water). 
Additionally, the integrity of the RNA was confirmed by electrophoresis on 0.8% 
agarose gel containing 2,000x GelRed (Cambrigde BioScience, Cambrigde, UK). 
The RNA separates down on gel according to its molecular mass and two abundant 
28S and 18S rRNA bands are visualised under UV light. 
 
2.4 Reverse transcription of RNA 
Reverse transcription (RT) is the process in which single stranded RNA is converted 
to complementary DNA (cDNA). The extracted RNA is denatured losing its secondary 
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structure allowing random hexomers to anneal to the RNA template. Finally, the 
reaction is heated to a high temperature to inactivate RNA-dependent DNA 
polymerase and to terminate the reaction. 
All RT reactions were performed using Life Technologies High-Capacity Reverse 
Transcription Kit (Life Technologies, Warrington, UK). To generate a 2x RT master 
mix, all reagents were combined as below: 
Component Volume/Reaction (μL) 
10x RT Buffer 2.0 
25x dNTPs mix (100 mM) 0.8 
10x RT Random Primers 2.0 
Multiscribe Reverse Transcriptase 1.0 
RNase Inhibitor 1.0 
Nuclease-free H2O 3.2 
TOTAL VOLUME PER REACTION 10.0 
 
1 µg of RNA was diluted with nuclease free water to a final volume of 10 µL before 10 
µL of 2x RT master mix was added. 20 µL of sample was loaded onto a thermal 
cycler (Life Technologies, Warrington, UK) and incubated at 25ºC for 10 mins 
followed by 37ºC for 120 mins and then 85ºC for 5 mins to terminate the reaction. 
 
2.5 Conventional Polymerase Chain Reaction (PCR) 
To amplify the regions of DNA or cDNA, oligonucleotide primers which are 
complementary to the 3’ and 5’ ends of this region are used. Double stranded DNA  
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is denatured using high temperature, and finally to allow primers annealing process, 
the temperature is lowered to be later increased for Taq polymerase to start the 
extension of oligonucleotides generating complementary DNA strands.  
All conventional PCRs were carried out using New England Biolabs reagents  
(NEB, Herts, UK). In a 25 μL reaction, the following components were combined: 10x 
reaction buffer (final concentration 1x), dNTPs (200 µM), Taq DNA polymerase 
(0.025 units/μL), forward and reverse primers (0.4 μM) and DNA template ˂1,000 ng. 
Samples were transferred to a thermal cycler and heated to 94ºC for 2 mins (hot 
start), then cycled 35 times at 94ºC for 20 s, 56ºC (depending on annealing 
temperature of the primers) for 20 s and 72ºC for 1 min per 1 kb. Finally, samples 
were incubated at 72ºC for 5 mins and stored at -20ºC until required. 
 
2.6 Relative quantitative polymerase chain reaction (qPCR) 
Real-time PCR is a technique used to detect and quantify the initial amount of the 
template. It monitors the fluorescence emitted by a reporter during each reaction 
cycle which its intensity is proportional to the amount of PCR product generated. 
Real-time PCR quantifies the abundance of transcript. The point at which the target 
sequence is detected is called the cycle threshold (Ct). The Ct value of a gene of 
interest is subtracted from the Ct of a housekeeping gene resulting in the ∆Ct value.  
The oligonucleotide primers are complementary to the 5’ and 3’ ends of a region of 
interest amplifying cDNA. The presence of the fluorogenic probe which is chemically 
synthesised with a fluorescent reporter dye at the 5’ end and a quencher dye  
at the 3’ end allows quantification of the target transcript by fluorescence. The probe 
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binds to the DNA template and when the primer is extended, the probe is cleaved by 
the 5’-3’ exonuclease activity of Taq DNA polymerase. It leads to separation of the 
reporter dye from the quencher dye increasing the fluorescence emitted by the latter. 
Then, the probe is removed from the DNA template, and the primer extension 
continues until it reaches the end of DNA strand.  
All real-time PCR experiments were carried out using Life Technologies gene 
expression assays (Life Technologies, Warrington, UK).  The 18S rRNA was used as 
a housekeeping gene at a final concentration of 25 mM each. The control reactions 
were carried out in separate wells from target gene expression measurements 
(singleplex) in 96-well plates (Life Technologies, Warrington, UK). The reactions were 
set up in triplicate by combining the following components: 5 µL of 2x Master Mix,  
0.5 µL of either 18S mixture or 20x expression assay, 100 ng of cDNA and nuclease 
free water to a final volume of 10 µL per well. Plates were sealed with a clear 
adhesive film (Life Technologies, Warrington, UK) and finally run on 7500 real-time 
PCR system (Life Technologies, Warrington, UK) for 40 cycles. All data was 
expressed as Ct values and used to calculate ∆Ct (Ct of gene of interest – Ct of 
18S). They were expressed as arbitrary units (A.U. = 1000x2-∆Ct). Fold change was 
calculated using the 2-∆∆Ct method. 
 
2.7 11β-HSD1 enzyme activity assay 
This technique allows measurement of the interconversion between the rodent 
inactive 11-DHC (A) and active corticosterone (B) by 11β-HSD1. This protocol was 
carried out on both monolayers of intact cells, microsomes and whole tissue 
explants. 
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Confluent cell monolayers were washed once with PBS, then incubated in serum free 
medium containing 100 nM of either 11-DHC enriched with 20,000 cpm/reaction 
tritiated [1,2,6,7-3H(N)]-11-DHC (3H-11-DHC) (for in-house synthesis see section 
below) or 100 nM of corticosterone enriched with 20,000 cpm/reaction of tritiated 
[1,2,6,7-3H(N)]-corticosterone (3H-corticosterone) (GE Healthcare, Bucks, UK). 
Incubations were carried out at 37ºC under a 5% CO2 atmosphere for 30 mins (liver) 
and 2 h (quadriceps). Reaction medium was transferred to glass test tubes and 5 mL 
of dichloromethane was added. Steroids were extracted from medium by vortexing 
the tubes for 20 seconds followed by centrifugation at 1,000 g for 10 mins in order to 
separate aqueous from organic phases. Then the aqueous phase was aspirated, and 
the organic phase containing the steroids was evaporated at 55ºC using an air 
blowing sample concentrator (Techne, New Jersey, US). Steroids were re-suspended 
in 40 μL of dichloromethane, and using a Pasteur pipette they were spotted onto a 
silica coated thin layer chromatography plate (Thermofisher, Surrey, UK) followed by 
a non-radiolabelled 5 μL of 11-DHC/corticosterone (10 mM in ethanol). Each spot 
was separated by 1.5 cm from adjacent samples and 2 cm from the bottom of the 
plate. Thin layer chromatography (TLC) was used to separate the steroids in 200 mL 
of chloroform:absolute ethanol (92:8) mobile phase for 1.5 h. Radioactivity of the 
separated 3H-11-DHC/3H-corticosterone was measured using a Bioscan 200 imaging 
scanner (LabLogic, Sheffield, UK). To assign the radioactivity peaks with the correct 
steroids, the position of cold steroids, were visualised under UV light. The percentage 
conversion was calculated using region counts for the individual peaks and enzyme 
activity was expressed in pmoles of steroid converted per mg of protein per hour 
(pmol/mg/h). 
Chapter 2                                                                                                                       General Methods 
 
74 
 
Fresh tissue explants (~20 mg/well) or 100 µg muscle microsomes were added to  
1 mL of serum free media and the above protocol was followed. Enzyme activity was 
expressed as pmoles of steroid converted per g of tissue per hour (pmol/g/h) 
or % conversion respectively.  
 
2.7.1 3H -11-DHC production 
Because tritiated 3H-11-DHC is not commercially available, consequently it was 
generated from 3H-corticosterone (GE Healthcare, Bucks, UK). 20 μL of 3H-
corticosterone (1 mCi/mL) was incubated with 250 μg of homogenised mouse 
placenta in 500 μL of 0.1 M potassium phosphate buffer (80.2 mL of 1 M K2HPO4, 
19.8 mL of 1 M KH2PO4, 900 mL of H2O), pH 7.4, with 500 μM NAD
+. Conversion was 
carried out at 37ºC in a shaking water bath overnight. Steroids were extracted by 
addition of 5 mL of dichloromethane. Tubes were vortexed for 20 s and centrifuged at 
1,000 g for 10 mins to separate aqueous and organic phases. The aqueous phase 
was aspirated and the organic phase with steroids was evaporated at 55ºC using an 
air blowing sample concentrator (Techne, New Jersey, US). Steroids were  
re-suspended in 70 μL of dichloromethane, spotted onto a silica coated thin layer 
chromatography plate (Thermofisher, Surrey, UK) using a Pasteur pipette and 
separated by TLC using 200 mL of chloroform:absolute ethanol (92:8) as the mobile 
phase for 1.5 h. The position of 3H -11-DHC was established by reading the silica 
plates using a Bioscan 200 imaging scanner (LabLogic, Sheffield, UK). The silica at 
the 3H-11-DHC position was scraped into a glass tube and 300 μL of 100% ethanol 
was added for steroid elution. The tubes were incubated at 4ºC overnight. To 
separate the eluted 3H-11-DHC and silica, the tubes were centrifuged at 1,000 g for  
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5 mins. Quality and radioactivity of 3H-11-DHC were determined  
by separating 5 μL of stock by TLC. Number of counts was measured using the 
Bioscan 200 imaging scanner (Figure 2-3). Finally, the stock was diluted in ethanol  
to ~1,000 counts/μL which is equivalent of 1.5 pmol/µL. 
 
Figure 2-3 Representative of Bioscan traces of 3H-11-DHC 
 
2.8 Protein extraction 
The extraction of soluble proteins from cell monolayers or tissue explants was carried 
out using cell lysis buffer supplemented with protease inhibitors and detergent. 
Centrifugation was applied to remove insoluble cell debris such as membrane lipids. 
Monolayer of cells: 
Cell monolayers were placed on ice and washed with cold PBS. For cells grown in 
12-well plates, 40 μl of RIPA buffer (1 mM EDTA, 150 mM NaCl, 0.25% SDS,  
1% NP40, 50 mM Tris pH 7.4), protease inhibitor cocktail (Roche, Sussex, UK) and 
phosphatase inhibitor (Thermofisher, Surrey, UK) were added. Subsequently, the 
cells were scraped, cell lysates were transferred to Eppendorf tubes, incubated  
at -80°C for 20 mins, thawed out on ice and centrifuged at 14,000 g for 15 mins at 
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4°C. The supernatant containing soluble proteins was transferred to fresh Eppendorf 
tubes and stored at -80°C prior to further protein concentration assessment  
(Section 2.10). 
Mouse tissue explants: 
Tissue was quickly harvested and snap-frozen in liquid nitrogen. To extract proteins, 
~20 mg of tissue was homogenised in 1.5 mL of RIPA buffer using a mechanical 
homogeniser. Tissue homogenates were incubated at -80°C for 20 mins, thawed out 
on ice and centrifuged at 14,000 g for 15 mins at 4°C. Finally, the supernatant 
containing soluble proteins was collected and transferred to fresh Eppendorf tubes 
and either was used immediately to assess protein concentration (Section 2.10) or 
stored at -80°C.  
 
2.9 Microsomal preparation 
Microsomes contain lipids and proteins from the ER, Golgi, plasma membrane and 
transport vesicles. Murine hepatic and muscle microsomes were prepared by 
differential centrifugation. The extraction of microsomes from tissues was carried out 
using a lysis buffer supplemented with protease inhibitors.  
Tissue explants were homogenised in sucrose buffer (0.25 M sucrose, 20 mM 
Hepes; pH 7.2) using a PowerGen 125 homogeniser (Fisher Scientific, 
Loughborough, UK) and centrifuged at 12,000 g at 4ºC for 15 mins. The supernatant 
from the first centrifugation was removed, the mitochondrial pellet was re-suspended 
in 25 ml of MOPs buffer (100 mM KCl, 20 mM NaCl, 1 mM MgCl2, 20 mM MOPs; 
pH 7.2), and centrifugation was repeated at 100,000 g for 1 h. Subsequently, the 
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cytosolic fraction was aliquoted and stored at -80ºC whereas the microsomal pellet 
was washed with MOPs buffer by centrifugation at 100,000 g at 4ºC for 1 h three 
times, re-suspended in MOPs buffer, immediately frozen in liquid nitrogen and stored 
at -80ºC prior to assessment of protein concentration (up to 6 months; Section 2.10). 
A cocktail of protease inhibitors (1 mM phenylmethylsulfonylfluoride, 1 μM pepstatin 
A, 1 μM leupeptin, and 1 μg/mL aprotinin) was added to sucrose and MOPs buffers.  
 
2.10 Measuring protein concentration 
Total protein concentration from both cells monolayer and mouse tissue explants was 
assessed using the 96-well BioRad RC DC protein assay (BioRad, Herts, UK). This 
assay is based on the Lowry method, but has been modified to be reducing agent 
compatible (RC) and also detergent compatible (McCroskery et al. 2003). Prior to 
quantification, protein reacts with the copper in an alkaline copper tartrate solution. 
Finally, folin reacts with the copper treated protein leading to the generation of 
various reduced folin species of a characteristic blue colour that can absorb 
minimally at 405 nM and maximally at 750 nM. 
Protein concentration was assessed according to the manufacturer protocol (BioRad, 
Herts, UK). The protein standards were made by dissolving bovine serum albumin 
(BSA) in RIPA buffer at final concentration 16 mg/mL. It was then serially diluted to 
obtain the following concentrations: 0.5, 1, 2, 4 and 8 mg/mL (Figure 2-4). 5 µL of 
sample or protein standards was added per well of a 96-well plate in triplicate. 
Subsequently, 25 µL of an alkaline copper tartrate solution (solution A) combined 
with surfactant solution (solution S) in a 1:50 ratio followed by 200 µL of a folin 
solution (solution B) was added to each well. The assay was incubated at room 
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temperature for 10 mins prior to absorbance being read at 690 nM on a Vector3 1420 
multilable counter (PerkinElmer, Bucks, UK). 
 
Figure 2-4 Representative BSA protein standard curve for the BioRad protein 
assay 
 
 
2.11 Immunoblotting  
Immunoblotting allows measuring the relative amounts of specific proteins in a mixed 
protein sample (Towbin et al. 1979). To remove all secondary and tertiary structures 
of proteins, proteins are boiled in a strong reducing agent. Negative charged proteins 
are separated according to their molecular mass using SDS-Page electrophoresis. 
The small proteins migrate fast and large proteins migrate slowly. Separated proteins 
are transferred to either a polyvinylidene difluoride (PVDF) or nitrocellulose 
membrane using electrical current. These membranes strongly bind proteins and any 
antibodies that they are exposed to. To prevent these non-specific bindings, the 
membrane is incubated in a blocking solution containing a generic protein such as 
milk or BSA. Subsequently, membranes are incubated with a primary antibody which 
specifically recognises the protein of interest and then with a secondary antibody 
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which is directed against the primary antibody and is conjugated to horseradish 
peroxidase (HRP). HRP catalyses a reaction involving the oxidation of luminal 
leading to emission of a blue light which is proportional to the amount of protein 
hybridised to the antibody on the membrane. Finally, the reaction is captured  
on a photographic film. 
Between 20-40 µg of proteins or 10-25 µg of microsomes were combined with an 
appropriate volume of 5x loading buffer and denatured at 98ºC for 3 mins. Proteins 
were separated with 10-12% gradient SDS-PAGE gel (BioRad, Herts, UK) using 
Precision Plus Protein Standard (BioRad, Herts, UK) as a marker. The samples were 
run at 140 V for 1 h 30 mins, and protein transfer to nitrocellulose membrane  
(GE Healthcare, Bucks, UK) was conducted at 140 mA for 1 -2 h.  To visualise the 
protein bands, the membrane was incubated in Ponceau stain with agitation for 60 s 
and rinsed with water. Electrophoresis and protein transfer were carried out in 
BioRad mini protein 3 apparatus (BioRad, Herts, UK). The membranes were blocked 
in 10 mL of blocking buffer containing 5% milk in PBS-0.05% Tween at room 
temperature for 1 h, followed by overnight incubation with the primary antibody at 
4ºC. After washing with 10 mL of washing buffer (PBS-0.05% Tween) for 15 mins 
three times, the membranes were incubated with the secondary antibody at room 
temperature for 1 h. Subsequently, the membranes were washed with 10 mL of 
washing buffer (PBS-0.05% Tween) for 15 mins three times. Antigen-antibody 
complexes were detected using Enhanced Chemiluminescence (ECL; GE 
Healthcare, Bucks, UK). The reaction mixture (1 mL per membrane for 5 mins) was 
made by combining both substrate A and substrate B at a 50:50 ratio. Finally, 
photographic film (Perkin Elmer, Surrey, UK) was placed over the membranes  
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in the dark and exposed for 30 s to 30 mins followed by development on Compact X4 
automatic film processor (Xograph Imageing Systems, Gloustershire, UK). To 
remove bound primary/secondary antibodies, the membranes were stripped by 
incubating them in stripping buffer (2% SDS, 100 mM β-mercaptoethanol, 50 mM 
Tris, pH 6.8) at 50°C for 1 h with gentle agitation. Afterwards, the membranes were 
washed with 10mL of washing buffer 3 times for 15 mins followed by re-probing with 
a different primary antibody.  
 
2.12 H6PDH enzyme activity assay 
This technique allows measuring the H6PDH activity by NADPH generation in murine 
hepatic and muscle microsomes. 
H6PDH enzyme activity was measured by spectrophotometric detection of NADPH 
upon the addition of 10 mM NADP+ and 10 mM G6P to hepatic microsomes (30 µg of 
protein) or skeletal muscle microsomes (100 µg of protein) in a total volume of 300 
µL using the Ultrospec 2100pro spectrophotometer (Amersham Biosciences). 
Microsomes were permeabilised at 4ºC with 0.5% Triton X-100 for 30 mins to allow 
the free access of the cofactor and substrate to the intraluminal enzyme and 
incubated in the MOPs buffer at 37ºC. Absorbance readings were taken at 340 nm at 
20 sec intervals for 3 mins. 
 
2.13 NAD+ assay 
BioVision’s NADH/NAD+ Quantification Kit (Cambridge Bioscience, Cambridge, UK) 
provides a convenient tool for sensitive detection of the intracellular nucleotides: 
NADH, NAD+ and their ratio. The NAD+ Cycling Enzyme Mix in the kit specifically 
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recognises NADH/NAD+ in an enzyme cycling reaction. The reaction specifically 
detects NADH and NAD+ only. The enzyme cycling reaction significantly increases 
the detection sensitivity and specificity. NADt (NAD+ and NADH) or NADH can be 
quantified by comparing with standard NADH. 
For cultured cell monolayers: medium was removed and cells were washed with cold 
PBS, transferred into a micro-centrifuge tube and centrifuged at 1,500 g for 5 mins. 
The cells were extracted with 400 µl of NADH/NAD+ extraction buffer by freeze/thaw 
two cycles (20 min on dry-ice, then 10 mins at room temperature), vortexed  
for 10 s and centrifuged at 16,100 g for 5 min. The extracted NADH/NAD+ 
supernatant was transferred into a labelled tube.  
For tissue explants: ~20 mg of tissue was washed with cold PBS and homogenised 
in 400 µl of NADH/NAD+ extraction buffer in a micro-centrifuge tube  followed by 
centrifuging at 13,200 g for 5 min. The extracted NADH/NAD+ supernatant was 
transferred into a new tube. To make a standard curve, 10 µL of the 1 nmol/µL NADH 
standard was diluted with 990 µL NADH/NAD+ extraction buffer in order to generate 
10 pmol/µL standard NADH which was added (2, 4, 8, 10 µL) into a 96-well plate in 
duplicate. The final volume to 50 µL was made up with NADH/NAD+ extraction buffer. 
Subsequently, 50 µL of extracted samples were transferred into a 96-well plate. To 
measure NADH, NAD+ was decomposed in 200 µL of the extracted samples by heat 
shock at 60ºC for 30 mins before reaction. The samples were cooled down on ice, 
and 50 µL of NAD+ decomposed samples were transferred into a plate.  
100 µL of NAD+ cycling mix (100 µL of NAD+ cycling buffer and 2 µL of NAD+ cycling 
enzyme mix) was added into each well to convert NAD+ to NADH followed  
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by the plate incubation at room temperature for 5 mins. Finally, 10 µL of NADH 
developer was added into each well, and after 2 hours of incubation at room 
temperature, the absorbance readings nm were taken at OD 450 at 20 s intervals for 
100 s. 
 
2.14 DNA isolation 
DNA is isolated from tissue explants using the phenol/chloroform extraction followed 
by ethanol precipitation. The aqueous phase contains DNA which is precipitated with 
100% ethanol and sodium acetate solution. 
Approximately 20 mg of tissue explants was collected from each animal and 
transferred into an Eppendorf tube containing digestion buffer which was made by 
combining the following components: 96 µL of 10x PCR buffer (Bioline, London, UK), 
4 µL of 50 mM MgCl
2
(Bioline, London, UK), 5 µL of Tween-20, 885 µL of H2O and 
100 µL 2 mg/mL proteinase K (Promega, Southampton, UK). Subsequently,  
100 µL of digestion buffer was added to each tissue sample and incubated in a hot 
block at 56ºC for 2 h or until tissues were digested. After incubation, the samples 
were vortexed and placed in a hot block at 99ºC for 20 mins in order to denature the 
proteinase K enzyme. One volume of phenol/chloroform was added to each sample 
followed by centrifugion at 14,000 g at 4ºC for 15 mins. The upper aqueous phase 
was transferred into a fresh tube and 1/10 the volume of 3 M sodium acetate solution 
with 2.5 volumes of 100% ethanol was added to precipitate DNA. The mixture was 
incubated for 30 mins on ice and centrifuged for 10 mins at 14,000 g. Subsequently, 
the supernatant was discarded, the pellet was washed with 1 mL of 70% ethanol and 
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allowed to air dry at room temperature for 5 mins. Finally, the pellet was  
re-suspended in 50 µL of H2O, and DNA was stored at 4ºC until needed. 
DNA concentration was measured using the NanoDrop ND-1000 UV-Vis 
Spectrophotometer (Thermofisher, Surrey, UK). The OD260/OD280 ratio indicates the 
DNA purity, and only the ratios in the range of 1.8 were used. All measurements 
were made using 1.5 µL of DNA with respect to a blank consisting of nuclease free 
water. 
 
2.15 Quantification of mtDNA 
The NovaQUANT™ Mouse Mitochondrial to Nuclear DNA Ratio Kit  
(Merck Serono Ltd., Feltham, UK) compares the levels of nuclear to mitochondrial 
DNA in a mouse DNA sample. The mtDNA copy number to that of nuclear DNA 
(nDNA) is compared by real-time PCR using a set of four optimised PCR primer pairs 
targeting two nuclear and two mitochondrial genes. A single assay is run using four 
wells, whereby each well individually measures the expression of one of four gene 
targets. A nuclear gene 1 is compared to that of mitochondrial gene 1 and a nuclear 
gene 2 to mitochondrial gene 2. Finally, the ratios are calculated which are averaged 
to represent the mtDNA copy number per cell. 
Approximately 2 ng of DNA was used in each reaction well. DNA was diluted using 
DNase/RNase-free water to the final volume of 10 µL. An equal volume of  
2x RT2 Fast SYBR Green Mastermix (Life Technologies, Warrington, UK) was added 
into the tube containing DNA aliquot. Finally, 20 μl of sample mix was transferred into 
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each well, and the plate was sealed with a plate sealer, briefly centrifuged and run 
using real-time PCR (Section 2.6).  
Data was analysed by averaging the copy numbers calculated from the NADH 
dehydrogenase, subunit 1/beclin 1 (ND1/BECN) pair and the NADH dehydrogenase, 
subunit 6/nebulin (ND6/NEB) pair. The Ct value from the ND1 gene was subtracted 
from the BECN1 Ct to obtain ΔCt1, and the ND6 Ct was subtracted from NEB to 
obtain ΔCt2. The average number of mitochondrial DNA copies was calculated by 
adding n= 2∆Ct1 and n=2∆Ct2 as in the table below:  
Target Ct ∆Ct 2∆Ct Average Number of Copies 
NDI 18 
∆Ct1=9.5 724 
677 
BECNI 27.5 
ND6 17.6 
∆Ct2=9.3 630 
NEB 26.9 
 
2.16 Metabolomics technology 
Metabolomics is the field of measuring all small molecules below 1,500 Da called 
metabolites in a biological sample in one single experiment  
(Adamski and Suhre 2013). 
Blood from male mice (H6PDH KO and WT), aged 8 weeks old, was obtained by 
cardiac puncture and immediately centrifuged at 1,000 g in heparin-coated tubes. 
Plasma was transferred to cryotubes and snap-frozen. Subsequently, mice were 
sacrificed by neck dislocation using Schedule 1 method, and tissue explants (liver 
and quadriceps) were quickly excised from each animal to be snap-frozen in liquid 
nitrogen and stored at -80°C until metabolites extraction. Frozen tissues were 
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homogenised in the tubes containing ceramic beads of 1.4 mm diameter using 
extraction solvents (100% ethanol/10 mM potassium phosphate buffer; 85/15 v/v,  
3 µL per mg of tissue). The AbsoluteIDQ p150 kit (Biocrates Life Sciences AG, 
Austria) was prepared as described by the manufacturer. A 10 μl aliquot of plasma or 
tissue extract was loaded onto the plate followed by drying of samples under the 
nitrogen stream, derivatisation of amino acids with 5% phenylisothiocyanate (PITC), 
drying of samples and extracting metabolites and internal standards with 5 mM 
ammonium acetate in methanol. Subsequently, the samples were centrifuged 
through the filter membrane and diluted with 600 µL MS running solvent. The final 
metabolites were quantified with reference to appropriate internal standards using 
flow injection coupled with tandem mass spectrometry (FIA-MS/MS) analysis on a 
4000 QTRAP instrument (ABSciex, Germany) coupled to a high-performance liquid 
chromatography (HPLC) Prominence (Shimadzu Deutschland GmbH, Germany) 
(Adamski and Suhre 2013).  
 
2.17 Animal work 
All animal experiments and procedures were approved under the British Home Office 
Guidance (Animals Scientific Procedures) Act 1986 (Project Licence, PPL 30/2764). 
Mice were housed in standard pathogen-free conditions on a 12 h light/12 h dark 
cycle with access to standard rodent chow (when not fasting) and water ad libitum. 
 
2.17.1 Genotyping 
A sample of mouse tissue (ear clippings or tail tip) was collected from each animal 
and transferred into a labelled Eppendorf tube. Digestion buffer was made by 
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combining the following components: 96 µL of 10x PCR buffer (Bioline, London, UK), 
4 µL of 50 mM MgCl2 (Bioline, London, UK), 5 µL of Tween-20, 885 µL of H2O and 
100 µL of 2 mg/mL proteinase K (Promega, Southampton, UK). Subsequently,  
100 µL of digestion buffer was added to each tissue sample and incubated in a hot 
block at 56ºC for 2 h or until tissues were digested. After incubation, the samples 
were vortexed and then placed in a hot block at 99ºC for 20 mins in order to denature 
the proteinase K enzyme. Finally, the samples were left to cool down and centrifuged 
at 1,000 g for 1 min. DNA was stored at 4ºC until needed. 
 
2.17.2 Breeding scheme 
Figure 2-5 shows the breeding scheme for a conditional gene targeting for all Cre/+ 
lines. Mice carrying the recombinase transgene and being homozygous for the floxed 
gene are ~12.5% of total offspring (Joyner 2001). 
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Figure 2-5 Schematic representation of the breeding strategy for the generation 
of conditional KO in muscle 
The symbol ∆ indicates deleted allele generated by recombination of the floxed locus 
while the symbol “+” indicates wt locus. 
 
 
2.17.3 Tissue collection 
Mice were sacrificed by neck dislocation (Schedule 1 method), and then tissue 
explants were quickly excised from each animal to be snap-frozen in liquid nitrogen 
for RNA/protein extraction (Section 2.3/2.8) or used fresh for 11β-HSD1 activity 
assay (Section 2.7). 
 
2.18 Statistical analysis 
Unpaired Student t-tests were used to compare single treatments to control using 
SigmaStat 3.1 (Systat Software, CA, US) whereas one way ANOVA on ranks was 
used to compare multiple treatments or times using SigmaStat 3.1. To perform 
statistical analysis on real-time PCR data, mean values of ∆Ct were used.
  
 
 
 
 
 
 
 
 
 
Chapter 3- Expression and activity of the 
G6PT/H6PDH/G6Pase-β/11β-HSD1 
metabolic unit in the SR of skeletal 
muscle
Chapter 3                  Expression and activity of the G6PT/H6PDH/G6Pase-β/11β-HSD1 metabolic unit                                                  
 
89 
 
3.1 Introduction 
Skeletal muscle is a major component of the human body that accounts for 
approximately 40% of the total body mass and provides support and movement to 
the skeleton (Smith and Muscat 2005). It plays a key role in glucose utilisation and 
has numerous vital metabolic functions being the major contributor to global insulin 
sensitivity (Larsen et al. 2008;Schuler et al. 2005).  
This study focuses on investigating the G6PT(Slc37a4)/H6PDH/G6Pase-β/11β-HSD1 
enzymatic pathway within the SR. G6PT transfers a substrate, G6P, from cytosol into 
the SR lumen which is further metabolised by either G6Pase-β to produce glucose 
(Gluc) and inorganic phosphate (Pi) (Shieh et al. 2003) or by H6PDH to generate a 
cofactor, NADPH, for 11β-HSD1 mediated GC activation. 11β-HSD1 converts 
cortisone (11-DHC in rodents) to the active GC, cortisol (corticosterone in rodents), 
and thus amplifies local GC action (Figure 3-1) (Lavery et al. 2008b). In this study, 
the main focus is the interaction of these enzymes in skeletal muscle and their 
contributions to local GC action.  
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Figure 3-1 The G6PT/H6PDH/G6Pase-β/11β-HSD1 pathway in the SR of skeletal 
muscle 
 
Previous investigations have shown that H6PDH global knockout (H6PDHKO) mice 
display fasting hypoglycaemia, increased basal- and insulin-stimulated glucose 
uptake as well as elevated glycogen storage (Lavery et al. 2007). The absence of 
H6PDH also switches the activity of 11β-HSD1 from an oxo-reductase to a 
dehydrogenase inactivating GCs. The H6PDHKO mice developed muscle myopathy 
affecting type IIb fibres and demonstrated reduced locomotor activity  
(Lavery et al. 2008b). Importantly, in H6PDHKO mice, the metabolic changes were 
accompanied by ER stress and subsequent activation of the UPR pathway with 
dysregulated expression of numerous genes involved in maintaining ER homeostasis 
(Lavery et al. 2008b;Walter and Ron 2011). In addition, H6PDHKO mice had 
increased 11β-HSD1 mRNA expression (Semjonous et al. 2011) and decreased 
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G6PT expression (Lavery et al. 2008b) in skeletal muscle. In cultured primary 
hepatocytes from H6PDHKO mice, G6Pase was not significantly induced; however, a 
trend towards up-regulation was observed (Rogoff et al. 2007). Interestingly,  
11β-HSD1/H6PDH KO (DKO) mice also exhibited myopathy and retained many of 
the metabolic differences seen in H6PDHKO mice. The DKO phenotype has 
confirmed a GC and 11β-HSD1 independent role for H6PDH in controlling metabolic 
homeostasis and insulin sensitivity in skeletal muscle (Semjonous et al. 2011).  
The first aim of this chapter is to understand the impact of H6PDH on cellular and SR 
G6P metabolism independently of other metabolic tissues such as liver and adipose, 
a muscle-specific knockout of H6PDH (H6MKO) was generated. This was to define 
the role of H6PDH in skeletal muscle and its impact on metabolic homeostasis as 
well as to determine the physiological effects of H6PDH in muscle upon glucose 
homeostasis and insulin sensitivity. 
The aim of this chapter is also to evaluate undifferentiated myoblasts with that of 
differentiated myotubes and characterise the gene expression of these four pivotal 
enzymes involved in G6P metabolism with concurrent GC generation across myocyte 
differentiation using murine C2C12 and primary skeletal muscle cells.  
 
3.2 Methods 
3.2.1 C2C12 cell culture 
Proliferating C2C12 myoblasts were cultured in DMEM supplemented with 10% FCS 
and seeded into 12-well TC plates. Differentiation was initiated when cells reached 
60-70% confluence by replacing proliferation media with DMEM supplemented 
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 with 5% horse serum and carried on for 8 days. Prior to treatment, cells were 
incubated in serum-free DMEM for 4 h. 
 
3.2.2 Primary skeletal muscle cells 
Skeletal myofibres were isolated from mouse EDL muscle. Primary myoblasts were 
maintained in 12-well TC plates in 1mL of DMEM supplemented with 10% horse 
serum and 0.5% chick embryo extract. Differentiation was initiated by replacing 
proliferating medium with DMEM supplemented with 2% horse serum and 0.5% chick 
embryo extract after myoblasts reached 60-70% confluence. Differentiation medium 
was replaced every 48 h. After 8 days of differentiation, myoblasts fused to form 
multinucleated myotubes. 
 
3.2.3 Cell treatments 
All cell treatments were carried out using serum free medium. GM was changed to 
FCS free DMEM 4 h before each treatment. Cells were treated with dexamethasone 
(DEX; 1 µM), insulin (1 µM), GR antagonist, Ru38486 (5 µM), and combination of 
DEX with insulin and DEX with Ru38486. In experiments using RU38486, cells were 
pre-treated with RU38486 for 10 mins before adding DEX in DMEM media. Cell 
treatments were carried out for 24 h.  
 
3.2.4 RNA extraction 
Total RNA was extracted on day 0, 2, 4, 6 and 8 of C2C12 differentiation or from 20 
mg of tissue explants using Tri-reagent system. RNA concentration was determined 
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spectrophotometrically at OD260 and integrity assessed by agarose gel 
electrophoresis. 1μg of RNA was used for reverse transcription (see Section 2.4).  
  
3.2.5 Real-time PCR 
Primers and probes for all genes were supplied by Life Technologies; 11β-HSD1 
(Mm00476182_m1), H6PDH (Mm00557617_m1), G6PT (Mm00484574_m1), 
G6Pase-β (Mm00616234_m1), α-actin (Mm00808218_g1), myogenin 
(Mm00440387_m1), HSPa5 also known as BiP (Mm00517691_m1) and DDIT3 
(Mm00492097_m1). mRNA levels were determined using the ABI 7500 sequence 
detection system (Life Technologies, Warrington, UK). Reactions were performed in 
singleplex in triplicates as described in Section 2.6 and normalised against the 18S 
rRNA housekeeping gene.  
 
3.2.6 H6PDH enzyme activity assay 
The H6PDH activity was measured in 30 µg of liver and 100 µg of muscle 
microsomes from H6PDH KO and WT mice. Detection of NADPH was recorded upon 
the addition of 10 mM NADP+ and 10 mM G6P using the Ultrospec 2100pro 
spectrophotometer (Amersham Biosciences, Chalfont St Giles, UK). Absorbance 
readings were taken at 340 nm at 20 sec intervals for 3 mins. 
 
3.2.7 11β-HSD1 activity assay 
Mouse tissue explants (~20 mg) were incubated with 100 nM 11-DHC or 
corticosterone supplemented with a tritiated tracer. Steroid incubation took place for 
4 h for muscle tissue and 30 mins for liver. Subsequently, steroids were extracted 
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using dichloromethane, separated using a mobile phase consisting of 
chloroform/absolute ethanol (92:8) by thin layer chromatography and scanned using 
a Bioscan 200 imaging scanner (LabLogic, Sheffield, UK). 11β-HSD1 activity was 
expressed as pmol of corticosterone or 11-DHC generated per g of tissue per hour of 
incubation. 
 
3.2.8 Histology 
Quadriceps muscle was harvested from H6PDH global KO mice and then fixed in 
10% neutral buffered formalin. Each muscle from both KO and WT mice (n=3 for 
each genotype) was paraffin embedded and cut into 5 µm sections to be stained by 
hematoxylin and eosin (H&E) to provide a histological detail of muscle structure. 
Muscle tissue was analysed from mice of 4 and 7 weeks of age. 
 
3.2.9 Immunoblotting 
Microsomes were extracted from tissue explants, and their concentration was 
determined as described in Section 2.10. For H6PDH immunoblotting, 10 μg of 
microsomal protein was resolved on 10% SDS-PAGE gels. Proteins were transferred 
to nitrocellulose membranes for 1 h at 100 V, and then primary, H6PDH  
(Santa Cruz Biotechnology, Heidelberg, Germany), and secondary antibodies  
(Dako, Glostrop, UK) were used at a dilution of 1:1,000 and 1:25,000 respectively. 
Membranes were re-probed for BiP antibody (BD Biosciences, Oxford, UK) used as a 
loading control at a dilution of 1:1,000. Bands were visualised using ECL detection kit 
(GE Healthcare, Bucks, UK). 
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3.2.10 Rodent protocol 
All animal experiments and procedures were carried out in accordance with the 
British Home Office Guidance (Animals Scientific Procedures) Act 1986  
(Project Licence, PPL 30/2764). Mice were housed in standard pathogen-free 
conditions on a 12 h light/12 h dark cycle with access to standard rodent chow (when 
not fasting) and water ad libitum. 
On the day of experiment, mice were sacrificed by cervical dislocation. Liver, skeletal 
muscle (quadriceps, tibialis anterior (TA), soleus), heart, kidney and lung were 
removed and snap-frozen in liquid nitrogen for characterisation of DNA 
recombination and mRNA expression. To measure 11β-HSD1 activity, tissue 
explants were freshly harvested in the serum-free DMEM and immediately used for 
the assay. 
 
3.2.11 Genotyping 
The H6PDH knockout 1st allele mice were purchased from the EUCOMM  
(The European Mouse Mutant Archive – EMMA, Munich, Germany) programme that 
employs a KO 1st allele strategy in which a SA-βgeo-pA reporter cassette (SA, splice 
acceptor; βgeo, β-galactosidase/neomycin phosphotransferase fusion gene; pA, 
bovine growth hormone polyadenylation sequence) flanked by FRT (flippase 
recognition target) sequence is inserted into the 1st intron of H6PDH inactivating the 
gene. This global knockout was called H6KO. At the same time target exon was 
floxed by the LoxP sites. A conditional allele was generated by Flp recombinase 
expression to remove the reporter gene (data not shown). The Cre recombinase 
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expression is under the control of the Acta1 promoter, and will excise exon 3 coding 
the catalytic domain of the conditional H6PD allele in skeletal muscle (Figure 3-2).  
 
Figure 3-2 A schematic representation of the H6KO allele and Acta1-Cre 
The H6KO allele will be crossed with a Flp deleted strain in order to generate a 
conditional allele which after breeding with muscle-specific Cre mice (Acta-Cre), will 
generate H6MKO mice. 
 
To generate H6MKO, floxed homozygous H6KO mice on a C57BL/6 background 
were crossed with Acta1-Cre transgenic mice (C57BL/6 background, targeting Cre 
expression to skeletal muscle and heart). This generated mice devoid of H6PDH 
activity in skeletal muscle cells. Genotyping PCR was carried out on ear clip DNA 
using following gene specific primers (5′-3′) (Figure 3-3): 
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Figure 3-3 Primers used for H6MKO genotyping  
The Ef4685 and L3r4688 primers were used to confirm successful deletion of exon 3 
which inactivated H6PD function whereas the CreF/R primers confirmed gene knockout 
specific to skeletal muscle. 
 
 
3.2.11.1 Fasting blood glucose measurement 
Mice were fasted for 16 h (n=6/group), and then blood samples were taken by tail 
nick. Blood glucose was measured using a Onetouch Ultra glucometer. 
 
3.2.11.2 Analysis of urinary GC metabolites 
Urine was collected from 8- to 14-wk-old female mice on filter paper from four 
members of each group (H6MKO and WT). Subsequently, the samples were 
analysed by repetitive scanning using GC/MS instrument at the Steroid Mass 
Spectrometry Core Facility within CEDAM, University of Birmingham. Corticosterone 
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metabolites were identified through interpretation of their mass spectra. Individual 
components were quantified by relating the peak areas on the TIC (total-ion-current) 
chromatograms to the peak area of the stigmasterol internal standard. Individual 
steroids were quantified as a percentage of the total corticosterone metabolites 
(Lavery et al. 2006). 
 
3.2.12 Statistical analysis 
Statistical comparisons were performed using Prism 4 (GraphPad, CA). Data were 
presented with statistical significance defined as P<0.05. Where data were normally 
distributed, unpaired Student t-tests were used to compare single treatments to 
control whilst one way ANOVA on ranks was used to compare multiple treatments or 
times using SigmaStat 3.1 (Systat Software, CA, US). To perform statistical analysis 
on real-time PCR data, mean values of A.U. were used. 
 
3.3 Results  
3.3.1 11β-HSD1, H6PDH, G6PT and G6Pase-β pathway expression during 
C2C12 differentiation 
To show that C2C12 cell line was differentiating correctly according to the muscle-
specific profile differentiation markers, α-actin (p<0.05 for day 4 and 6 vs. day 0) and 
myogenin (p<0.01 for day 6 vs. day 0; p<0.001 for day 2, 4 and 8 vs. day 0), 
significantly increased their mRNA expression reaching the highest peak at day 4 
(Figure 3-4). 
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Figure 3-4 The mRNA expression of differentiation markers: α-actin  
and myogenin 
*p<0.05; **<0.01; *** p<0.001 vs. control: day 0 myoblasts. All data are the mean A.U. 
values ±SEM from n=4 experiments by ANOVA (Newman-Keuls post test). 
 
11β-HSD1 significantly increased its mRNA expression during differentiation (p<0.05 
for day 6 vs. day 4; p<0.01 for day 4 vs. day 0 and p<0.001 for day 8 vs. day 0, 2, 4 
and 6). H6PDH expression was also elevated in mature myotubes (p<0.05 for day 8 
vs. day 0 and for day 6 vs. day 4; p<0.01 for day 8 vs. day 4). There was no 
significant change in the gene expression of G6PT and G6Pase-β (Figure 3-5).  
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Figure 3-5 Changes in expression of 11β-HSD1, H6PDH, G6PT and G6Pase-β 
across C2C12 differentiation 
**<0.01; *** p<0.001 vs. control: day 0 myoblasts and φ<0.05; φφ<0.01 vs. day 4. All 
data are the mean A.U. values ±SEM from n=4 experiments by ANOVA (Newman-
Keuls post test). 
 
3.3.2 11β-HSD1, H6PDH, G6PT and G6Pase-β pathway expression during 
primary skeletal muscle cells differentiation 
Similarly to C2C12, primary skeletal muscle cells were able to differentiate correctly 
across an 8 day period; however, to a lesser degree. The muscle-specific profile 
differentiation markers, α-actin mRNA (p<0.05 for day 8 vs. day 2; p<0.01 for day 8 
vs. day 0 and day 6 and for day 4 vs. day 2; p<0.001 for day 8 vs. day 4)  
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and myogenin mRNA (p<0.05 for day 8 vs. day 2, 4 and 6; and p<0.01 for day 8  
vs. day 0) were significantly elevated reaching the highest peak at day 8 (Figure 3-6).  
 
Figure 3-6 The mRNA expression of differentiation markers: α-actin  
and myogenin across primary muscle cells differentiation 
*<0.05, **<0.01 and *** p<0.001. All data are the mean A.U. values ±SEM from n=4 
experiments by ANOVA (Newman-Keuls post test). 
 
11β-HSD1 significantly increased its mRNA expression reaching the highest peak at 
day 8 (p<0.05 for day 8 vs. day 0; p<0.01 for day 8 vs. day 4) whereas H6PDH 
mRNA expression was elevated in mature myotubes at day 6 and 8 (p<0.05 for day 8 
vs. day 4; p<0.01 for day 6 vs. day 0, 2 and 4). Similarly to C2C12, G6PT and 
G6Pase-β did not change their mRNA expression over the 8 day differentiation time 
course (Figure 3-7).  
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Figure 3-7 Changes in expression of 11β-HSD1, H6PDH, G6PT and G6Pase-β 
across primary muscle cells differentiation 
*<0.05; **<0.01 day 8 vs. day 6 and 4 respectively for 11β-HSD1; *<0.05 day 6 vs. day 
4 and **<0.01 day 6 vs. day 0, 2 and 4 for H6PDH. All data are the mean A.U. values 
±SEM from n=4 experiments by ANOVA (Newman-Keuls post test). 
 
3.3.3 C2C12 myoblasts gene expression in response to GC and insulin 
treatment 
To investigate the regulation of G6PT/H6PDH/G6Pase-β/11β-HSD1 pathway, we 
studied their response to both GC and insulin, important regulators of muscle glucose 
metabolism (Figure 3-8). 
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Figure 3-8 The mRNA expression of key components involved in GC metabolism 
in C2C12 myoblasts 
11β-HSD1, H6PDH, G6PT and G6Pase-β expression measured using real-time PCR 
following treatment with DEX (1 μM, 24 h) with or without GR antagonist, Ru38486, 
insulin (*<0.05; **<0.01; φ<0.05 and φφ<0.01 vs. no treatment). All data are the mean 
A.U. values ±SEM from n=3 experiments by ANOVA (Newman-Keuls post test). 
 
Treatment of undifferentiated C2C12 myoblasts with DEX significantly increased  
11β-HSD1 mRNA expression (p<0.01). Insulin had no effect. Moreover, combination 
of DEX with insulin also increased 11β-HSD1 expression (p<0.05) while DEX 
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combined with Ru38486 decreased (p<0.05). H6PDH mRNA expression of C2C12 
myoblasts was significantly greater when treated with DEX (p<0.05) and DEX 
combined with insulin (p<0.05). This was probably due to DEX effect, as insulin on its 
own did not have any effect. G6PT and G6Pase-β did not change their mRNA 
expression in response to GC and insulin treatments. 
 
3.3.4  C2C12 myotubes gene expression in response to GC and insulin 
treatment 
In C2C12 myotubes differentiated for 5 days, 11β-HSD1 mRNA expression was not 
significantly changed after treatment with DEX, Ru38486, DEX combined with insulin 
or Ru38486. No effect of Ru38486 treatment on 11β-HSD1 mRNA expression 
suggests that GC inhibitor did not work properly. Additionally, combination of DEX 
and insulin significantly increased H6PDH mRNA expression (p<0.01) when 
compared to no treated cells. Similarly to myoblasts, G6PT and G6Pase-β did not 
change their mRNA expression in response to GC and insulin treatments  
(Figure 3-9). 
Chapter 3                  Expression and activity of the G6PT/H6PDH/G6Pase-β/11β-HSD1 metabolic unit                                                  
 
105 
 
 
Figure 3-9 The mRNA expression of key components involved in GC metabolism 
in C2C12 myotubes 
11β-HSD1, H6PDH, G6PT and G6Pase-β expression measured using real-time PCR 
following a 24 h treatment with DEX (1 μM) with or without GR antagonist, Ru38486 (5 
µM), insulin (1 μM) with or without DEX and Ru38486 (** p<0.01 vs. no treatment). All 
data are the mean A.U. values ±SEM from n=3 experiments by ANOVA (Newman-
Keuls post test). 
 
Increased expression of differentiation markers (α-actin, myogenin) during the 
transition from proliferating to differentiating C2C12 and primary skeletal muscle cells 
was shown in order to confirm their ability to differentiate. C2C12 cells had greater 
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expression of these genes compared to primary cells suggesting that the time of 
maturation from myoblasts to myotubes varies between different cell models. 
Elevated mRNA expression of 11β-HSD1 and H6PDH in response to differentiation 
signals might highlight the importance of these genes in skeletal muscle development 
and underline their central role within SR. To investigate further the role of H6PDH as 
the redox regulator of glucose and GC metabolism within the SR of skeletal muscle, 
H6PDH muscle-specific mouse model (H6MKO) was generated and compared to the 
global H6KO mice. 
 
3.3.5 H6MKO generation and evaluation 
3.3.5.1 H6PDH global KO (H6KO) characterisation 
Firstly, a novel knockout H6PD allele (H6KO), in which initial recombination of the 
LacZ reporter cassette into intron 2 is intended to completely knockout H6PD gene, 
was evaluated. Characterisation of 11β-HSD1 activity and muscle function in H6KO 
is important as these mice are expected to recapitulate the phenotype of previously 
generated H6PDH global knockout (H6PDHKO) mice and could not be used for 
H6MKO generation (Lavery et al. 2006). 
H6PDH mRNA expression in muscle and liver were significantly decreased when 
compared to wild type mice (Figure 3-10).  
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Figure 3-10 Successful H6PDH knock down in H6KO mice 
Measurement of H6PDH mRNA gene expression in A.U. by real-time PCR in 
quadriceps and liver explants from 7-8 weeks old H6KO mice. ** p<0.01 vs. WT liver, 
*** p<0.001 vs. WT muscle; n=4/group. All data are the mean A.U. values ±SEM.   
 
Additionally, hepatic and skeletal muscle microsomes were used to assess H6PDH 
enzyme activity in H6KO and WT mice using G6P as a substrate and NADP+ cofactor 
for murine H6PDH. High level of activity in WT mice and no activity in the hepatic 
microsomes from H6KO mice were recorded; however, residual H6PDH activity was 
still detected in skeletal muscle microsomes from H6KO mice (Figure 3-11).  
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Figure 3-11 Residual H6PDH enzyme activity in H6KO muscle microsomes 
H6PDH activity was determined spectrophotometrically by measuring the production of 
NADPH at 340 nm in the reaction containing the H6PDH-specific substrate G6P with 
readings taken at 20 s intervals for 3 mins. All data are the mean values ±SEM 
(n=3/group). 
                               
The 11β-HSD1 activity in muscle and liver explants in H6KO was switched off as 
previously described in H6PDHKO mice (Lavery et al. 2006) (Figure 3-12).  In liver 
and muscle (quadriceps), there was a reduction of an oxo-reductase activity whereas 
there was a significant increase of a dehydrogenase activity in liver and subtle,  
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but not significant in muscle. These data suggest that the H6KO mice endorse 
anticipated 11β-HSD1 biochemistry.  
 
Figure 3-12 H6KO mice displayed reduced oxo-reductase and increased 
dehydrogenase 11β-HSD1 activity 
The 11β-HSD1 enzyme activity in liver and muscle explants from H6KO and WT mice. 
* p<0.05, ** p<0.01 vs. WT. All data are the mean values ±SEM (n=3/group).  
 
In addition, the visual appearance of TA, consisting of type IIb fibres, was markedly 
changed in 7-10 weeks old H6KO mice compared with WT. H&E staining of H6KO 
TA muscle showed elevated atrophic and vacuolated type fibres (Figure 3-13B) 
whilst no such histological features were evident in WT mice (Figure 3-13A). The 
H6KO mice which were 7 or more weeks of age presented the features of the 
myopathy seen in previously generated H6PDHKO mice. Unlike TA, soleus muscle 
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from H6KO mice did not present the full phenotype of myopathy, and centralised 
nuclei were the only feature seen in its sections (Figure 3-13D) when compared to 
WT soleus (Figure 3-13C).  
 
Figure 3-13 Histological defects in skeletal muscle of H6KO mice 
Muscle sections of TA (A and B) and soleus (C and D) from WT (A and C) and H6KO 
(B and D) mice at 7-10 weeks stained with H&E. Vacuoles are present predominantly 
in type IIb fibres (B) when compared to control (A) and type I fibres which have only 
centralized nuclei shown by arrows (D) (each representative image is from n=3/group). 
The reference bar is 80 µM. 
 
We measured the H6KO myopathy markers associated with ER stress and activation 
of the UPR pathway. ER stress indicators, DNA damage-inducible transcript 3 
(DDIT3) and Heat Shock 70 kDa Protein 5 (HSPa5) (Figure 3-14), were elevated in 
quadriceps from the H6KO mice at 8 weeks of age. 
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Figure 3-14 Increased ER stress response in H6KO muscle 
Induction of ER stress markers, DDIT3 and HSPa5, in muscle (quadriceps) from  
8 weeks old H6KO and WT mice. All data are the mean A.U. values ±SEM from 
n=4/group experiments (* p<0.05, *** p<0.001 vs. WT). 
 
3.3.5.2 Characterisation of H6MKO mouse model 
H6PDH is an enzyme responsible for the NADPH production within the ER/SR 
lumen. However, it is also an important, 11β-HSD1 independent, regulator of the SR 
metabolic function. To eliminate the muscle-specific GC effects seen in H6PDH 
global KO mice, H6PDH muscle-specific mouse model (H6MKO) was generated. 
The expression of Cre recombinase used to produce H6MKO model is under the 
control of the Acta1 (alpha actin) promoter and is expected to excise exon 3 coding 
the catalytic domain of the conditional H6PD allele in skeletal muscle (Figure 3-15).  
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Figure 3-15 Generated H6MKO allele with exon 3 being removed by Acta1-Cre 
recombinase activity 
 
To validate H6MKO model (Cre/+;fl/fl), we assessed DNA recombination between the 
LoxP sites using genomic DNA from an ear clip (Figure 3-16).  
 
Figure 3-16 PCR detection of a Cre band and a KO allele using DNA isolated  
from an ear clip  
 
Initial characterisation of H6MKO mice using genomic DNA isolated from a range of 
tissues showed that recombination of the conditional to the KO allele is skeletal 
muscle-specific (Figure 3-17). Skeletal muscle (quadriceps and TA) was the only 
tissue to show recombination for removal of exon 3, with other tissues (including liver 
and kidney) remaining normal for floxed exon 3 H6PD allele. 
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Figure 3-17 Successful DNA recombination skeletal muscle-specific 
L-liver, K-kidney, Q-quadriceps, TA-tibialis anterior. 
 
After successful DNA recombination specific to skeletal muscle, H6PDH mRNA 
expression was assessed in the quadriceps and TA muscles of 14 weeks old 
H6MKO and WT mice by real-time PCR and was shown to be approximately 27% 
and 22% in the H6MKO compared to WT mice respectively (Figure 3-18A). 
Additionally, H6PDH protein was not detected in muscle (quadriceps) of H6MKO 
mice (Figure 3-18B). 
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Figure 3-18 H6PDH mRNA and protein expression measured in tissue explants 
from H6MKO and WT mice 
H6PDH mRNA expression in muscle (quadriceps and TA) showed significant reduction 
in H6MKO mice (A). All data are the mean A.U. values ±SEM (*<0.05; n=4/group).  
No H6PDH protein expression in muscle of H6MKO mice (B); α-tubulin was used as a 
loading control.  
 
 
 
In addition, the expression of ER stress markers was measured in a number of 
muscle tissues from H6MKO and WT mice of 14 weeks of age. There was a 
significant induction in DDIT3 and HSPa5 expression in quadriceps and TA muscles 
from H6MKO mice whereas in soleus muscle, there was a significant increase of 
DDIT3 expression and no change in HSPa5 expression (Figure 3-19). 
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Figure 3-19 Increased expression of ER stress markers in H6MKO mice  
Significant induction of DDIT3 mRNA expression in quadriceps, tibialis anterior (TA) 
and soleus muscle from H6MKO mice (A); elevated HSPa5 mRNA expression in 
quadriceps and TA whilst no change observed in soleus muscle from H6MKO mice (B). 
All data are the mean A.U. values ±SEM from n=4/group (*<0.05, **<0.01 vs WT). 
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3.3.5.3 Blood glucose  
H6MKO and matching WT mice were exposed to 16 h fasting in order to determine 
blood glucose levels. H6MKO mice displayed slightly decreased glucose level as WT 
mice in the fasting state. This did not reach statistical significance (Figure 3-20). 
 
Figure 3-20 Lack of significant difference in fasting blood glucose in H6MKO 
compared to WT mice  
Blood glucose concentration was determined after 16 h of food deprivation. All data are 
the mean values ±SEM from n=6/group (8-12 wk). 
 
 
3.3.5.4 Urinary GC analysis 
To assess systemic GC metabolism in H6MKO mice, we examined urinary GC 
metabolites derived from inactive 11-DHC or active corticosterone. Previously, we 
have demonstrated that H6PDHKO mice (both male and female) excreted the 
majority of their GC as metabolites of 11-DHC compared with WT (Figure 3-21B). 
Surprisingly, in urine from H6MKO mice, the proportion of 11-DHC metabolites was 
similar to WT (Figure 3-21A) suggesting that lack of H6PDH and subsequently 
NADPH cofactor for oxo-reductase activity of 11β-HSD1 enzyme in skeletal muscle 
was not sufficient enough to change the proportion of 11-DHC or corticosterone 
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metabolites. This supports that urinary ratio might be more driven by H6PDH-11β-
HSD1 enzyme complex from other tissues. 
 
Figure 3-21 Analysis of urinary steroid metabolites  
11-DHC metabolites as percent of corticosteroid metabolites in female H6MKO and WT 
mice. H6MKO mice excreted approximately 11% of corticosteroids as metabolites of 
11-DHC whereas WT mice >9% (A). All data are the mean values ±SEM from 
n=4/group (8-12 wk). Both male and female H6PDHKO mice excreted >90% and >60% 
of corticosteroids as metabolites of 11-DHC respectively (B) (Lavery et al. 2007).  
 
 
 
The H6MKO mouse model was generated and fully characterised using Acta1-Cre 
mouse line in order to evaluate the H6PDH role in muscle metabolism independently 
of other metabolic tissues. Despite the successful H6PDH knockout specific to the 
skeletal muscle, the preliminary fasting blood glucose and urine analysis measured in 
H6MKO mice were indistinguishable from WT mice highlighting the importance of the 
cross talk between adipose tissue and liver, but also could be due to an insufficient 
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number of mice tested. Consequently, further research was carried out utilising 
global H6KO mouse colony. 
 
3.4 Discussion 
The aim of this chapter was to assess the expression of the SR G6PT/H6PDH/11β-
HSD1 axis in models of differentiating skeletal muscle cells. Additionally, a further 
enzyme G6Pase-β was also examined in term of its expression. Furthermore, I also 
established some basic regulation by insulin and GC, as major determinants of 
muscle energy homeostasis. These four enzymes are involved in G6P metabolism 
within the SR ultimately influencing the SR NADPH/NADP+ ratio and GC metabolism.  
I have shown that across C2C12 myocytes and primary myoblasts differentiation, 
there was a significant increase in differentiation markers (α-actin, myogenin) during 
the transition from proliferating to differentiating muscle cells. However, this was 
observed to a lesser degree in primary myoblasts. Myogenin is a muscle-specific 
basic helix-loop-helix (bHLH) transcription factor inducing myogenesis, and α-actin is 
involved in muscle contraction (Moran et al. 2002). I have also shown increased  
11β-HSD1 and H6PDH mRNA expression across differentiation. Both these genes 
are involved in GC activation within the ER/SR lumen. Increased expression  
of 11β-HSD1 during differentiation process suggests intracellular GC role in the 
differentiation of skeletal myoblasts to mature myotubes (Biedasek et al. 2011). Thus 
it would appear that there was a coordinated up-regulation of 11β-HSD1 and H6PDH 
in response to differentiation signals, which were not present for G6PT and  
G6Pase-β. Therefore, these data might confirm the importance of these genes in 
skeletal muscle development. 
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Treatment of both C2C12 myoblasts and myotubes with DEX significantly enhanced 
the expression of 11β-HSD1 which generates active GCs. Expression of H6PDH was 
also significantly elevated in both myoblasts and myotubes. This indicates that DEX 
increases 11β-HSD1 enzyme expression suggesting that systemic GCs can enhance 
11β-HSD1 expression in the skeletal muscle which may have consequences for 
ageing and inflammatory aspects. Furthermore, treatment of C2C12 with DEX and 
GC antagonist, Ru38486, showed decrease in the 11β-HSD1 and H6PDH 
expression in C2C12 myoblasts compared to the treatment with DEX only. In 
differentiated C2C12 myotubes, co-incubation with Ru38486 did not change  
11β-HSD1 expression and partially, but not significantly, blocked DEX effects upon 
H6PDH expression. C2C12 treatments did not change G6PT and G6pase-β 
expression neither in myoblasts nor in myotubes. It shows that active GC level may 
not affect G6P transport into the ER/SR lumen by G6PT or its utilisation by G6Pase-β 
to produce glucose and inorganic phosphate in muscle. The Ru38486 inhibitor was 
not sufficient enough to completely reverse DEX effect. This is a GR antagonist to a 
lesser extent as it also shares progesterone receptor-blocking activity. Other 
methods involving inhibition of GR receptor could be carried out such as knocking 
down of GR in the cell culture or using another available GR antagonist 
(guggulsterone). However, similarly to Ru38486, guggulsterone is not GR-specific as 
it also inhibits mineralocorticoid, androgen and progesterone receptors. 
These data confirm that both C2C12 and primary muscle cells are good models to 
study glucose and GC metabolism in skeletal muscle. 
Secondly, to address further the important role of H6PDH in the regulation of  
11β-HSD1 and muscle SR redox, we established H6MKO mice to compare with 
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global H6KO mice. Fasting glycaemia and urinary GC metabolite excretion were 
measured. The H6KO mice recapitulated myopathy and ER stress seen in previously 
generated H6PDHKO mice (Lavery et al. 2008b); therefore, I have proceeded with 
further breeding in order to generate H6MKO mouse model. Subsequently, the 
H6MKO model was generated and characterised. I have shown a successful DNA 
recombination, significant knockout of H6PD gene on mRNA and protein level as well 
as partial and residual H6PDH activity in hepatic and muscle microsomes 
respectively. In addition, there was also induction in mRNA expression of DDIT3 and 
HSPa5 suggesting the presence of ER stress which leads to myopathy development. 
Although fasting glucose analysis showed no significant differences between H6MKO 
and WT mice, a slight reduction in blood glucose levels in H6MKO mice was 
recorded. This lack of power could be due to not sufficient number of mice in the 
study. Importantly, a previous study demonstrated lowered fasting glucose levels in 
H6PDHKO mice as an indicator of relative hypoglycaemia (P < 0.001)  
(Lavery et al. 2007). H6MKO mice have the same level of 11-DHC metabolites in 
urine as WT mice. Although skeletal muscle is a major component of the human 
body, the expression of SR enzymes was not observed to the same level as in other 
metabolic tissue such as liver. Low expression of H6PDH was not sufficient to 
increase dehydrogenase activity intracellularly, and this might clarify why there was 
no induction of 11-DHC metabolites in H6MKO mice. While skeletal muscle 
phenotype was fully recapitulated, the global GC metabolism did not differ from WT 
and most likely could be determined by other tissues. Due to lack of time and 
resources, further experiments using H6MKO colony could not be continued. Beside 
basic phenotyping and measurement of fasting blood glucose levels and urinary 
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metabolites, it would be interesting to carry out glucose and insulin tolerance tests, 
muscle strength test and also apply high fat diet experiments to investigate muscle 
H6PDH role in obesity. 
Further study was continued using global H6KO mouse model to analyse the 
underlying mechanisms of myopathy and insulin sensitivity development in the 
absence of H6PDH.  
We propose that further investigation of the associated role of H6PDH-11β-HSD1 in 
the skeletal muscle may be valuable in understanding its function in homeostasis  
and its potential role and manipulation in metabolic disease such as T2DM and 
insulin resistance. Therefore, the aim of next chapter was to generate an 11β-HSD1 
muscle-specific KO mouse mode.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Chapter 4- Evaluating the muscle-specific role 
of 11β-HSD1 
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4.1 Introduction 
The occurrence of obesity, T2DM and insulin resistance has now reached epidemic 
proportions and still continues to rise. On average, obesity is associated with a 
decreased life expectancy of at least 9 years increasing obesity-related health 
problems such as insulin resistance, a major risk factor for T2DM and CVD that 
increase morbidity and mortality (Kopelman et al. 2007). However, despite the 
magnitude of the clinical problems, the precise molecular mechanisms that contribute 
to pathogenesis of obesity-related insulin resistance and its pathologies remain 
unknown.  
Skeletal muscles play a key role in glucose utilisation accounting for 80-90% of 
peripheral glucose uptake, and they are also the major contributors to global insulin 
sensitivity. The effects of GC excess upon skeletal muscle are exemplified in patients 
with Cushing’s syndrome who, in addition to the classic phenotype of central obesity 
and insulin resistance (leading to T2DM in some), also develop profound proximal 
myopathy affecting predominantly type II fibres (Khaleeli et al. 1983). Furthermore, 
intracellular GC generation is increased as it has been shown that expression and 
activity of 11β-HSD1 are elevated in skeletal muscle of diabetic individuals and 
pharmacological inhibition of 11β-HSD1 is insulin sensitising  
(Biedasek et al. 2011;Morgan et al. 2009). To date, the precise mechanisms 
underpinning this observation have not been identified. 
GCs have potent effects upon carbohydrate and lipid metabolism. Previous studies 
have mainly focussed on their role in hepatic carbohydrate metabolism where they 
drive gluconeogenesis. In adipose tissue, GC effects are complicated; the lipolytic 
action of GC is well described (Slavin et al. 1994), but they can also redistribute into 
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visceral site as seen in Cushing’s syndrome. So far, the action of GCs upon 
carbohydrate and lipid metabolism in skeletal muscle has not been explored in detail. 
Skeletal muscle could play as important role as the liver and adipose tissue when 
considering the metabolic development of insulin resistance, and therefore the 
mechanisms by which GC metabolism can influence muscle phenotype requires a full 
investigation. 
Observations in patients with Cushing’s syndrome provide an insight into the 
pathogenic action of excess endogenous GCs in humans. However, in the vast 
majority of cases of simple obesity and insulin resistance, circulating GC levels are 
not elevated (Fraser et al. 1999). In key metabolic target tissues such as liver, 
adipose and muscle, local GC availability is controlled by a series of enzymes that 
either regenerate or inactivate cortisol. Intracellular glucocorticoid metabolism is 
mediated by 11β-HSD1, which activates cortisol from hormonally inactive cortisone in 
humans and 11-DHC to corticosterone in rodents. The 11β-HSD1 active site is within 
the ER/SR lumen where it is dependent upon the cofactor provider, the enzyme 
H6PDH, to maintain a high NADPH/NADP+ ratio required to support its  
oxo-reductase activity (Figure 4-1) (Lavery et al. 2008a). 
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Figure 4-1 Schematic representation of the G6PT/H6PDH/11β-HSD1 pathway  
in the ER/SR 
 
Interestingly, a recent study of healthy old and young people has found a significant 
association between increased muscle 11β-HSD1 expression and lower quadriceps 
strength. Elevated cortisol generation within muscle by 11β-HSD1 might contribute to 
loss of muscle strength with age, a key component of sarcopenia. Therefore, 
inhibition of 11β-HSD1 could be beneficial in preventing or delaying sarcopenia in 
order to increase healthspan (Kilgour et al. 2013). 
Experiments in transgenic mouse models have helped with better understanding of 
11β-HSD1 function in vivo in a number of metabolically important tissues such as 
liver (Lavery et al. 2012) and adipose (Bujalska et al. 2007). Over-expression  
of 11β-HSD1 in adipose causes all features of metabolic syndrome including obesity 
whereas over-expression in liver leads to insulin resistance without obesity  
(Paterson et al. 2004). Importantly, circulating corticosterone levels were not 
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increased in either models suggesting elevated intracellular GC availability underpins 
the observed phenotypes. Conversely, mice lacking 11β-HSD1 globally have lower 
tissue GC levels and display a cardio-protective phenotype on high fat diet  
(Masuzaki et al. 2001;Morton et al. 2001).  
The rodent model of Cushing syndrome and exogenous GC excess has been 
recently generated (Morgan et al. 2014). WT mice administrated with corticosterone 
(Cort) in drinking water displayed decreased grip strength paralleled to reduced mass 
of type IIb fibre-rich muscles but not the type I fibre-rich soleus muscles. In addition, 
Cort-treated mice had increased mRNA expression of several key atrophy markers 
including MuRF1 and atrogin1 as well as FoxO1, a transcription factor that regulates 
muscle mass. Interestingly, 11β-HSD1 global knockout mice were protected from 
skeletal muscle myopathy induced by Cort administration (Morgan et al. 2014). 
The functional importance of 11β-HSD1 was further shown using the selective  
11β-HSD1 inhibitor, A1, which was able to abolish the actions of 11-DHC in rodents 
and cortisone in humans promoting serine-307 phosphorylation of IRS1 and 
threonine-308 phosphorylation of Akt/PKB (Morgan et al. 2009). Phosphorylation of 
IRS1 negatively regulates its function by decreasing its affinity for the insulin receptor 
and increasing proteasomal degradation. These data show the importance of  
11β-HSD1 as a critical regulator of skeletal muscle insulin sensitivity and provide a 
new tool to investigate the role of GCs and 11β-HSD1 selective inhibitors in insulin 
resistance. Moreover, gene expression analysis using an in vivo rodent model has 
suggested that this may be mediated by alterations in lipid metabolism such as 
decreased lipogenesis, lipolysis and FFA availability (Morgan et al. 2009).  
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Deletion of 11β-HSD1 specifically in the liver in 11β-HSD1 LKO mice has shown 
subtle stimulation of the HPA axis increasing systemic GC production whereas their 
metabolic parameters are relatively minor. The LKO mouse model suggests the 
importance of other GC target tissues in determining global metabolic phenotype 
(Lavery et al. 2012). To investigate the role of 11β-HSD1 and GC availability in 
skeletal muscle, we have generated 11β-HSD1 muscle-specific knockout mice 
(HSD1MKO). We hypothesise that 11β-HSD1 inhibition within skeletal muscle plays 
as important role in the insulin sensitisation process as liver and adipose. 
On the basis of previous findings, we assume that inhibition of 11β-HSD1 in rodent 
skeletal muscle and abolishment of pre-receptor GC regeneration within the myocyte, 
will enhance insulin sensitivity, glucose utilisation and decrease intramuscular 
triglyceride accumulation and mobilisation ameliorating obesity and diabetes upon 
high fat feeding. We also hypothesise that muscle 11β-HSD1 contribute significantly 
to systemic GC levels and can impact upon metabolic GC biomarkers.  
In order to assess the skeletal muscle-specific contribution to the metabolic 
phenotype seen in 11β-HSD1 global knockout (HSD1GKO) mice, I have generated 
HSD1MKO mouse model using Cre-LoxP technology.   
 
4.2 Methods 
4.2.1 Primary skeletal muscle cells 
Primary cultures derived from skeletal muscle consisting mainly of myoblasts and 
myofibroblasts were isolated from mouse EDL muscle. Primary cells were maintained 
in 12-well TC plates in 1mL of DMEM supplemented with 10% horse serum  
and 0.5% chick embryo extract. Most of the myofibroblasts attached to the plate 
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surface during initial incubation period (2 hours). They were cultured until they 
reached 80% confluence to be subsequently used for 11β-HSD1 activity assessment. 
Myoblasts were transferred to a new 12-well plate and when they reached 60-70% 
confluence, differentiation was initiated by replacing proliferating medium with DMEM 
supplemented with 2% horse serum and 0.5% chick embryo extract. Differentiation 
medium was replaced every 48 h. After 8 days of differentiation, myoblasts fused to 
form multinucleated myotubes.  
 
4.2.2 RNA extraction 
Total RNA was extracted from 20 mg of tissue using Tri-reagent system. RNA 
concentration was determined spectrophotometrically at OD260 and integrity assessed 
by agarose gel electrophoresis. 1μg of RNA was used for reverse transcription (see 
Section 2.4). 
 
4.2.3 Real-time PCR 
11β-HSD1 (Mm00476182_m1) mRNA level was determined using the ABI 7500 
sequence detection system (Life Technologies, Warrington, UK). Primers and probes 
for all genes were supplied by Life Technologies. Reactions were performed in 
singleplex in triplicates as described in Section 2.6 and normalised against the 18S 
rRNA housekeeping gene.  
 
4.2.4 11β-HSD1 activity assay 
Tissue explants (~20 mg), 100 µg of muscle microsomes, confluent primary 
myofibroblasts or differentiated myotubes were incubated with 100 nM 11-DHC 
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supplemented with a tritiated tracer. Steroid incubation was carried out for 4 h for 
muscle tissue explants, microsomes and primary cells whilst 30 mins for liver. 
Subsequently, steroids were extracted using dichloromethane, separated using a 
mobile phase consisting of chloroform/absolute ethanol (92:8) by thin layer 
chromatography, and scanned using a Bioscan 200 imaging scanner  
(LabLogic, Sheffield, UK). 11β-HSD1 activity was expressed as pmol of 
corticosterone generated per g of tissue per hour of incubation or as a % conversion. 
 
4.2.5 Microsomes preparation 
Liver and skeletal muscle microsomes were prepared from 4- to 8-weeks old mice by 
differential centrifugation techniques as described in Section 2.9. The microsomal 
pellet was re-suspended in MOPs buffer and then immediately frozen in liquid 
nitrogen and stored at -80ºC (up to 6 months) prior to assessment of protein 
concentration.  
 
4.2.6 Rodent protocol 
All animal experiments and procedures were carried out in accordance with the 
British Home Office Guidance (Animals Scientific Procedures) Act 1986  
(Project Licence, PPL 30/2764). Mice were housed in standard pathogen-free 
conditions on a 12 h light/12 h dark cycle with access to standard rodent chow (when 
not fasting) and water ad libitum. 
On the day of experiment, mice were sacrificed by cervical dislocation, then liver, 
skeletal muscle (quadriceps, TA, soleus), heart, kidney and lung were removed and 
snap-frozen in liquid nitrogen for characterisation of DNA recombination and mRNA 
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expression. To measure 11β-HSD1 activity, tissue was freshly harvested in the 
serum-free DMEM and used directly for the assay. 
 
4.2.7 Generation of 11β-HSD1 muscle-specific knockout (HSD1MKO) 
The Cre/LoxP technology can be used to delete loxP-flanked chromosomal DNA 
sequences in selected tissue of transgenic animals (Rao and Monks 2009). To 
generate HSD1MKO mouse model, I have used three different muscle-specific Cre 
lines.  
Firstly, we have purchased a transgenic mouse expressing Cre recombinase under 
the control of a skeletal muscle-specific promoter from the mef2c gene. The Cre 
expression in this transgenic line is exclusively restricted to all skeletal muscle from 
early in development. Secondly, as an alternate method, the Acta1-Cre transgenic 
was purchased from the Jackson Laboratory (Maine, US). The Acta1-Cre transgenic 
mice have Cre recombinase gene driven by the Acta1 promoter that encodes  
α-skeletal muscle actin expressed as the major component of the thin filament in 
skeletal muscle (Saito et al. 2011a). This Cre activity is restricted to skeletal muscle 
tissue and heart. These mice have been used to breed with the conditional  
11β-HSD1 all on the C57BL/6 background to generate the HSD1MKO mice. Thirdly,  
I have also tested muscle creatine kinase Cre (MCK-Cre) transgenic mouse line that 
have Cre recombinase gene driven by the MCK promoter. 
 
4.2.7.1 Genotyping 
The following primers were used for genotyping of HSD1MKO mice to confirm the 
presence of the Cre transgene: 
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PCR detection of the HSD11B1 KO alleles was carried out using P1+P2 primers 
which give a 138 bp product for a WT allele and a 172 bp product for a conditional 
allele containing a 3′ LoxP site (Lox+/+). After a P2 binding site is removed and 
P1+P3 are brought into proximity producing a 279 bp KO band confirming successful 
Cre recombination and exon 5 removal. The occurrence of two bands represents het 
(both KO and WT bands are present). The following primers were used: 
 
 
PCR reactions were carried out as in Section 2.5, and 2.2 % agarose gel was run to 
confirm the size of the product. 
 
4.3 Results 
4.3.1 HSD1MKO validation 
To characterise the HSD1MKO mice model, DNA, RNA and 11β-HSD1 enzyme 
activity work were assessed. 
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In the first strategy, the Cre cDNA was cloned under the control of the mef2c skeletal 
muscle promoter to design mef2c-73k-Cre construct (Heidt and Black 2005); 
however, DNA extraction from tissue explants did not show successful recombination 
of this gene in skeletal muscle tissue. I have repeated these experiments three times 
(including mRNA screening and 11β-HSD1 activity assays), and after getting the 
same results, the colony was closed down (data not shown). As the Mef2c-Cre in 
these experiments appeared to be no functional, a second strategy was carried out; 
we purchased Acta1-Cre transgenic mice expressing Cre recombinase under the 
control of Acta1 (alpha actin) promoter (Figure 4-2A) (Saito et al. 2011b) from the 
Jackson Laboratory. I assessed recombination between the LoxP sites using 
genomic DNA isolated from an ear clip (Figure 4-2B) as previously shown in liver 
(Figure 4-2C) in our group (Lavery et al. 2012). 
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Figure 4-2 Targeting strategy and HSD1MKO validation  
Targeting strategy for HSD1MKO generation. The exon 5 of a conditional allele was 
flanked with LoxP sites and bred with the muscle-specific Acta1-Cre mice to design 
knockout allele (A). PCR detection of a knockout allele validating the HSD1MKO 
model. PCR products derived from HSD1 primer sets on DNA isolated from an ear clip 
(B) (n=3/group). Successful knockout of 11β-HSD1 in liver (C) (Lavery et al. 2012). 
 
Initial characterisation of HSD1MKO mouse line has shown that recombination of a 
conditional to a KO allele is skeletal muscle-specific. Skeletal muscle (quadriceps, 
soleus and TA) was the only tissue to show recombination for removal of exon 5 
whilst other tissues (including liver, lung, kidney and also heart although it expresses 
Acta1 gene) remained normal for floxed exon 5 HSD11B1 alleles (Figure 4-3). 
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Figure 4-3 Genomic DNA recombination is specific to the skeletal muscle 
(quadriceps, TA, soleus)   
Abbreviations: TA (tibialis anterior). 
 
Following successful DNA recombination specific to skeletal muscle, 11β-HSD1 
mRNA expression was assessed in the quadriceps muscle by real-time PCR. 
Unexpectedly, there was no significant difference between HSD1MKO and WT mice 
on mRNA level (Figure 4-4). 
 
Figure 4-4 11β-HSD1 mRNA expression measured in quadriceps explants 
There was no significant reduction of 11β-HSD1 expression in muscle from HSD1MKO 
mice. All data are the mean A.U. values ±SEM from n=7-8/group. 
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Additionally, validation of the HSD1MKO model at the mRNA level was also carried 
out in a number of tissues (liver, heart, lung, kidney, quadriceps, soleus and TA), and 
11β-HSD1 expression was compared to the same tissue collected from WT mice 
(Figure 4-5). However, there was no significant reduction in 11β-HSD1 mRNA 
expression in quadriceps, TA and soleus muscle tissues.  
 
Figure 4-5 11β-HSD1 mRNA expression measured in tissue explants  
from HSD1MKO and WT mice 
11β-HSD1 expression in the muscle tissues showed no significant difference between 
HSD1MKO and WT mice. All data are the mean fold change values ±SEM from n=7-
8/group for quadriceps (quad), n=4/group for other tissues. Abbreviations: TA (tibialis 
anterior).  
 
To further characterise the HSD1MKO model, the 11β-HSD1 oxo-reductase activity 
was measured in quadriceps explants from HSD1MKO and WT mice (Figure 4-6). 
Again, there was no significant difference between HSD1MKO and WT muscle 
explants in the ability to reduce 11-DHC to corticosterone. This confirmed the mRNA 
data, but did not corroborate with the level of recombination seen at the DNA level. 
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Figure 4-6 The 11β-HSD1 enzyme activity in quadriceps muscle explants  
Representative activity traces. All data are the mean values ±SEM from n=3/group in 
triplicate. 
 
To further validate our model, the oxo-reductase activity of 11β-HSD1 in the SR was 
measured in microsomes prepared from skeletal muscles. The activity was measured 
in intact microsomes pre-incubated with or without 10 mM G6P and 10 mM NADPH 
for 30 mins. Previously, we have shown that in the presence of the substrate, 
conversion of 11-DHC to corticosterone was elevated in WT mice  
(Lavery et al. 2006). As expected, the activity seen in HSD1MKO and WT 
microsomes pre-incubated with G6P and NADPH was increased; however, 
disappointly, there was no significant difference in activity between HSD1MKO and 
WT mice (Figure 4-7). 
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Figure 4-7 Measurement of 11β-HSD1 oxo-reductase activity in muscle 
microsomes derived from HSD1MKO and WT mice 
Below each graph is indicated whether microsomes were intact or pre-incubated with 
G6P and NADPH. All data are the mean values ±SEM from n=3/group in triplicate. 
 
In addition, 11β-HSD1 activity was also measured in myotubes and myofibroblasts 
using murine primary skeletal muscle cells. Again, there was no significant difference 
between HSD1MKO and WT cells in the ability to reduce 11-DHC to corticosterone 
(Figure 4-8). Despite successful recombination at the DNA level, this supports the 
mRNA data and activity measured in both muscle explants and muscle microsomes.  
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Figure 4-8 Measurement of 11β-HSD1 oxo-reductase activity  
11-DHC reduction in primary myotubes (A) and in primary myofibroblasts (B) derived 
from HSD1MKO and WT male mice. All data are the mean values ±SEM from 
n=3/group in triplicate. 
 
The HSD1MKO mouse model was generated using Acta1-Cre mouse line and 
characterised in order to study GC-dependent mechanism affecting muscle 
metabolism. However, the line was closed down due to only partial and no significant 
loss of 11β-HSD1 expression. As third strategy, I have tested a muscle-specific 
MCK-Cre line, expressing Cre recombinase in skeletal muscle under the control of 
the muscle creatine kinase promoter (MCK-Cre mice). Again, a successful 
recombination on DNA levels was achieved whilst 11β-HSD1 mRNA expression and 
11β-HSD1 oxo-reductase activity remained unchanged when compared to WT mice 
(data not shown). 
 
4.4 Discussion 
Previous studies using transgenic animal models have highlighted the critical role of 
11β-HSD1 in the regulation of metabolic phenotype in different tissues. 
Overexpression of 11β-HSD1 in liver leads to insulin resistance and hypertension 
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(Paterson et al. 2004) whereas overexpression in adipose tissue results in visceral 
obesity, insulin resistance, hypertension and dyslipidemia (Masuzaki et al. 2001). 
Interestingly, circulating corticosterone levels were not elevated in both models 
suggesting that increased intracellular GC availability underpins the observed 
phenotypes. Consequently, this has led to the development of selective 11β-HSD1 
inhibitors as a potential novel therapy for patients with diabetes, obesity, and 
hypertension (Rosenstock et al. 2010). 
The HSD1GKO mice are protected from the adverse metabolic consequences of 
exogenous GC administration including skeletal myopathy (Morgan et al. 2014). As 
muscle is a prime determinant of insulin sensitivity playing a major role in glucose 
and lipid homeostasis, we believe that inhibiting 11β-HSD1 in muscle would be of 
great importance. Thus, selective 11β-HSD1 inhibitors are a promising therapy to 
limit the side effects associated with GC excess. To further examine 11β-HSD1 and 
GC availability in skeletal muscle, a muscle-specific knockout of 11β-HSD1 was 
generated by expressing Cre recombinase under the control of three different 
skeletal muscle-speciﬁc promoters from the mef2c, Acta1 and MCK genes. According 
to actual knowledge, the Cre expression in these transgenic lines should be 
completely restricted to skeletal muscle and heart from early stage in development 
and should be present in all types of skeletal muscles including fast and slow ﬁbers 
(Agrawal et al. 2012;Bruning et al. 1998;Heidt and Black 2005). However, mRNA 
expression (sequences of primers and probes covered deleted exon 5) and  
11β-HSD1 activity (p=0.4385) were still present in skeletal muscle tissues of the 
knockouts despite high level recombination at DNA level (see Figure 4-3). This was 
in contrast to previously demonstrated efficiency with our successful knockout of  
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11β-HSD1 restricted only to liver (Lavery et al. 2012). As muscles are highly 
heterogeneous tissues, we hypothesised that there could be additional non-myocyte 
cell types highly expressing 11β-HSD1 present within skeletal muscle tissue such 
myofibroblasts, satellite cells and stromal cells (Figure 4-9).  
 
Figure 4-9 The constituent cell types of skeletal muscle 
 
To validate the genotype, myotubes and myofibroblasts were isolated from the EDL 
muscle and 11β-HSD1 activity was measured. Despite correct validation on genetic 
level, there was still oxo-reductase activity in HSD1MKO myotubes to similar level 
seen in WT. Initial characterisation of HSD1MKO mouse model demonstrated that 
skeletal muscle was the only tissue to show recombination for removal of exon 5; 
however, the high levels of 11β-HSD1 expression in different muscle types and  
11β-HSD1 activity still remained in the muscle explants, muscle microsomes and 
primary myotubes/myofibroblasts. Disappointingly, despite using three different Cre 
mouse lines, we were unable to generate a successful mouse model with 11β-HSD1 
activity depleted only in skeletal muscle. This could be due to the nature of muscle 
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tissue precluding it complete depletion; however we believe, there is still potential of 
applying 11β-HSD1 inhibitors to protect from myoatrophy caused by GC 
administration and excess.  
Regardless of successful DNA recombination to similar level seen in LKO mouse 
model, high expression of mRNA (muscle explants) and activity (muscle explants, 
muscle microsomes and primary myotubes) was still detected. Cre mediated 
recombination is never 100% and being a syncytialised cell type, it could be that high 
NADPH cofactor and remaining functional HSD11B1 gene in some nuclei of muscle 
fibres were sufficient enough to reduce 11-DHC almost to the same level seen in WT 
mice across the cell. If successful, this would have been an excellent model to 
determine a number of important points regarding 11β-HSD1, examining its function 
in the regulation of muscle glucocorticoid production and muscle energy metabolism 
in health and disease. 
We propose that GC metabolism in skeletal muscle is controlled by 11β-HSD1 to 
lesser degree than in other tissues. Urine analysis from our H6MKO mouse model 
confirms that pre-receptor GC metabolism in muscle is not sufficient to increase 
extracellular circulating GC level as previously seen in H6PDHKO, HSD1GKO and 
DKO mice (Semjonous et al. 2011). This has been probably caused by the 
contribution of all organs as systemic GCs were also not changed in LKO mice 
(Lavery et al. 2012).  
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 5- Novel stress response in H6PD 
depleted skeletal muscle  
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5.1 Introduction 
H6PDH plays an important role in maintaining NADPH levels and redox environment 
within the SR regulating skeletal muscle SR NADPH/NADP+ ratio and local GC 
generation (Lavery et al. 2006;Lavery et al. 2008b). In an effort to outline further the 
roles that H6PDH and 11β-HSD1 play in metabolism and muscle function, a 
H6PDH/11β-HSD1 DKO mouse has been developed in which the dehydrogenase 
activity of 11β-HSD1 seen in the H6PDHKO mouse was negated. Effectively, the 
DKO model has returned GC metabolism, GC sensitivity and the HPA axis set point 
to levels seen in the 11β-HSD1KO mouse. Critically, in contrast to the 11β-HSD1KO 
mice, DKO mice have phenocopied the salient features of H6PDHKO mice displaying 
type IIb fibre myopathy associated with reduced skeletal muscle mass and poor force 
generation contributing to decreased locomotor activity. The H6PDHKO mice have 
also displayed insulin sensitisation, increased muscle glycogen deposition and 
maintained fasting hypoglycaemia (Figure 5-1) (Lavery et al. 2008b; 
Semjonous et al. 2011). These findings are consistent with an 11β-HSD1 and GC 
independent function of H6PDH in which SR G6P metabolism and NADP+/NADPH 
redox status are important for maintaining muscle homeostasis. 
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Figure 5-1 Model of H6PDH deficiency and skeletal muscle myopathy 
The H6PDHKO mice display a number of metabolic changes including skeletal muscle 
myopathy, increased glucose uptake, ER stress and subsequently elevated UPR 
activation. 
 
 
In addition, H6PDH deletion disrupts the ER redox balance and eventually, in 
H6PDHKO mice, ER stress responses and the UPR pathway are triggered and 
regulated by the expression of numerous genes involved in maintaining ER 
homeostasis (Figure 5-2) (Lavery et al. 2008b;Walter and Ron 2011).  
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Figure 5-2 A model for the activation of the UPR in the H6PDHKO mice 
The loss of H6PDH and consequently change in NADPH/NADP+ ratio affects the redox 
balance of the ER resulting in unfolded protein accumulation and activation of the 
PERK, ATF6 and IRE1 pathways. They slow general protein translation and increase 
the expression of specific chaperones, degradative proteins and enzymatic pathways 
that expands SR volume. Abbreviations: BiP (binding immunoglobulin protein), PERK 
(PKR-like ER protein kinase), ATF6 (activating transcription factor -6), IRE1 (inositol 
requiring enzyme 1), eIF1α (eukaryotic initiation factors 1α), XBP1 (X-box-binding 
protein 1). 
 
In H6PDHKO mice, there is a complex interplay of GCs, insulin sensitivity and ER 
stress, as explained earlier. The majority of metabolic and structural changes appear 
to be age-related and secondary to an initial early life triggers when the ER 
stress/UPR pathways are initiated. A number of integrated factors might be involved 
including change in GC metabolism, increase of SR redox sensitivity or metabolic 
changes affecting intermediary metabolism. H6PDH contributes to the NADPH 
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content and SR redox environment (Rogoff et al. 2010). Microsomes from H6PDHKO 
SR are more oxidised than WT SR microsomes, as shown by an increased 
NADP+/NADPH ratio (Zielinska et al. 2011). 
Previously, bioinformatic analysis of microarray data, using the Affymetrix human 
mouse genome 430 2.0 oligonucleotide array set and complied with the Minimum 
Information about a Microarray Experiment standard, generated from the TA and 
soleus muscles of 4 weeks old H6PDHKO mice identified a large set of differentially 
expressed genes (>300) that group into a number of pathways such as structural 
components, polyamine biosynthesis, purine salvage, intermediary metabolism and 
most prominently ER/SR stress and the UPR. The ER/SR stress and UPR activation 
affect the normal protein-folding environment of the ER/SR and consequently their 
transit through the ER/SR. This is an important determinant of myopathy progression 
in H6PDHKO mice (Lavery et al. 2008b). Because myopathy does not develop from 
birth, it is important to identify the preceding triggers initiating ER stress that might be 
informative to protein response. An analysis of changes in the expression of the top 
ranked de-regulated genes indicated that a number of metabolic pathways precede 
changes in the UPR pathway by 1 to 2 days post weaning. This analysis was based 
on just the top 2 de-regulated metabolic and UPR genes (Figure 5-3).  
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Figure 5-3 Bioinformatics analysis of microarray data in the H6PDHKO mice 
(unpublished data) 
 
I wish to extend this analysis and by qPCR screening additionally assess an 
extended panel of the most up- or down-regulated genes, not involved in the ER or 
UPR stress response. The aim of this chapter is to generate genes expression profile 
in order to determine early changes in transcription which might be potential 
indicators of perturbations leading to the development of myopathy and SR stress in 
H6PD depleted muscle.  
 
5.2 Methods 
5.2.1 C2C12 cell culture 
Proliferating C2C12 myoblasts were cultured in DMEM supplemented with 10% FCS 
and seeded into 12-well TC plates. Differentiation was initiated when cells reached 
60-70% confluence by replacing GM with DMEM medium supplemented  
with 5% horse serum and was carried on for 8 days.  
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5.2.2 Cell treatments 
C2C12 treatment was commenced upon differentiation day 4 when cells fused to 
form myotubes. Cells were grown for 24 h in glucose-free GM and also in the 
presence of different glucose concentrations such as 25 mM, 12.5 mM and 4 mM.  
All cell treatments were carried out using serum free medium. GM was changed to 
FCS-free DMEM 4 h before each treatment. Cells were treated with DEX (1 µM) and 
insulin (1 µM) for 24 h.  
 
5.2.3 RNA extraction 
Total RNA was extracted on day 0, 2, 4, 6 and 8 of C2C12 differentiation and also 
from ~20 mg of tissue explants using Tri-reagent system. RNA concentration was 
determined spectrophotometrically at OD260 and its integrity assessed by agarose gel 
electrophoresis. 1 μg of RNA was used for reverse transcription (see Section 2.3). 
 
5.2.4 Real-time PCR 
Gene expressions have been measured using Life Technologies primers and probes; 
AMPD1 (Mm01308676_m1), AMD1 (Mm04207265_gH), SMOX (Mm00461100_m1), 
FRZB (Mm00441378_m1), MYH2 (Mm01332564_m1), PYCR1 (Mm00522674_m1), 
EEF2 (Mm01171434_g1), PRRX1 (Mm00440932_m1), ENO3 (Mm00468267_m1), 
MTHFD2 (Mm00485276_m1), NMRK2 (Mm01172895_m1), NAMPT 
(Mm00451938_m1), NMNAT1 (Mm01257929_m1), NADSYN1 (Mm00513448_m1), 
NMRK1 (Mm00521050_m1), AFMID (Mm00510774_m1), NMNAT2 
(Mm00615393_m1), NMNAT3 (Mm00513791_m1), INDO (Mm00492586_m1), QPRT 
(Mm00504998_g1) and NAPRT1 (Mm01205844_g1). mRNA levels were determined 
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using the ABI 7500 sequence detection system (Life Technologies, Warrington, UK). 
Reactions were performed in singleplex in triplicates as described in Section 2.6 and 
normalised against the 18S rRNA housekeeping gene.  
 
5.2.5 Cell fractions preparation 
The microsomal, cytosolic and mitochondrial fractions were prepared from skeletal 
muscle of 14 weeks old WT mice by differential centrifugation techniques as 
described in Section 2.9. The supernatant from the first centrifugation was removed 
and the mitochondrial pellet was re-suspended in MOPs buffer. Followed by the 
centrifugation at 100,000 g for 1 h, the cytosolic supernatant was collected. The 
microsomal pellet was re-suspended in MOPs buffer after a series of washes. All cell 
fractions were immediately frozen in liquid nitrogen and then stored at -80ºC (up to 6 
months) prior to assessment of protein concentration.  
 
5.2.6 Immunoblotting 
Proteins were extracted from C2C12 cells and tissue explants. Their concentration 
was determined as described in Section 2.10. For nicotinamide riboside kinase 2 
(NMRK2) and nicotinamide phosphoribosyltransferase (NAMPT), 25 μg of protein 
whereas for NMRK2, NAMPT and BiP, 25 µg of microsomal, cytosolic and 
mitochondrial fractions were resolved on 10% SDS-PAGE gels. Proteins were 
transferred to nitrocellulose membranes at 140 mA for 1 h 30 mins. Primary NMRK2 
(1:1,000) and NAMPT (1:1,000) antibodies were purchased from Generon Ltd 
Marketplace, UK whereas secondary antibodies from Dako, Glostrop, UK were used 
at a dilution of 1:10,000 and 1:1,000 respectively. The BiP antibody (BD Biosciences, 
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Oxford, UK) was used at a dilution of 1:1,000. Membranes were re-probed for  
α-Tubulin and primary and secondary antibodies used at a dilution of 1:1,000 
(Abcam, Cambridge, UK). Bands were visualised using ECL detection kit  
(GE Healthcare, Bucks, UK). 
 
5.2.7 NAD+ assay 
The NADH/NAD+ supernatant was extracted from C2C12 cells grown in the medium 
containing different glucose concentrations and from ~20 mg of muscle tissue 
explants. A BioVision’s NADH/NAD+ Quantification Kit was used to detect NADH, 
NAD+ and their ratio as described in the Section 2.13. The readings at OD 450 nm 
were taken after 2 hours of incubation at room temperature. 
 
5.2.8 Histology 
Quadriceps muscle was harvested from mice and then fixed in 10% neutral buffered 
formalin. Each muscle, from both 3 and 8 weeks old H6KO and WT mice (n=3 for 
each age), was paraffin embedded and cut into 5 µm sections to be stained by H&E 
to provide histological details of muscle structure.  
 
5.2.9 Rodent protocol 
Mice were housed in standard conditions on a 12 h / 12 h light-dark cycle with access 
to standard rodent chow and water ad libitum. All procedures were carried out in 
accordance with the UK Animals (Scientific Procedures) Act, 1986. On the day of 
experiment mice were sacrificed by cervical dislocation, then liver and skeletal 
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muscle (quadriceps, TA, soleus) tissues were removed, snap-frozen in liquid nitrogen 
and stored at -80ºC.  
 
5.2.10 Statistical analysis 
Where data were normally distributed, unpaired Student t-tests were used to 
compare single treatments to control using SigmaStat 3.1 (Systat Software, CA, US). 
One way ANOVA on ranks was used to compare multiple treatments, doses or times 
using SigmaStat 3.1. Statistical analysis on PCR data was performed on mean ΔCt 
values.  
 
5.3 Results  
5.3.1 Defining early metabolic factors leading to myopathy development 
through transcriptional profiling 
To identify novel stress response genes, involved in the perturbation of the SR redox 
environment, that initiate ER stress, the analysis were extended to additional panel of 
the most up- or down-regulated genes, not involved in the ER or UPR stress 
response (Table 5-1). I have evaluated the H6KO muscle at 3 weeks of age, when no 
ER stress and myopathy are evident (Figure 5-4A) and compared these to 8 week 
old myopathy-affected muscle (Figure 5-4B) in order to define the earliest changes 
that precede myopathy. 
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Figure 5-4 Histological defects in skeletal muscle of H6KO 
Quadriceps sections stained with H&E show vacuoles present predominantly in type IIb 
fibres in 8 weeks old H6KO mice shown by black arrows (B) when compared  
to 3 weeks old mice (A) (representative image shown from n=3/group). The reference 
bar is 80 µM. 
 
Unlike at 8 weeks old H6KO mice, at 3 weeks only 5 genes: AMD1, PYCR1, 
MTHFD2 and MYH2 were moderately, albeit significantly differentially expressed, 
though not to the same degree as at 8 weeks (Table 5-1). However, the most striking 
and highly significant difference observed at 3 weeks was elevated expression  
(~85-fold increase) of the gene, NMRK2, also known as muscle integrin binding 
protein (MIBP) or integrin binding protein 1 beta 3 (ITG1BP3)  
(Bieganowski and Brenner 2004). 
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Table 5-1 Gene expression in quadriceps from H6KO and WT mice 
Data are presented as A.U., mean ± standard deviation (SD). ↔ No significant change 
in expression, ↓ gene down-regulated, ↑ gene up-regulated compared to WT; n=4. 
Abbreviations: AMPD1 [adenosine monophosphate deaminase 1 (isoform M)], AMD1 
(adenosylmethionine decarboxylase 1), SMOX (spermine oxidase), FRZB (frizzled-
related protein), MYH2 (myosin, heavy polypeptide 2, skeletal muscle, adult), PYCR1 
(pyrroline-5-carboxylate reductase 1), EEF2 (eukaryotic translation elongation factor 2), 
PRRX1 (paired related homeobox 1), ENO3 (enolase 3, beta muscle), MTHFD2 
[methylenetetrahydrofolate dehydrogenase (NAD+ dependent)]. 
 
 
 
 
Gene 
Symbol 
mRNA expression 
(A.U.±SD) 
P value 
mRNA expression 
(A.U.±SD) 
P value 
3 weeks old 8 weeks old 
WT KO WT KO 
AMPD1 90.4±24.1 76.5±12.9 ↔ 59.4±7.8 5.2±1.8 3. 1E-13 ↓ 
AMD1 4.5±0.6 3.3±0.3 0.03 ↓ 46.1±8.1 6.2±0.2 6.13E-05 ↓ 
SMOX 6.9±3.6 3.9±1.4 ↔ 21.3±7.4 7.4±0.8 0.0097 ↓ 
FRZB 1.4±0.3 2.2±0.6 ↔ 0.5±0.1 0.2±0.05 0.00015 ↓ 
MYH2 8.7±3.0 33.7±9.4 0.01 ↑ 5.7±2.6 24.6±4.1 0.00024 ↓ 
PYCR1 0.7±0.05 0.9±0.1 0.003 ↑ 0.4±0.05 2.0±0.3 1.1E-05 ↑ 
EEF2 49.9±20.9 93.0±18.0 ↔ 54.1±3.9 116.7±7.9 7.67E-06 ↑ 
PRRX1 3.6±0.8 5.5±1.0 ↔ 3.3±0.2 0.08±0.04 1.32E-08 ↓ 
ENO3 254.7±47.4 259.2±96.9 ↔ 228.3±33.8 173.1±9.3 0.019 ↓ 
MTHFD2 4.5±0.6 3.3±0.3 0.03 ↓ 0.3±0.03 4.2±0.4 1.43E-06 ↑ 
NMRK2 0.7±0.2 66.9±7.0 2.69E-11 ↑ 5.73±2.34 83.27±15.9 1.05E-10 ↑ 
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5.3.2 NMRK2 as the most up-regulated gene in 3 week old H6KO mice 
To further revaluate the NMRK2 mRNA data in the muscle of 3 weeks old H6KO 
mice, we examined NMRK2 protein expression (25 kDa) by Western immunoblotting. 
Protein expression of NMRK2 was also significantly increased compared to age 
matched WT controls (Figure 5-5).   
 
Figure 5-5 NMRK2 mRNA and protein level induction in the 3 weeks of age H6KO 
mice compared to WT mice 
α-Tubulin was used as a loading control. All data are the mean A.U. values ±SEM from 
n=4/group (***˂0.001).  
 
5.3.3 Elevated cellular NAD+ content associated with increased NMRK2  
A major pathway proposed to determine skeletal muscle NAD+ cellular content is the 
NMRK2 mediated salvage of nicotinamide riboside (NR)  
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(Bieganowski and Brenner 2004). NMRK2 was highly up-regulated in H6KO mice; 
therefore, we measured tissue level of NAD+. This assay demonstrated that indeed 
NAD+ levels were also increased associated with elevated expression of NMRK2 due 
to deficiency of H6PDH (Figure 5-6). 
 
Figure 5-6 Increase in cellular NAD+ content in H6KO mice when compared to WT 
mice 
NAD+ induction in pre-myopathy affected quadriceps muscle. All data are the mean 
values ±SEM from n=4/group (*<0.05). 
 
 
5.3.4 NAMPT and NMNAT1 expression increased in H6KO mice 
NMRK2 expression and NAD+ content were highly up-regulated in muscle of H6KO 
mice; thus, we assessed the mRNA expression of other genes involved in NAD+ 
metabolism such as NAMPT and nicotinamide mononucleotide adenylyltransferase 
1 (NMNAT1) (Figure 5-7). 
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Figure 5-7 Schematic pathway of NAMPT, NMNAT1 and NMRK2 activity leading 
to NAD+ generation 
The major route to NAD+ in muscle is via NAMPT salvage of NAM, and the NMRK2 
mediated salvage of NR.  
 
There was a significant up-regulation of both NAMPT and NMNAT1 in 3 weeks old 
H6KO mice when compared to matching WT; however, not to the same degree as 
NMRK2 (Figure 5-8). 
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Figure 5-8 Induction of NAMPT and NMNAT1 mRNA expression in H6KO mice  
NAMPT and NMNAT1 mRNA expression was increased in quadriceps muscle from 
H6KO mice when compared to WT mice. All data are the mean A.U. values ±SEM from 
n=4/group (*˂0.05). 
 
5.3.5 NMRK2 is critically involved in NAD+ salvage 
NMRK2 expression is restricted to skeletal muscle, and to a lower degree heart 
playing a role in NAD+ metabolism (Bieganowski and Brenner 2004). NAD+ is an 
essential redox coenzyme and is generated by a number of routes, including through 
the salvage of the dietary vitamin NR. To examine the relative importance of NMRK2 
in muscle NAD+ metabolism, we screened the expression of all known genes 
involved in NAD+ metabolism in the slow twitch rich soleus, and fast twitch rich TA 
muscle, with the results displayed as a heat map in Figure 5-9. The microarray 
results showed that, in soleus and TA skeletal muscles, NMRK2 was the most highly 
expressed gene followed by NAMPT. Interestingly, NAD synthetase 1 (NADSYN1), a 
key rate limiting enzyme in NAD+ classical de novo and the Preiss-Handler pathways, 
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was not expressed in soleus and TA muscle tissues. These data suggest that the 
NMRK2 and NAMPT mediated NAD+ salvage pathways are predominantly 
responsible for regulating NAD+ content in skeletal muscle.   
 
Figure 5-9 De novo, Preiss-Handler and salvage routes to NAD+ synthesis  
in soleus (sol) and TA muscle 
Only the salvage routes were expressed, and NMRK2 appeared at the mRNA level to 
be the most abundantly expressed with fast twitch TA muscle having the greatest 
expression. Abbreviations: AFMID (Arylformamidase), INDO (Indoleamine  
2,3-dioxygenase 1), QPRT (Quinolinate phosphoribosyltransferase), NAPRT1 
(Nicotinate phosphoribosyltransferase domain containing 1). 
 
 
 
A 5-fold enrichment of NMRK2 mRNA in the more glycolytic type IIb fibre rich TA 
compared to type I fibre rich soleus is shown in Figure 5-10. This correlates with the 
fibre type affected most severely by myopathy in H6KO mice. NMRK2 expression  
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is more prominent in fast-twitch muscle fibres that have a higher metabolic capacity 
compared to slow-twitch muscle fibres (Chang et al. 2014) suggesting type IIb fibres 
are more sensitive to change in NAD+ content.  
 
Figure 5-10 NMRK2 was enriched in type II fibre rich TA muscle 
NMRK2 mRNA and protein expression was greatly increased in TA muscle compared 
to soleus muscle from 3 weeks old WT mice. α-Tubulin was used as a loading control. 
All data are the mean A.U. values ±SEM from n=3/group (*˂0.05). Abbreviations: SOL 
(soleus), TA (tibialis anterior). 
 
The salvage of NAM through the NAMPT and the salvage of NR through NMRK2 are 
the major routes of NAD+ biosynthesis in skeletal muscle. Therefore, I also examined 
NAMPT expression in TA and soleus muscles. There was increase; however, not 
significant in NAMPT mRNA and protein expression in TA compared to soleus 
muscle (Figure 5-11) suggesting that NMRK2 salvage pathway contributes more to 
NAD+ synthesis in fast twitch muscle type than NAMPT. 
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Figure 5-11 NAMPT mRNA and protein expression in TA muscle  
There was no significant difference in NAMPT mRNA and protein expression between 
soleus and TA muscles. α-Tubulin was used as a loading control. All data are the mean 
A.U. values ±SEM from n=3/group (*˂0.05). Abbreviations: SOL (soleus), TA (tibialis 
anterior), NS (not significant). 
 
5.3.6 NMRK2 expression is restricted to cytosol 
To localise NMRK2 pathway to a cell-specific compartment, I have investigated the 
expression of NMRK2 within different cell fractions including microsomes, cytosol and 
mitochondria as well as I used whole muscle tissue (TA) as a positive control. I have 
shown that NMRK2 was prominently expressed in the cytosolic fraction whereas 
NAMPT expression was most highly expressed in cytosol and to a lower degree in 
mitochondria (Figure 5-12). I applied BiP as a positive control as its expression is 
believed to be restricted to microsomes; however, I still found a subtle BiP 
expression in mitochondria, probably due to its presence in the mitochondria 
associated-ER membranes (MAMs) formed between the ER and the mitochondria 
(Giorgi et al. 2011). 
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Figure 5-12 NMRK2 expression restricted to cytosolic fraction of skeletal muscle 
BiP and α-Tubulin were used as positive controls for microsomes and all fractions 
respectively.  
 
5.3.7 NMRK2 and NAMPT expression across C2C12 differentiation 
The C2C12 differentiating muscle cell line was used as a good model to study 
muscle metabolism; therefore, I assessed NMRK2 expression patterns as C2C12s 
differentiated from myoblasts to myotubes across 8 day period. The NMRK2 mRNA 
and protein expression was low in undifferentiated myoblasts at day 0 and was 
already significantly increased by day 2 and further elevated across the 8 days of 
myotubes differentiation. This induction appeared to plateau once the C2C12 cells 
have fully differentiated and formed myotubes (between days 4-6). These results 
corroborate that NMRK2 pathway was up-regulated across muscle cells 
differentiation and may be important for their normal development  
(Figure 5-13).  
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Figure 5-13 NMRK2 mRNA and protein induction across C2C12 cell 
differentiation  
α-Tubulin was used as a loading control. All data are the mean A.U. values ±SEM from 
n=4 (*<0.05, **<0.01, ***<0.001 vs. day 0.) by ANOVA (Newman-Keuls post test). 
. 
In addition, I measured NAMPT mRNA and protein expression in C2C12 over  
the 8 day differentiation time course. In contrast to NMRK2, expression of NAMPT 
was already present in myoblasts at day 0 and was continuously expressed at a 
similar level across the 8 day of muscle cells differentiation (Figure 5-14) suggesting 
that NAMPT is similarly expressed in both myoblasts and mature muscle cells and 
may not be essential for differentiation and development of C2C12 muscle cell line. 
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Figure 5-14 NAMPT mRNA and protein expression across C2C12 cell 
differentiation  
NAMPT mRNA and protein expression did not change across differentiating C2C12.  
α-Tubulin was used as a loading control. All data are the mean A.U. values ±SEM from 
n=4 by ANOVA (Newman-Keuls post test). 
 
5.3.8 Changes of NMRK2 and NAMPT expression in C2C12 cells followed by 
insulin and GC treatment 
To identify modification of NMRK2 and NAMPT expression by hormonal factors 
relevant to this study, C2C12 myoblasts were differentiated for 5 days until they 
formed myotubes and then treated with DEX or insulin for 24 hours. DEX increased 
NMRK2 (p=0.2033) and NAMPT (p=0.3847) mRNA expression; however, these 
changes were not statistically significant. Treatment with insulin did not alter NMRK2 
or NAMPT mRNA expression (Figure 5-15). 
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Figure 5-15 NMRK2 and NAMPT regulations by DEX and insulin in C2C12 
myotubes  
No significant differences in NMRK2 and NAMPT mRNA expression after DEX and 
insulin treatment. All data are the mean A.U. values ±SEM from n=3 by ANOVA 
(Newman-Keuls post test). 
 
5.3.9  NMRK2 expression in glucose-deprived C2C12 
These analyses were extended to assess other systems that have been previously 
shown to increase muscle cell NAD+ content (Fulco et al. 2008). One such method is 
to restrict glucose availability in C2C12 muscle cells in culture. 
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Following 24 hour glucose restriction in C2C12 myotubes growth media from 
optimised 25 mM glucose to 4 mM, a dose-dependent increase in NMRK2 mRNA 
and protein expression was recorded. Measurement of monolayer cellular NAD+ 
content indeed showed a correlation with increased NAD+ levels (Figure 5-16). This 
implies that NMRK2 can be up-regulated during metabolic stress and further lead to 
increase of cellular NAD+ biosynthesis in order to maintain NAD+ content.  
 
Figure 5-16 Glucose restriction in C2C12 myotubes increased NMRK2 mRNA  
and protein expression which was associated with elevated NAD+ levels  
By ANOVA, *˂0.05 vs. control (25 mM), **˂0.01 vs. control (25 mM) and 12.5 mM.  
α-Tubulin was used as a loading control. All data are the mean A.U. values ±SEM from 
n=4 by ANOVA (Newman-Keuls post test). 
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5.4 Discussion 
To identify novel factors responding to altered SR redox caused by H6PDH 
deficiency, I have screened for differentially expressed genes in H6KO muscle prior 
to myopathy, SR stress and UPR activation as well as after the development of 
muscle wasting and fibrosis. I have identified a potential novel stress response 
pathway that may sense and respond to perturbation of the SR redox environment. 
The most differentially-expressed gene, being 85-fold over-represented in H6KO 
muscle without yet of signs of myopathy compared to controls, was NMRK2. 
Adaptation to H6PDH depletion involved early induction of NMRK2 expression which 
I found was restricted to cytosol of muscle and was preferentially expressed in 
glycolytic fast fibres such as TA, severely affected by myopathy in H6KO mice 
compared to soleus type I slow twitch fibres. This implicates a fibre type-specific 
relationship for NMRK2 expression that was higher in fast twitch muscle to regulate 
glycolytic metabolism and to replenish energy demands loss during anaerobic 
exercise. NMRK2 salvage and phosphorylation of NR, an essential vitamin, can 
elevate cellular NAD
+ content as in H6KO mice. NMRK2 has emerged as a skeletal 
muscle-specific pathway capable of regulating NAD+ biosynthesis which is subject to 
subcellular compartmentalisation, and these data suggest that NAD+ biosynthesis 
and NMRK2 are mechanisms for increasing NAD+/NADP+ flux in response to redox 
perturbations in the SR.  
NMRK2 has only recently been identified as an enzyme that metabolises a newly 
identified dietary vitamin precursor, NR, found in food, particularly in milk and grains 
to cycle NAD+ salvage and is continuously delivered to muscle once absorbed into 
the circulation (Bogan et al. 2008). NAD+ is an essential redox co-enzyme that can 
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also be consumed by the sirtuins family of protein deactylases which can signal to 
improve mitochondrial function and insulin sensitivity (Tempel et al. 2007). However, 
skeletal muscle-specific overexpression of SIRT1 did not increase whole-body 
energy expenditure or insulin sensitivity in young mice (White et al. 2013). NMRK2 
acts as a kinase phosphorylating NR to NMN which is subsequently converted to 
NAD+ by the enzyme NMNAT1 (Figure 5-17) (Bieganowski and Brenner 2004).  
 
Figure 5-17 Schematic synthesis pathways of NAD+ 
Two major routes to NAD+ in skeletal muscle are via NAMPT salvage of NAM and 
NMRK2 salvage of NR. The boxed sections represent active pathways in skeletal 
muscle, with the solid rectangle detailing the NMRK2 route to NAD+ synthesis. 
 
NMRK2 belongs to the NMRK family of proteins which is found in most eukaryotes, 
from yeast to humans (Bieganowski and Brenner 2004). There are two isoforms of 
this enzyme in humans and rodents, NMRK1 and NMRK2. The amino acid 
sequences of these enzymes are highly conserved. NMRK belongs  
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to the deoxynucleoside kinase and nucleoside monophosphate (NMP) kinase 
superfamily although the sequence conservation is very low (less than 20% identity)  
(Khan et al. 2007). In humans, NMRK2 consists of 230 amino acids with a high 
activity against NR, and in the mouse NMRK2 is highly homologous to the human 
protein but with a C-terminal amino acid truncation containing 195 amino acids.  
A previous study in zebrafish has demonstrated a potential role for NMRK2 in muscle 
morphogenesis. The NMRK2 orthologue in zebrafish was shown to potentiate laminin 
polymerisation, possibly through NAD+ dependent ADP-ribosylation and subcellular 
localisation of the integrin-associated adaptor protein paxillin (Goody et al. 2010). 
Additionally, in dystrophic zebrafish lines NMRK2b-mediated NAD+ synthesis is 
necessary for normal myogenesis with supplementation of NAD+ significantly 
reducing muscle degeneration and improving muscle structure (Goody et al. 2012). 
The translational importance of the NMRK2 for skeletal muscle metabolic function 
was shown recently as mice fed NR demonstrated widespread metabolic remodelling 
in skeletal muscle. This response was mediated by induced NAD+ in skeletal muscle, 
consequently activating SIRT1 and SIRT3 culminating in elevated oxidative 
metabolism and protection against high-fat diet-induced obesity (Canto et al. 2012). 
Taken together, manipulation of NAD+ precursors and enzymes involved in NAD+ 
biosynthesis, as potential future therapeutic approaches for treatment of a broad 
spectrum of muscular disorders, could improve muscle metabolic function and insulin 
sensitivity.  
NAD+ consumption by SIRT signalling demonstrates the necessity to maintain 
appropriate NAD+ pools within the cell, particularly during periods of metabolic stress. 
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This shows the importance of NAD+ biosynthesis pathways, which still remain poorly 
defined in skeletal muscle, to synthesise and replenish cellular NAD+.  
NMRK2 mediated NAD+ salvage also works concurrent with the NAMPT pathway. 
Both NAMPT and NMRK2 generate NMN, the common precursor molecule 
converted into NAD+ by NMNAT1. In H6KO mice, the expression of NAMPT and 
NMNAT1 was significantly increased; however, not to the same level as NMRK2. The 
expression of NMRK2 and NAMPT, as the main muscle NAD+ salvage pathways, 
was also examined across C2C12 cell differentiation. NMRK2 expression was 
significantly elevated from day 2 to reach the greatest level on day 4 of myofibrillar 
differentiation whereas NAMPT was continuously expressed.  
NMRK2 mediated NAD+ salvage, from NR, has provided a novel pathway for energy 
homeostasis in skeletal muscle. Muscle glucose restriction increases NAD+ level 
(Fulco et al. 2008) and here I demonstrate glucose restriction, with a concurrent 
increase in NAD+ content, enhanced NMRK2 pathway as a novel mechanism leading 
to elevated NAD+ content. This NMRK2 and subsequently NAD+ induction along with 
increased fast twitch fibre expression further support that the salvage of NR through 
NMRK2 plays an important role in maintaining NAD+ levels during metabolic stress, 
such as calorie restriction, in order to prevent NAD+ depletion and large shifts in 
cellular redox status. 
These data suggest NMRK2 can act as a stress response gene to increase the 
availability of NAD
+
. As NAD
+ can be converted to NADP+ through NAD+ kinase, 
there is a possibility the NMRK2 mediated NAD
+ salvage pathway in muscle is 
sensing changes in the SR NADPH/NADP
+ ratio in H6KO mice (Figure 5-18). NAD+ 
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is a substrate for the SIRT family of deacetylases, with SIRT1 and SIRT3 activation 
leading to enhanced muscle oxidative metabolism (Bieganowski and Brenner 2004). 
In H6KO mice, higher NAD+ content may increase SIRT activation and alter 
metabolism resulting in increased insulin sensitivity, and this theory is being explored 
in this model.  
 
 Figure 5-18 Summary of the association of NAD+ salvage through the NMRK2 
pathway with H6PDH deficiency  
Enhanced NMRK2, NAMPT and NMNAT1 expression increase NAD+ content which 
may lead to changes in muscle metabolism. 
 
Microarrays in healthy tibialis anterior (type IIb fibre rich) and soleus (type I fibre rich) 
muscle imply that both NMRK2 and NAMPT salvage pathways are the primary routes 
involved in NAD+ replenishment in skeletal muscle. NMRK2 is muscle-specific 
whereas NAMPT is ubiquitously expressed suggesting an important role for NMRK2 
in skeletal muscle NAD+ bioavailability. Increased NMRK2 mediated NR salvage and 
consequently NAD+ metabolism in H6KO mice may be critical for establishing and 
maintaining SR NAD(P)(H) and regulating SR resident metabolism.  
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Skeletal muscle-specific expression of NMRK2 may play an important role in 
maintaining cellular NAD+ pools in muscle by increasing its levels especially during 
metabolic stress. Whereas NAMPT mediated salvage could maintain basal NAD+ 
content, but would be unable to retain appropriate NAD+ levels under cellular stress. 
Therefore, NMRK2 expression may be increased to enhance NAD+ salvage to 
maintain cellular redox status and ensure downstream metabolic adaptations occur.  
In this chapter, I have identified the potential importance of the skeletal muscle-
specific route to NAD+ salvage and synthesis through the activity of the NMRK2 
pathway. This novel adaptive mechanism responds to SR perturbation in H6KO 
mice. NMRK2 salvages NR for the ultimate generation of NAD+. Delivering NR to 
muscle can elevate NAD+ bioavailability, increase mitochondrial function and 
stimulate insulin sensitivity, which suggests that NMRK2 plays a pivotal role in the 
physiology of muscle energy metabolism (Canto et al. 2012). Defining the importance 
of muscle NAD+ salvage pathways (particularly through NMRK2) to the maintenance 
of intracellular NAD+ provision and the regulation of energy metabolism will extend 
our understanding of muscle physiology. This will illuminate strategies to ‘boost’ 
NAD+ dependent energy metabolism to delay or prevent muscle diseases such as 
sarcopenia and prolong healthspan.  
Skeletal muscle NMRK2 mediated NAD+ salvage is important to the ability of muscle 
to adapt to fluctuating cellular and subcellular NAD+ requirements, and that salvage 
pathways can be further manipulated to increase levels of NAD+ during ageing and 
exercise as a mean to prevent or delay sarcopenia and increase healthspan. 
Measurements of NAD+ and related metabolites could serve as an indicator of 
muscle metabolic status in health or disease. Liquid chromatography/mass 
Chapter 5                                                         Novel stress response in H6PD depleted skeletal muscle 
172 
 
spectrometry methods should be applied to study NAD+ metabolism in mouse muscle 
cells, tissue, subcellular fractions (e.g. mitochondria, SR) and blood during lifespan 
or/and in response to exercise. To determine the importance of NMRK2 and NAMPT 
to the ability of muscle to regulate NAD+ availability and therefore mitochondrial 
function and energy homeostasis, NMRK2 muscle-specific KOs should be generated, 
and the consequences for age related sarcopenia and response to exercise further 
examined in this model.  
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 6- Metabolomic profiling of H6PD 
depleted muscle 
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6.1 Introduction 
H6PDH is an important factor in setting the redox status of the ER/SR lumen by 
generating NADPH. In H6KO mice, alterations in SR redox lead to SR stress and 
consequently to activation of the UPR pathways in skeletal muscle as a result of 
perturbed SR homeostasis (Lavery et al. 2008b). The role of H6PDH in muscle SR is 
still enigmatic as are the underlying mechanisms leading to myoatrophy in its 
absence. I wish to examine aspects of the metabolic profile associated with H6PDH 
deficiency in muscle by applying metabolomics technology. 
Metabolomics reveals changes in metabolite levels which are a driving force in the 
manifestation of phenotypes. Applying this technology in my study may help to 
identify biomarkers of muscle mass reduction and provide functional observations of 
muscle metabolic and energetic state due to H6PD depletion. This set of data should 
help with better understanding the correlation of muscle myopathy with metabolic 
changes and SR stress in the absence of H6PDH. 
In Chapter 5, I screened for differentially expressed genes in H6KO muscle prior to 
myopathy and SR stress, and identified NMRK2 gene as a novel stress marker and 
highlighted its potential as an adaptive mechanism. In addition to this expression 
profiling, I applied targeted metabolomics to identify perturbations of the metabolic 
homeostasis and thereby to offer an access to biomarkers of metabolic pathways 
that are impacted by H6PDH depletion leading to myopathy development.  
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6.2 Methods 
6.2.1 Rodent protocol 
Mice were housed in standard conditions on a 12 h / 12 h light-dark cycle with access 
to standard rodent chow and water ad libitum. All procedures were carried out in 
accordance with the UK Animals (Scientific Procedures) Act, 1986. Male mice (H6KO 
and WT), aged 8 weeks old, were sacrificed by cervical dislocation  
(Schedule 1 method). All cardiac blood was collected for plasma isolation. Tissue 
explants (liver and quadriceps muscle) were removed, snap-frozen in liquid nitrogen 
and then stored at -80°C until metabolite extraction. 
 
6.2.2 Method 
Liver, quadriceps muscle and plasma were collected from H6KO and matching WT 
control mice. Frozen tissue explants were homogenised in the tubes containing 
ceramic beads of 1.4 mm diameter using extraction solvents (Section 2-16). The 
AbsoluteIDQ p150 kit (Biocrates Life Sciences AG, Austria) was prepared as 
described by the manufacturer. A 10 μl aliquot of plasma or tissue extract was used 
for PITC-derivatisation of amino acids, extraction with organic solvent and several 
liquid handling steps. Metabolites were quantified with a reference to appropriate 
internal standards using FIA-MS/MS on a 4000 QTRAP instrument (AB Sciex, 
Germany) coupled to a HPLC Promincence (Shimadzu Deutschland GmbH, 
Germany).  
The application areas of the AbsoluteIDQ p150 kit are diverse because of the broad 
metabolite spectrum. In total, 163 metabolites divided into 6 groups were measured 
(Table 6-1). 
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Table 6-1 List of metabolites measured and their application areas  
Taken from http://www.biocrates.com/products/research-products/absoluteidq-p150-kit.
  
 
 
6.2.3 Experiment set up 
The metabolomic analysis was conducted in collaboration with Prof. Jerzy Adamski 
from the German Research Center for Environmental Health in Munich, Germany. 
We applied the AbsoluteIDQ p150 kit to generate a metabolic profile in liver, 
quadriceps muscle and blood plasma from H6KO mice and matching controls. Mice 
were collected at 8 weeks of age at 10 am in the fed state. At this age, all 
phenotypes were fulminating in the H6KO showing evidence of SR stress, the UPR 
activation and myopathy. The experiment was set up as shown in Figure 6-1.  
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Figure 6-1 Schematic representation of targeted metabolomics set up 
Liver, quadriceps muscle explants and blood plasma were collected from each animal 
(n=11 and n=9 for H6KO and WT respectively). 
 
 
6.2.4 RNA extraction 
Total RNA was extracted from ~20 mg of tissue explants using Tri-reagent system. 
RNA concentration was determined spectrophotometrically at OD260 and its integrity 
assessed by agarose gel electrophoresis. 1 μg of RNA was used for reverse 
transcription (see Section 2.4). 
 
6.2.5 Real-time PCR 
The sequence of all primers was as below: 
CYTC:  FWD: 5’-GCAAGCATAAGACTGGACCAAA-3’  
REV: 5’-TTGTTGGCATCTGTGTAAGAGAATC-3’ 
COX1:  FWD: 5’-TTCGCCATCATATTCGTAGG-3’ 
REV: 5’-TGTGGTGTAAGCATCTGGGT-3’  
COX4:  FWD: 5’- GTGCTGATCTGGGAGAAGAGCTA-3’ 
REV: 5’-GGTTGCCCTCATGTCCAGCAT-3’ 
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COX5:  FWD: 5’-TTCAAGCAGAGGAGATGGTG-3’ 
REV: 5’-CCAAACACGACAACTCCAAC-3’ 
CS:       FWD: 5’-CCGTGCTCATGGACTTGGGCCTT-3’ 
REV: 5’-CCCCTGGCCCAACGTAGATGCTC-3’ 
The mRNA levels were determined using the ABI 7500 sequence detection system 
(Life Technologies, Warrington, UK). Primers for all genes were supplied by Eurofins 
Genomics (Valiant Way, UK). Reactions were performed in singleplex in triplicates as 
described in Section 2.6 using SYBR® Green master mix from Life Technologies and 
normalised against the 18S rRNA housekeeping gene system (Life Technologies, 
Warrington, UK). 
 
6.2.6 Quantification of mitochondrial DNA (mtDNA)  
DNA (~2 ng) from quadriceps muscle of 12-14 weeks old H6KO and matching 
controls was used to compare the mtDNA copy number to that of nDNA by real-time 
PCR using a set of four optimised PCR primers specific to cytochrome-b 
(mitochondrial) and β-globulin (nuclear). The number of mitochondrial DNA copies 
was calculated by using the following formula n= 2∆Ct [∆Ct=Ct (nDNA)-Ct (mtDNA)]. 
 
6.2.7 Statistical analysis 
Where data were normally distributed, unpaired Student t-test was used to compare 
single treatments to control using SigmaStat 3.1 (Systat Software, CA, US).  
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6.3 Results  
6.3.1 Lack of metabolic phenotype in liver and plasma 
There were no significant changes in metabolic profile in blood plasma from H6KO 
mice when compared to WT. In liver used as a control, out of 163 metabolites 
analysed, only the ratio of hydroxylated to non-hydroxylated ceramide 
phosphocholines (sphingomyelins) was decreased and isovalerylcarnitine content 
was increased in H6KO mice. We believe, these changes do not contribute to the 
metabolic phenotype observed in H6KO mice. 
 
6.3.2 Metabolic changes in muscle of H6KO mice 
H6KO quadriceps muscle had pronounced metabolomic phenotype in comparison to 
that of liver and plasma. Table 6-2 shows the absolute quantification for each 
metabolite in its class and significant changes. The list of all 163 metabolites and 
their alterations in quadriceps muscle due to H6PDH deficiency is supplemented in 
the Appendix (Table S-1). 
 
 
Table 6-2 Number of metabolites changed in H6PDH depleted muscle 
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6.3.2.1 Increased amino acids content in muscle of H6KO mice  
Differences in amino acids content and their potential role in development of the 
phenotype seen in H6KO mice were assessed. Out of 13 proteinogenic amino acids 
analysed, glutamine (Gln; p<0.001), arginine (Arg; p<0.001), proline (Pro; p<0.01), 
tryptophan (Trp; p<0.01) and glycine (Gly; p<0.05) were significantly elevated  
(Figure 6-2). This suggests muscle breakdown that increases amino acids levels. 
 
Figure 6-2 Changes in amino acids content in atrophic muscle 
Gln, Arg, Pro, Trp and Gly were significantly increased in H6KO mice compared to WT. 
All data are the mean values ±SEM (*<0.05; **<0.01; ***<0.001). 
Chapter 6                                                                       Metabolomic profiling of H6PD depleted muscle 
181 
 
6.3.2.2 H6PDH depleted muscle has reduced arginase activity  
An Orn/Arg ratio, representing greatly impaired arginase activity, was significantly 
decreased in H6KO mice (p<0.001) compared to WT (Figure 6-3A). These changes 
reflect a diminished ornithine (Orn) level (p<0.05) (Figure 6-3B). Depletion in 
arginase activity, together with decreased mRNA expression of SMOX and AMD1 
shown in Table 5-1, may affect synthesis of downstream targets such as growth 
signals (polyamines).  
 
Figure 6-3 Impaired arginase activity in H6PD depleted muscle 
Decreased ornithine content in H6KO mice (A); reduction in Orn/Arg ratio, an indicator 
of arginase activity, in H6KO mice (B). All data are the mean values ±SEM (*<0.05; 
***<0.001). 
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In H6KO muscle, there was also significant decline in branched-chain amino 
acids content such as leucine/isoleucine (xLeu) (p<0.05) (Figure 6-4). This could 
represent muscle undergoing breakdown of amino acids that can directly enter 
energetic pathways. 
 
Figure 6-4 Alterations in branched-chain amino acids 
The sum of leucine and isoleucine was lowered in H6KO mice compared to WT. All 
data are the mean values ±SEM (*<0.05). 
 
 
6.3.2.3 Increased acylcarnitines content in H6PD depleted muscle 
The screening of 40 acylcarnitines showed six being significantly elevated including 
acetylcarnitine (C2), butyrylcarnitine (C4), valerylcarnitine (C5), decanoylcarnitine 
(C10:1), malonylcarnitine/hydroxybutyrylcarnitine (C3-DC/C4-OH) as well as 
fumarylcarnitine/hexanoylcarnitine (C4:1-DC/C6) (Figure 6-5). Acylcarnitines 
represent byproducts of fat, glucose and amino acid mitochondrial oxidation. This 
work contributes to increasing evidence that elevated acylcarnitines may act  
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as biomarkers of defects in fat metabolism and may be an indication of mitochondrial 
dysfunction (Sampey et al. 2012).  
 
Figure 6-5 Increased acylcarnitines level in H6KO mice 
Out of 40 acylcarnitines, C2, C4, C5, C10:1, C3-DC/C4-OH and C4:1-DC/C6 were 
significantly up-regulated in myopathy-affected muscle. All data are the mean values 
±SEM (*<0.05; **<0.005; ***<0.001). 
 
These elevations of acylcarnitines were concomitant with a significant induction of 
acetylcarnitine to free carnitine ratio (C2/C0; p<0.05), and short chain acylcarnitines 
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to free carnitine ratio [(C2+C3)/C0; p<0.01] in atrophic muscle (Figure 6-6). Both 
ratios are indication of defects in β-oxidation activity 
(http://www.biocrates.com/images/Produktfolder_MetaDis_Einzelseiten.pdf). 
 
Figure 6-6 Induction of acylcarnitines ratios 
The ratios of acetylcarnitine to free carnitine (A) and short chain acylcarnitines to free 
carnitine (B) were significantly increased in quadriceps muscle due to H6PDH 
deficiency. All data are the mean values ±SEM (**<0.005). 
 
6.3.2.4 Alterations of membrane lipids content in H6KO mice 
In muscle, the most obvious effect was on the membrane lipids; many of the lipids 
were about 50% greater than the control. One reason for this is that in H6KO muscle 
cell, the membrane lipids are being scavenged for oxidation and building up as  
C2-C6 acylcarnitines were elevated. 
Additionally, the majority of lysoPhosphatidylcholines was increased (Figure 6-7) and 
the level of 40 phosphatidylcholines was also dysregulated in H6KO mice  
(Table 1 in Appendix).  
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Figure 6-7 Changes in lysoPhosphatidylcholine (lysoPC) content in muscle from 
H6KO mice  
The levels of C16:0, C17:0, C18:0, C18:1, C18:2, C20:3 and C20:4 were elevated in 
H6KO mice. All data are the mean values ±SEM (*<0.05; **<0.01; ***<0.001). 
 
 
Total phosphatidylcholine (PC) content was depleted (Figure 6-8A) suggesting they 
might be salvaged at the membrane for energy leading to induction of total lysoPC 
content (Figure 6-8B). As expected, the ratio of total lysoPC/total PC was significantly 
increased in H6KO mice (Figure 6-8C) indicating perturbation of membrane lipids, 
potentially causing membrane leakage and further interactions between muscle SR 
and cytosol. 
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Figure 6-8 Changes in total lysoPC and total PC content 
Decreased total PC content (A) was correlated with increased total lysoPC level (B) 
leading to induction of total lysoPC/total PC ratio in H6PD depleted muscle. All data are 
the mean values ±SEM (**<0.01; ***<0.001). 
 
 
6.3.3 Elevated mitochondrial biogenesis in atrophic muscle 
Here, we demonstrate that skeletal myopathy is associated with a range of metabolic 
and energetic changes within muscle cell reflecting alterations in metabolite content. 
Metabolomic profiling revealed dysregulation of amino acids and lipid metabolism 
that potentially affect mitochondrial function. 
PGC-1α, a key regulator of energy metabolism, was previously shown to be 
increased in H6KO mice (Lavery et al. 2008b). In addition, I measured the mRNA 
expression of pyruvate dehydrogenase kinase, isozyme 4 (PDK4), a downstream 
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target of PGC-1α. I found induction in PDK4 mRNA expression in H6PD depleted 
muscle (Figure 6-9). 
 
Figure 6-9 Increased PDK4 mRNA expression in H6KO mice 
All data are the mean A.U. values ±SEM from n=8-9/group (*<0.05). 
 
Mitochondrion is a major site for energy production, β-oxidation and energy 
metabolism. Alterations in lipid metabolism and amino acids content may affect 
energy metabolism; therefore, I determined mitochondrial abundance in H6PD 
depleted muscle. The changes in mtDNA may provide insight into the processes that 
either initiate or propagate mitochondrial dysfunction that is implicated in a vast array 
of diseases and conditions including cancer and ageing (Phillips et al. 2014). 
The mitochondrial DNA to nuclear DNA ratio (mtDNA:nDNA) as an estimate for the 
number of mtDNA copy number was significantly increased in quadriceps explants 
from H6KO mice compared to WT (p<0.001) (Figure 6-10).  
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Figure 6-10 Elevated mtDNA:nDNA ratio in H6KO mice  
All data are the mean values ±SEM from n=10/group (***<0.001 vs. WT). 
 
Additionally, the mRNA expression of a number of mitochondrial- and  
nuclear-encoded genes was measured in myopathy-affected muscle. There was a 
significant induction in mRNA expression of mitochondrial-encoded genes including 
cytochrome C oxidase (COX) subunit 1, 4 and 5 (Figure 6-11A) as well as in the 
mRNA expression of nuclear-encoded genes such as cytochrome C (CYTC) and 
citrate synthase (CS) expression (Figure 6-11B). This was correlated with elevated 
mtDNA copy number in H6KO mice. 
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Figure 6-11 Increased expression of mitochondrial genes 
Elevated expression of mitochondrial-encoded genes: COX 1, 4 and 5 (A); Increased 
mRNA expression of nuclear-encoded genes: CYTC and CS (B). All data are the mean 
values ±SEM from n=8-9/group (*<0.05, **<0.01, ***<0.001 vs. WT). 
 
 
6.4 Discussion 
In Chapter 5, I identified a large set of significantly dysregulated genes in H6KO 
mice. They group into a number of common pathways such as structural, polyamine 
biosynthesis, purine salvage, intermediary metabolism and ER/SR stress. NMRK2 
expression was the most up-regulated in H6KO mice which was associated  
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with elevated muscle NAD+ content. A previous study has shown that despite 
myopathy, these mice had enhanced glycogen storage, insulin sensitivity and 
protection from diet-induced insulin resistance (Lavery et al. 2007). H6KO muscle 
also displayed elevated mitochondrial biogenesis with increased expression of 
mitochondrial encoded genes and increased mitochondrial copy number; all 
phenotypes consistent with NAD+ dependent SIRT1 and SIRT3 activity  
(Canto et al. 2012).  
The metabolomics results are combined in Figure 6-12. 
 
Figure 6-12 Summary of metabolomic changes due to H6PDH deficiency  
Changes in AC and lipids content in association with increased PDK4 mRNA 
expression might lead to energy stress in H6KO mice whereas reduction of arginase 
activity and decreased mRNA expression of SMOX and AMD1 may impinge on growth 
signals (polyamines). Abbreviations: AC (acylcarnitines), FFA (free fatty acid), NO 
(nitric oxide), PC (phosphatidylcholine). 
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H6PDH deficiency impacts on amino acids metabolism that could contribute to 
aspects of the phenotype such as insulin sensitisation through elevated arginine and 
subsequent nitric oxide (NO) content. It has been previously shown that impaired NO 
bioavailability is correlated with the development of insulin resistance (Sydow et al. 
2005) and endothelial NO synthesis and insulin sensitivity are positively related in 
healthy humans (Petrie et al. 1996). Also, decreased arginase activity and 
consequently ornithine content in association with reduced SMOX and AMD1 mRNA 
expression might lead to diminished growth signals such as polyamines. 
We propose that changes in protein synthesis and amino acid accumulation may 
lead to reduction in muscle mass (Lecker et al. 2006) and as a consequence 
influence ER stress, and also that increased glutamine may be associated with 
disrupted urea cycle and changes in amino acids content shown in patients with urea 
cycle disorder (Serrano et al. 2011). 
In H6KO mice, changes in ER/SR redox balance may affect cytosolic NADH/NAD+ 
redox leading to mitochondrial biogenesis activation as a potential rescue 
mechanism. I have identified a novel NMRK2 mediated stress response pathway and 
a number of alterations in metabolites of which many are membrane lipids. There are 
also other pathways that could be influenced by these redox changes such as TCA 
cycle; however, they need to be analysed further to confirm if any changes that occur 
are associated with H6PD depletion. 
In this chapter, metabolomics technology was applied in order to identify the factors, 
at the metabolic levels, contributing to muscle wasting seen in H6KO mice. I have 
recorded a number of metabolite changes including amino acids, acylcarnitines and 
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lipids that might contribute to dysregulation of redox metabolism, energy homeostasis 
and mitochondrial function; however, additional work needs to be carried out to 
investigate the downstream targets of changed pathways such acetyl-CoA, lactate 
and pyruvate. Despite the underlying mechanisms and factors directly leading to 
myopathy development in H6KO mice were not found, applying targeted 
metabolomics technology has provided insight into perturbations of energetic 
homeostasis in skeletal muscle.  
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The SR lumen contains a fully functional metabolic unit that regulates GC and energy 
metabolism in skeletal muscle. In this thesis, I have characterised the expression 
profile of the SR enzyme system, G6PT/H6PDH/G6Pase-β/11β-HSD1, across 
muscle cell differentiation and after GC and insulin treatments. I have shown that 
across C2C12 myocytes and primary myoblasts differentiation, there was a 
significant increase in 11β-HSD1 expression and a slight induction of H6PDH 
expression. Both these genes are involved in GC metabolism within the ER/SR 
lumen confirming their importance in differentiation of skeletal myoblasts to mature 
myotubes; therefore, in skeletal muscle development which was previously published 
for 11β-HSD1 (Biedasek et al. 2011). Increased mRNA expression of 11β-HSD1 after 
GC treatment indicates its essential role as a main regulator of GC metabolism in the 
SR. Thus it would appear that there is a coordinated up-regulation of 11β-HSD1 and 
H6PDH in response to differentiation signals which are not present for G6PT and 
G6Pase-β. In line with H6MKO, it makes this system important for regulation of 
steroids. However, when we knocked out H6PDH in muscle, it has appeared to be a 
phenocopy of global KO (Lavery et al. 2008b) developing SR stress and myopathy, 
but there were no changes in urinary 11-DHC metabolites suggesting that systemic 
features are potentially driven by contribution of other tissues. Expression of 
G6Pase-β in differentiating muscle cells was shown here for the first time. This would 
have a vital role in glucose recycling for energy metabolism in skeletal muscle. 
I have also generated HSD1MKO mouse model in order to evaluate the muscle-
specific role of 11β-HSD1 and GC metabolism in determining global metabolic 
phenotype. Using three different Cre lines, I successfully recombined the HSD11B1 
gene to a KO; however, 11β-HSD1 mRNA expression and activity remained at the 
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same level seen in WT. We cannot explain this phenomenon, but this could be due to 
the nature of muscle cells or a biological principle that makes it difficult to test.  
The HSD1MKO mouse model would have been an excellent model to determine 
11β-HSD1 function in the regulation of muscle GC and energy metabolism in health 
and disease. Though global 11β-HSD1 has not reported direct muscle phenotype 
(Semjonous et al. 2011), and when treated with Cort, these mice were protected from 
the reduced grip strength, decreased lean mass and diminished myofiber diameter. 
Moreover, Cort-mediated induction of muscle atrophy markers MuRF1, atrogin1 and 
FoxO1 was also blunted in HSD1GKO animals (Morgan et al. 2014). It would have 
been a great opportunity to test a range of muscle-specific GC and 11β-HSD1 
mediated phenotypes; however, despite successful recombination, the colony has 
been discontinued. 
H6KO mice developed skeletal myopathy; however, the precise underpinning 
molecular mechanisms are still unknown. To assess the future importance of H6PDH 
in muscle metabolism, further investigations were needed in order to find the basis of 
this muscle wasting associated with other metabolic changes such as increased 
insulin sensitivity and glycogen storage. In Chapter 5, I identified important NAD+ 
biosynthesis genes with NMRK2 being the most up-regulated gene in muscle of 
young H6KO mice without yet any signs of myopathy compared to WT controls. We 
believe, this adaptation to H6PD depletion involves early induction of NMRK2 
expression which was also greater in TA muscle that is affected by myopathy in 
H6KO mice when compared to soleus muscle protected from most atrophic changes. 
This implicates a fibre type-specific relationship for NMRK2 expression that was 
higher in fast twitch muscle to regulate glycolytic metabolism. In addition, microarrays 
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in WT TA and soleus muscle implied that both NMRK2 and NAMPT salvage 
pathways are the only routes involved in NAD+ replenishment in skeletal muscle 
(Lavery et al. 2008b). Whilst NAMPT was ubiquitously expressed, NMRK2 was a 
muscle-specific gene suggesting it may play an important role in skeletal muscle 
NAD+ bioavailability. Elevated NMRK2 mediated NR salvage and consequently NAD+ 
metabolism in H6KO mice may be critical for establishing and maintaining SR 
NAD(P)(H) as well as regulating SR resident metabolism.  
NMRK2 as a skeletal muscle-specific pathway is capable of regulating NAD+ 
biosynthesis through NR phosphorylation (Canto et al. 2012). Thus, NAD+ 
biosynthesis and NMRK2 may be mechanisms for increasing NAD+/NADP+ flux in 
response to redox perturbations within the SR seen in H6KO mice. 
I also determined NMRK2 and NAMPT expression across muscle cells differentiation. 
NMRK2 expression appeared to be switched on and significantly increased from day 
2 to day 4 of myofibrillar differentiation whereas NAMPT appeared to be continuously 
expressed. Skeletal muscle-specific expression of NMRK2 suggests it may play an 
important role in maintaining NAD+ pools in muscle to maintain cellular redox status 
and ensure that downstream metabolic adaptations occur.  
NMRK2 mediated NAD+ salvage has provided a novel pathway for energy 
homeostasis in skeletal muscle. NMRK2 protein expression increased during glucose 
restriction followed by an increase in NAD+ content. This NMRK2 and subsequently 
NAD+ inductions along with elevated fast twitch fibre expression further support that 
the salvage of NR through NMRK2 plays an important role in maintaining NAD+ 
levels during metabolic stress such as calorie restriction in order to prevent NAD+ 
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depletion and large shifts in cellular redox status. Additional evidence supporting the 
potential importance of NMRK2 in metabolic adaptation has been shown through its 
elevated expression in SK-Hep1 cancer cells (Hwang and Kim 2009). This induction 
of NMRK2 expression may allow such cells to exhibit a shift towards glucose-
dependent metabolism to drive cell growth. 
Despite myopathy, increased NMRK2 expression in H6KO was associated with 
elevated muscle cellular NAD+ content with enhanced glycogen storage, insulin 
sensitivity and protection from diet-induced insulin resistance. Interestingly, H6KO 
muscle displayed increased expression of mitochondrial encoded genes and 
elevated mitochondrial copy number. We propose that NMRK2 can act as a stress 
response gene to increase the availability of NAD+ in skeletal muscle. The NAD+ 
salvage pathway in muscle responds to changes in the SR NADPH/NADP+ ratio 
seen in H6KO mice suggesting the likelihood of the crosstalk between the SR and 
cytosol which has not been identified before. 
In Chapter 6, I investigated the association of muscle myopathy with metabolic 
changes and SR stress in the absence of H6PDH by applying metabolomics 
technology on H6KO mice and relevant WT controls. H6PDH deficiency caused a 
change in metabolic pathways consistent with increased amino acid and that could 
contribute to aspects of the phenotype in H6KO mice such as insulin sensitisation 
through elevated arginine and subsequent NO content. Changes in protein synthesis 
and amino acid accumulation could lead to a reduction in muscle mass  
(Lecker et al. 2006) and consequently may influence ER/SR stress. In addition to 
amino acids disruption, there were also defects in β-oxidation in H6PDH depleted 
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muscle which needs to be further analysed. Interestingly, in humans, high 
acetylcarnitine to carnitine ratio has been observed in patients with carnitine 
palmitoyltransferase II deficiency characterised by muscle pain and weakness 
consequently leading to the breakdown of muscle tissue (Wieser 1993). Our 
metabolomics data have revealed a number of metabolomic changes in skeletal 
muscle. This technology endorses the theory that energy stress could potentially be a 
signal for NMRK2 mediated salvage pathway and mitochondria. These data are 
being analysed in conjunction with the microarray data (Lavery et al. 2008b) in order 
to provide an insight into homeostatic responses on amino acid metabolism and  
β-oxidation during metabolic stress in skeletal muscle of H6KO mice.  
Although I did not identify drivers of the phenotype seen in H6KO mice, I looked at 
responses over time such as energy deprivation that leads to other pathways 
activation. One of the most important early changes is compensatory mechanism of 
increased NMRK2 to generate more NAD+ cofactor. Overall this thesis has led me to 
propose that in the H6PD depleted muscle, activation of SR stress pathways and 
perturbed SR NADPH/NADP+ redox homeostasis may be associated with high  
up-regulation of cytosolic NMRK2 and consequently increased cellular NAD+ content. 
A number of metabolite alterations may contribute to H6KO phenotype such as 
muscle wasting or insulin sensitivity which makes this model very complex  
(Figure 7-1).  
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Figure 7-1 Changes within skeletal muscle due to H6PDH deficiency 
 
Therefore, pathways governing NAD+ bioavailability, particularly NMRK2 may be 
critical for establishing and maintaining SR NAD(P)(H) and regulating SR resident 
metabolism. As we believe, there is a crosstalk between the SR and cytosol. 
Additional analysis need to be undertaken in order to investigate downstream targets 
involved in myopathy development in H6KO mice. 
The SR and energy metabolism need to be further investigated by implementing 
targeted LC/MS based metabolomics for the quantitative analysis of NAD+ 
metabolites in skeletal muscle. Measurements of NAD+ and related metabolites could 
serve as an indicator of muscle metabolic status in health or disease. As NAD+ and 
related metabolites are converted to one or more other metabolites during metabolic 
stress, a single measurement of NAD+ can be misleading, and the routine and 
accurate quantification of cellular NAD+ metabolites, representing multiple 
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biosynthetic routes and breakdown pathways, is necessary to progress in this field. 
This will demonstrate new biological relationships between pathways that determine 
NAD+ bioavailability and metabolism. 
I demonstrated that NMRK2 is enriched in fast-twitch glycolytic vs. oxidative muscle. 
The fast-twitch muscle displayed the greatest phenotypic change in H6KO mouse 
line. Using Affymetrix genome arrays and tissues from a KO mouse line and 
treatments, the transcriptomic profiles in TA and soleus muscle should be further 
analysed in order to integrate this with NAD+ metabolome and physiological data to 
understand the normal physiology of NMRK2 enrichment in glycolytic muscle. 
Identifying NMRK2 and NAD+ sensitive pathways in type II glycolytic fibres will 
provide insight into their preferential loss in ageing muscle and also give 
understanding of the molecular basis of fibre type specific metabolism.  
To support metabolomics analysis, mitochondrial respiration and β-oxidation should 
be measured from isolated mitochondria from TA and soleus muscles. Additionally, 
mRNA and protein expression of mitochondrial enzymes involved in β-oxidation as 
well as electron transport chain complexes I-IV, citrate synthase activities and protein 
abundances should be examined in mitochondrial preparations. To further 
understand the downstream NAD+ metabolism, the SIRT 1 and 3 activities need to 
be determined in total cellular, nuclear and mitochondrial extracts as well as protein 
deacetylation should be evaluated of known SIRT substrates. These data could help 
with better understanding of insulin sensitivity in myopathy-affected muscle. Fully 
defining the physiology of skeletal muscle is critical to design interventions to 
optimise an individual’s capacity to resist muscle-wasting diseases. 
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In this thesis, I have investigated a complex skeletal muscle unit, sarcoplasmic 
reticulum, which is a site of GC metabolism and other metabolic pathways including 
glucose utilisation as well as protein folding and trafficking. I have applied a number 
of transgenic mouse models to examine how the perturbations of SR genes can 
affect energetic and metabolic homeostasis. My main aim was to identify the role of 
H6PDH in muscle SR which is more enigmatic as H6KO mice develop an 11β-HSD1 
and GC- independent type IIb fibre skeletal muscle myopathy and activation of SR 
stress pathways that we believe is a result of perturbed SR NADPH/NADP+ redox 
homeostasis as well as the underlying factors or pathways leading to development of 
atrophic muscle which to date is still unknown. During my PhD, I have characterised 
a novel stress response salvage pathway in skeletal muscle leading to activation of 
NMRK2 which consequently increased cellular NAD+ content. These data suggest 
that NAD+ biosynthesis and NMRK2 are mechanisms for increasing NAD+/NADP+ 
flux in response to redox perturbations in the SR. I hypothesise that skeletal muscle 
NMRK2 mediated NAD+ salvage is important to the ability of muscle to adapt to 
fluctuating cellular and subcellular NAD+ requirements, and that salvage pathways 
can be manipulated to increase levels of NAD+ during metabolic stress such as 
ageing and exercise as means to prevent or delay sarcopenia and increase 
healthspan. Additionally, I have highlighted a number of alternations in lipid 
membrane content suggesting a possible crosstalk between the SR and cytosol 
which to date is still unidentified. Further experiments need to be carried out to 
investigate novel mechanisms and pathways linking NMRK2 expression, SR redox 
and the control of muscle energy metabolism and mitochondrial function in order to 
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improve skeletal muscle physiology to make extended lifespan health and disease-
free. 
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Table S-1 Overview of all detected metabolites using the AbsoluteIDQ p150 kit 
and their change in H6PDH depleted muscle 
For each metabolite analysed, the metabolites class, short name and full biological 
name are given. Significant alterations show p<0.05 when comparing H6KO mice to 
WT. ↔ No significant, ↓ decreased and ↑ increased metabolite concentration. 
 
Metabolite 
Class 
Short Name Full Biochemical Name 
Change in 
H6KO 
Sugars H1 Hexose ↔ 
A
m
in
o
 a
c
id
s
 
Arg Arginine ↑ p=0.00018 
Gln Glutamine ↑ p=4.44E-06 
Gly Glycine ↑ p=0.0024 
His Histidine ↔ 
Met Methionine ↔ 
Orn Ornithine ↓ p=0.016 
Phe Phenylalanine ↔ 
Pro Proline ↑ p=0.0027 
Ser Serine ↔ 
Thr Threonine ↔ 
Trp Tryptophan ↑ p=0.0032 
Tyr Tyrosine ↔ 
Val Valine ↔ 
xLeu xLeucine (Leucine/Isoleucine) ↓ 0.012 
A
c
y
lc
a
rn
it
in
e
s
 
C0 DL-Carnitine ↔ 
C2 Acetyl-L-carnitine ↑ p=5.63E-05 
C3 Propionyl-L-carnitine ↔ 
C3:1 Propenyl-L-carnitine ↔ 
C4 Butyryl-L-carnitine ↑ p=1.59E-05 
C4:1 Butenyl-L-carnitine ↔ 
C5 Valeryl-L-carnitine ↑ p=0.034 
C5:1 Tiglyl-L-carnitine ↔ 
C6:1 Hexenoyl-L-carnitine ↔ 
C8 Octanoyl-L-carnitine ↔ 
C8:1 Octenoyl-L-carnitine ↔ 
C9 Nonayl-L-carnitine ↔ 
C10 Decanoyl-L-carnitine ↔ 
C10:1 Decanoyl-L-carnitine ↑ p=0.033 
C10:2 Decanoyl-L-carnitine ↔ 
C12 Decanoyl-L-carnitine ↔ 
C12:1 Decanoyl-L-carnitine ↔ 
C14 Tetradecanoyl-L-carnitine ↔ 
C14:1 Tetradecenoyl-L-carnitine ↔ 
C14:2 Tetradecadienyl-L-carnitine ↔ 
C16 Hexadecanoyl-L-carnitine ↔ 
C16:1 Hexadecenoyl-L-carnitine ↔ 
C16:2 Hexadecadienyl-L-carnitine ↔ 
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A
c
y
lc
a
rn
it
in
e
s
 
C18 Octadecanoyl-L-carnitine ↔ 
C18:1 Octadecenoyl-L-carnitine ↔ 
C18:2 Octadecadienyl-L-carnitine ↔ 
C3-OH Hydroxypropionyl-L-carnitine ↔ 
C3-DC/C4-OH 
Malonyl-L-carnitine/Hydroxybutyryl-
L-carnitine 
↑ p=0.0024 
C5-DC/C6-OH 
Glutaryl-L-carnitine/ 
Hydroxyhexanoyl-L-carnitine 
↔ 
C5-M-DC Methylglutaryl-L-carnitine ↔ 
C3-DC-M/C5-
OH 
Methylmalonyl-L-
carnitine/Hydroxyvaleryl-L-carnitine  
↔ 
C5:1-DC Glutaconyl-L-carnitine ↔ 
C4:1-DC/C6 
Fumaryl-L-carnitine/Hexanoyl-L-
carnitine  
↑ p=0.0095 
C7-DC Pimelyl-L-carnitine ↔ 
C12-DC Dodecanedioyl-L-carnitine ↔ 
C14:1-OH Hydroxytetradecenoyl-L-carnitine ↔ 
C14:2-OH Hydroxytetradecadienyl-L-carnitine ↔ 
C16-OH Hydroxyhexadecanoyl-L-carnitine ↔ 
C16:1-OH Hydroxyhexadecenoyl-L-carnitine ↔ 
C16:2-OH Hydroxyhexadecadienyl-L-carnitine ↔ 
C18:1-OH Hydroxyoctadecenoyl-L-carnitine ↔ 
 
S
p
h
in
g
o
m
y
e
li
n
 
 
SM C16:0 Sphingomyeline C 16:0 ↑ p=3.59E-06 
SM C16:1 Sphingomyeline C 16:1 ↑ p=0.00054 
SM C18:0 Sphingomyeline C 18:0 ↔ 
SM C18:1 Sphingomyeline C 18:1 ↑ p=0.0031 
SM C20:2 Sphingomyeline C 20:2 ↔ 
SM C22:3 Sphingomyeline C 22:3 ↔ 
SM C24:0 Sphingomyeline C 24:0 ↔ 
SM C24:1 Sphingomyeline C 24:1 ↔ 
SM C26:0 Sphingomyeline C 26:0 ↔ 
SM C26:1 Sphingomyeline C 26:1 ↔ 
SM (OH) C14:1 Hydroxysphingomyeline C14:1 ↔ 
SM (OH) C16:1 Hydroxysphingomyeline C 16:1 ↔ 
SM (OH) C22:1 Hydroxysphingomyeline C 22:1 ↔ 
SM (OH) C22:2 Hydroxysphingomyeline C 22:2 ↑ p=0.045 
SM (OH) C24:1 Hydroxysphingomyeline C 24:1 ↔ 
 
Phosphati-
dylcholine 
 
PC aa C24:0 Phosphatidylcholine diacyl C 24:0 ↔ 
PC aa C26:0 Phosphatidylcholine diacyl C 26:0 ↔ 
PC aa C28:1 Phosphatidylcholine diacyl C 28:1 ↔ 
PC aa C30:0 Phosphatidylcholine diacyl C 30:0 ↓ p=4.06E-08 
PC aa C30:2 Phosphatidylcholine diacyl C 30:2 ↓ p=0.00069 
PC aa C32:0 Phosphatidylcholine diacyl C 32:0 ↓ p=0.0028 
PC aa C32:1 Phosphatidylcholine diacyl C 32:1 ↓ p=2.33E-05 
PC aa C32:2 Phosphatidylcholine diacyl C 32:2 ↓ p=0.0019 
PC aa C32:3 Phosphatidylcholine diacyl C 32:3 ↓ p=3.79E-13 
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P
h
o
s
p
h
a
ti
d
y
lc
h
o
li
n
e
 
 
PC aa C34:1 Phosphatidylcholine diacyl C 34:1 ↔ 
PC aa C34:2 Phosphatidylcholine diacyl C 34:2 ↔ 
PC aa C34:3 Phosphatidylcholine diacyl C 34:3 ↔ 
PC aa C34:4 Phosphatidylcholine diacyl C 34:4 ↓ p=0.049 
PC aa C36:0 Phosphatidylcholine diacyl C 36:0 ↔ 
PC aa C36:1 Phosphatidylcholine diacyl C 36:1 ↔ 
PC aa C36:2 Phosphatidylcholine diacyl C 36:2 ↑ p=0.00015 
PC aa C36:3 Phosphatidylcholine diacyl C 36:3 ↑ p=0.0022 
PC aa C36:4 Phosphatidylcholine diacyl C 36:4 ↔ 
PC aa C36:5 Phosphatidylcholine diacyl C 36:5 ↔ 
PC aa C36:6 Phosphatidylcholine diacyl C 36:6 ↓ p=0.00093 
PC aa C38:0 Phosphatidylcholine diacyl C 38:0 ↔ 
PC aa C38:1 Phosphatidylcholine diacyl C 38:1 ↔ 
PC aa C38:3 Phosphatidylcholine diacyl C 38:3 ↑ p=0.045 
PC aa C38:4 Phosphatidylcholine diacyl C 38:4 ↔ 
PC aa C38:5 Phosphatidylcholine diacyl C 38:5 ↓ p=1.11E-06 
PC aa C38:6 Phosphatidylcholine diacyl C 38:6 ↓ p=3.95E-05 
PC aa C40:1 Phosphatidylcholine diacyl C 40:1 ↔ 
PC aa C40:2 Phosphatidylcholine diacyl C 40:2 ↔ 
PC aa C40:3 Phosphatidylcholine diacyl C 40:3 ↔ 
PC aa C40:4 Phosphatidylcholine diacyl C 40:4 ↓ p=0.021 
PC aa C40:5 Phosphatidylcholine diacyl C 40:5 ↓ p=4.68E-05 
PC aa C40:6 Phosphatidylcholine diacyl C 40:6 ↓ p=0.0025 
PC aa C42:0 Phosphatidylcholine diacyl C 42:0 ↓ p=0.025 
PC aa C42:1 Phosphatidylcholine diacyl C 42:1 ↔ 
PC aa C42:2 Phosphatidylcholine diacyl C 42:2 ↓ p=0.024 
PC aa C42:4 Phosphatidylcholine diacyl C 42:4 ↔ 
PC aa C42:5 Phosphatidylcholine diacyl C 42:5 ↔ 
PC aa C42:6 Phosphatidylcholine diacyl C42:6 ↓ p=0.0011 
PC ae C30:0 Phosphatidylcholine acyl-alkyl C 30:0 ↓ p=0.00094 
PC ae C30:1 Phosphatidylcholine acyl-alkyl C 30:1 ↔ 
PC ae C30:2 Phosphatidylcholine acyl-alkyl C 30:2 ↔ 
PC ae C32:1 Phosphatidylcholine acyl-alkyl C 32:1 ↔ 
PC ae C32:2 Phosphatidylcholine acyl-alkyl C 32:2 ↔ 
PC ae C34:0 Phosphatidylcholine acyl-alkyl C 34:0 ↓ p=0.01 
PC ae C34:1 Phosphatidylcholine acyl-alkyl C 34:1 ↔ 
PC ae C34:2 Phosphatidylcholine acyl-alkyl C34:2 ↔ 
PC ae C34:3 Phosphatidylcholine acyl-alkyl C 34:3 ↑ p=0.00029 
PC ae C36:0 Phosphatidylcholine acyl-alkyl C 36:0 ↔ 
PC ae C36:1 Phosphatidylcholine acyl-alkyl C 36:1 ↔ 
PC ae C36:2 Phosphatidylcholine acyl-alkyl C 36:2 ↑ p=0.0037 
PC ae C36:3 Phosphatidylcholine acyl-alkyl C 36:3 ↑ p=0.00019 
PC ae C36:4 Phosphatidylcholine acyl-alkyl C36:4 ↔ 
PC ae C36:5 Phosphatidylcholine acyl-alkyl C 36:5 ↑ p=7.48E-05 
PC ae C38:0 Phosphatidylcholine acyl-alkyl C 38:0 ↓ p=8.96E-07 
PC ae C38:1 Phosphatidylcholine acyl-alkyl C 38:1 ↓ p=0.028 
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PC ae C38:2 Phosphatidylcholine acyl-alkyl C 38:2 ↑ p=0.00012 
PC ae C38:3 Phosphatidylcholine acyl-alkyl C 38:3 ↔ 
PC ae C38:4 Phosphatidylcholine acyl-alkyl C 38:4 ↔ 
PC ae C38:5 Phosphatidylcholine acyl-alkyl C 38:5 ↔ 
PC ae C38:6 Phosphatidylcholine acyl-alkyl C38:6 ↔ 
PC ae C40:0 Phosphatidylcholine acyl-alkyl C 40:0 ↓ p=0.011 
PC ae C40:1 Phosphatidylcholine acyl-alkyl C 40:1 ↓ p=0.0016 
PC ae C40:2 Phosphatidylcholine acyl-alkyl C 40:2 ↓ p=0.008 
PC ae C40:3 Phosphatidylcholine acyl-alkyl C 40:3 ↔ 
PC ae C40:4 Phosphatidylcholine acyl-alkyl C40:4 ↔ 
PC ae C40:5 Phosphatidylcholine acyl-alkyl C 40:5 ↓ p=0.0092 
PC ae C40:6 Phosphatidylcholine acyl-alkyl C 40:6 ↓ p=0.035 
PC ae C42:0 Phosphatidylcholine acyl-alkyl C 42:0 ↔ 
PC ae C42:1 Phosphatidylcholine acyl-alkyl C 42:1 ↔ 
PC ae C42:2 Phosphatidylcholine acyl-alkyl C 42:2 ↓ p=0.011 
PC ae C42:3 Phosphatidylcholine acyl-alkyl C 42:3 ↓ p=0.00045 
PC ae C42:4 Phosphatidylcholine acyl-alkyl C 42:4 ↓ p=0.016 
PC ae C42:5 Phosphatidylcholine acyl-alkyl C 42:5 ↓ p=0.0021 
PC ae C44:3 Phosphatidylcholine acyl-alkyl C 44:3 ↓ p=7.64E-07 
PC ae C44:4 Phosphatidylcholine acyl-alkyl C 44:4 ↓ p=0.012 
PC ae C44:5 Phosphatidylcholine acyl-alkyl C 44:5 ↓ p=0.032 
PC ae C44:6 Phosphatidylcholine acyl-alkyl C 44:6 ↔ 
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lysoPC a C14:0 lysoPhosphatidylcholine acyl C14:0 ↔ 
lysoPC a C16:0 lysoPhosphatidylcholine acyl C16:0 ↑ p=0.00021 
lysoPC a C16:1 lysoPhosphatidylcholine acyl C16:1 ↔ 
lysoPC a C17:0 lysoPhosphatidylcholine acyl C17:0 ↑ p=0.047 
lysoPC a C18:0 lysoPhosphatidylcholine acyl C18:0 ↑ p=0.00039 
lysoPC a C18:1 lysoPhosphatidylcholine acyl C18:1 ↑ p=0.00021 
lysoPC a C18:2 lysoPhosphatidylcholine acyl C18:2 ↑ p=0.00056 
lysoPC a C20:3 lysoPhosphatidylcholine acyl C20:3 ↑ p=0.0019 
lysoPC a C20:4 lysoPhosphatidylcholine acyl C20:4 ↑ p=0.0025 
lysoPC a C24:0 lysoPhosphatidylcholine acyl C24:0 ↓ p=0.0024 
lysoPC a C26:0 lysoPhosphatidylcholine acyl C26:0 ↔ 
lysoPC a C26:1 lysoPhosphatidylcholine acyl C26:1 ↔ 
lysoPC a C28:0 lysoPhosphatidylcholine acyl C28:0 ↔ 
lysoPC a C28:1 lysoPhosphatidylcholine acyl C28:1 ↔ 
lysoPC a C6:0 lysoPhosphatidylcholine acyl C6:0 ↔ 
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